Neuregulin 1-Erbb4 in the rodent prefrontal cortex: Investigations of schizophrenia-related behaviours and signalling pathways by Paterson, Clare
 
 
 
 
 
Paterson, Clare (2011) Neuregulin 1-Erbb4 in the rodent prefrontal 
cortex: investigations of schizophrenia-related behaviours and signalling 
pathways. PhD.
http://theses.gla.ac.uk/2374/
 
Copyright and moral rights for this thesis are retained by the author 
 
A copy can be downloaded for personal non-commercial research or 
study, without prior permission or charge 
 
This thesis cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the Author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the Author 
 
When referring to this work, full bibliographic details including the 
author, title, awarding institution and date of the thesis must be given. 
 
Glasgow Theses Service 
http://theses.gla.ac.uk/ 
theses@gla.ac.uk  
 
 
 
 
 
Neuregulin 1-Erbb4 in the rodent prefrontal cortex: 
Investigations of schizophrenia-related behaviours 
and signalling pathways 
 
Thesis submitted by: 
Clare Paterson BSc (Hons) 
 
Submitted in fulfilment of the requirements for the degree 
of Doctor of Philosophy 
 
 
 
Institute of Neuroscience and Psychology 
College of Medical, Veterinary and Life Sciences 
University of Glasgow 
February 2011 
  
 
 
 
 
 
The research reported within this thesis is my own work except where otherwise 
stated, and has not been submitted for any other degree. 
 
 
Clare Paterson 
 
 I 
 
Abstract 
 
Schizophrenia is a severe, chronic and debilitating psychiatric disorder.  Current 
therapies  have  no  efficacy  in  treating  the  cognitive  impairments  which  are 
largely  responsible  for  the  poor  quality  of  life  of  schizophrenia  patients  and 
contribute to the massive economic burden that is associated with the disorder. 
 
Although  it  is  known  that  schizophrenia  is  highly  heritable,  the  underlying 
genetic basis is still poorly understood due to the complex polygenetic nature of 
the disorder.  Several candidate genes which are thought to increase risk for the 
incidence  of  schizophrenia  have  been  identified.    Two  such  schizophrenia 
candidate genes are neuregulin 1 (NRG1) and v-erb-a erythroblastic leukaemia 
viral oncogene homolog 4 (ERBB4).  As well as the genetic evidence from genetic 
association  studies,  studies  of  animal  models  and  the  endogenous  biological 
functions of NRG1 and ERBB4 in the CNS suggest that these genes may play an 
important role in the pathophysiology of schizophrenia.  However, very little is 
known about the functions of these genes in specific brain regions in adulthood 
with respect to cognition.   
 
To  address  this,  I  have  utilised  recombinant  adeno-associated  viral  particles 
(rAAVs)  as  a  vehicle  to  mediate  knockdown  of  the  expression  of  Erbb4 
specifically within the medial prefrontal (mPFC) cortex of adult rats.  This allows 
for  a  spatially  and  temporally  controlled  investigation  of  the  role  that Erbb4 
signalling may play in prefrontal cortex-dependent behaviours in adulthood.   
 
Following initial in vitro and in vivo validation of the functionality of the rAAVs, 
further in vivo studies confirmed that, five weeks after stereotaxic injection of 
rAAVs encoding a short hairpin sequence corresponding to Erbb4 (shErbb4.rAAV), 
into  the  mPFC  of  rats,  there  was  significant  Erbb4  protein  knockdown,  as 
analysed  by  ELISA.    Subsequent  western  blot  analysis  revealed  that  Erbb4 
knockdown consequently increased the level of Nrg1 expression and decreased 
the activity of Akt signalling, but had no effect on Erk signalling.   
 
Erbb4 knockdown specifically within the mPFC increased performance accuracy 
in the 5-choice serial reaction time task at 5 weeks post-surgery. Furthermore, 
viral mediated Erbb4 knockdown specifically within the mPFC  heightened the II 
 
sensitivity  to  the  locomotor  inducing  effects  of  amphetamine.    There  were, 
however,  no  effects  of  Erbb4  knockdown  on  pre-pulse  inhibition  at  any  time 
points assessed.  These results indicate that Nrg1-Erbb4 signalling in the PFC 
modulates  cognitive  performance  but  not  sensorimotor  gating,  and  that 
dopaminergic transmission may be regulated by Nrg1-Erbb4 signalling.  
 
In  conclusion,  this  study  highlights  the  ability  of  viral  mediated  gene 
manipulation to investigate regionally specific roles of schizophrenia candidate 
genes in adulthood in terms of cognition and downstream signalling pathways.  
This  may  translate  to  a  better  understanding  of  how  these  genes  may  exert 
potentially  pathophysiological  effects  in  patients  and  ultimately  lead  to 
improved treatments.   
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 2 
1.1 Schizophrenia 
Schizophrenia is a chronic and debilitating psychiatric disorder in which, unlike 
many other neurological diseases, the onset of symptoms generally manifest in 
late adolescence/early adulthood.  The causes of the disorder are unclear but 
mostly  likely  result  from  genetic  and  environmental  factors  which  impact  on 
neurotransmitter systems in particular brain circuits.  Emil Kraepelin, a German 
psychiatrist,  first  described  schizophrenia  in  1893  and  termed  the  disorder, 
Dementia Praecox, to differentiate it from other forms of dementia.  However 
Dementia Praecox-meaning early dementia- was somewhat misleading as not all 
people with schizophrenia experience dementia.  Later, the psychiatrist Eugene 
Bleuler  renamed  Dementia  Praecox  and  coined  the  term  “schizophrenia”  in 
1908, and made the observation that schizophrenia appeared to be a group of 
diseases  as  it  had  multiple  effects  on  personality,  thought,  cognition  and 
motivation.  A recent systematic review of the epidemiology of schizophrenia 
indicates that approximately 7 per 1000 individuals will develop schizophrenia 
during their lifetime (McGrath et al., 2008).   Furthermore, men are at a slightly 
higher risk than women for developing schizophrenia, with a male:female risk 
ratio of 1.4:1 being identified in multiple studies (Aleman et al., 2003; McGrath 
et al., 2008).  With the lifelong duration of schizophrenia, the economic burden 
of the disorder is a huge cost to UK society, with an estimated cost of £6.7 
billion in 2004/5 in England alone (Mangalore & Knapp, 2007).   
 
1.1.1 Symptoms of schizophrenia 
Diagnosis  of  schizophrenia  is  carried  out  according  to  guidelines  set  by  the 
Diagnostic and Statistical Manual of Mental Disorders IV (DSM IV) in the USA and 
the International Classification of Diseases 10
th revision (ICD-10) in Europe.  Both 
guidelines state that in order to diagnose a patient with schizophrenia they must 
have a specific number of symptoms, which have been presented for a specific 
duration of time.  For example DSM IV states that the patient must have two or 
more  of  the  “characteristic”  symptoms  of  schizophrenia,  present  for  a 
significant portion of time during a one month period.  Schizophrenia is thought 
of as a spectrum disorder with many subtypes of schizophrenia being classified 
based on severity and presence of symptoms, including paranoid schizophrenia, 3 
catatonic  schizophrenia,  residual  schizophrenia  and  undifferentiated 
schizophrenia (ICD-10).  
 
The symptoms of schizophrenia have been broadly categorised into three groups 
including positive symptoms, negative symptoms and cognitive deficits.  Positive 
symptoms of schizophrenia are clinical features that are normally absent in the 
general population, for example hallucinations most commonly of an auditory 
nature,  delusions,  thought disorder and disorganised  speech  (ICD-10).  Unlike 
positive  symptoms,  which  reflect  an  excess  of  normal  functions,  negative 
symptoms  of  schizophrenia  are  observed  as  a  loss  of  thoughts,  feelings  or 
emotions  normally  present  in  the  general  population.    For  example  negative 
symptoms include the loss of motivation, withdrawal from society, inability to 
experience  pleasure  (anhedonia),  blunted  emotions  and  apathy.  It  is  these 
symptoms that are associated with the staggeringly high co-morbidity seen in 
schizophrenia  with  ~10%  schizophrenics  committing  suicide  (Meltzer  et  al., 
2002).  
 
The third classification of symptoms of schizophrenia is cognitive deficits, which 
are now widely recognised as a core feature of the disorder.  Seven cognitive 
domains  have  been  identified  to  be  deficient  in  patients  with  schizophrenia 
including;  working  memory,  processing  speed,  visual  and  verbal  learning  and 
memory, social cognition and attention and vigilance (Nuechterlein et al., 2004).  
Moreover,  the  importance  of  cognitive  deficits  in  schizophrenia  has  been 
emphasised by studies showing cognitive performance correlates with functional 
outcome in schizophrenia patients (Green, 1996, Green, 2006).  Poor cognitive 
performance, likely in combination with the effects of negative symptoms may 
explain  why  it  is  estimated  that  almost  80%  of  schizophrenia  patients  are 
unemployed (Mangalore & Knapp, 2007). 
 
1.1.2 Neuropathology of schizophrenia 
Unlike other disorders of the brain where distinct neuropathologies are evident 
with disease progression, such as amyloid plaques and neurofibrillary tangles in 
Alzheimer’s disease, schizophrenia is not associated with gross neuroanatomical 
changes.  Instead, subtle morphological and cytoarchitectural changes have been 4 
identified  in  the  post-mortem  studies  of  brains  of  patients  that  had 
schizophrenia.   
Lateral ventricular enlargement has been reported in schizophrenia since 1976 
(Johnstone  et  al.,  1976).  A  review  of  MRI  studies  revealed  that  the  median 
increase in ventricular size in schizophrenia is 40% (Lawrie & Abukmeil, 1998). 
This  review  also  revealed  this  enlargement  was  accompanied by  reduction  in 
brain  volume  of  an  average  of  3%,  with  medial  temporal  structures  being 
affected.  The morphology of other brain regions has also been implicated in 
being  affected  by  schizophrenia.    The  temporal  lobe  has  been  implicated  in 
particular  as  a  loss  in  size  of  this  region,  particularly  the  superior  temporal 
gyrus, has been correlated to the extent of auditory hallucinations (Shenton et 
al.,  1992).  Similarly,  Wible  et  al.,  (1995)  found  a  correlation  between  the 
reduction  in  frontal  lobe  volume  and  the  extent  of  negative  symptoms.  
However, studies have been confounded due to the use of post-mortem tissue 
from  patients  who  have  undergone  treatment  with  antipsychotics  for  long 
periods of time and also the variables between donors of the tissues e.g. age, 
period of antipsychotic treatment, and extent of clinical symptoms.  However, 
magnetic resonance imaging (MRI) studies in first episode schizophrenia patients 
have also shown global brain volume reductions (Steen et al., 2006; Vita et al., 
2006). 
 
There have also been cytoarchitectural abnormalities found in schizophrenia; for 
example  there  is  a  decrease  in  cellular  size  of  neurones  in  the  dorsolateral 
prefrontal cortex and hippocampus (Harrison, 1999).  This study also suggested 
that there is accompanying increase in neurone density in these brain regions.  
Dendritic spine and synapse densities have also been shown to be affected in cell 
subtypes in schizophrenia (Selemon & Goldman, 1999; Chen et al., 2008).  These 
cytoarchitectural  changes  may  lead  to  a  lack  of  connectivity  between  brain 
regions, possibly leading to the manifestation of positive, negative or cognitive 
symptoms  of  schizophrenia.    Further  evidence  for  dysconnectivity  of  brain 
regions  in  schizophrenia  stems  from  reports  showing  deficits  in  myelination, 
resulting  from  myelin  sheath  or  oligodendrocyte  abnormalities  (Konrad  & 
Winterer, 2008).  
 5 
Many of these findings have led to the development of the neurodevelopmental 
theory of schizophrenia.  This theory posits that an as yet unidentified pre- or 
neonatal insult to the brain, disrupts the function of late maturing brain regions 
such as the PFC that ultimately manifests as behavioural abnormalities later in 
life (Weinberger, 1987). 
 
1.2 Hypotheses of schizophrenia 
The underlying causes of the symptoms of schizophrenia are thought to be due 
to an imbalance of neurotransmitter levels in distinct brain regions.  However, it 
is common opinion that due to the complex nature of schizophrenia not a sole 
neurotransmitter pathway is affected.  Instead it is thought that alterations in 
multiple neurotransmitter systems converge and have feedback effects on each 
other. 
1.2.1 The dopamine hypothesis 
The dopamine (DA) hypothesis of schizophrenia was originally based upon the 
observations of Carlsson and Lindquist (1963), who proposed that hyperactivity 
of  DA  transmission  was  linked  to  the  positive  symptoms  of  schizophrenia.  
Furthermore, all typical antipsychotic drugs, which are somewhat effective in 
managing positive symptoms, have high affinity for the DA D2 receptor which is 
predominantly expressed in subcortical regions of the brain (Seeman, 2004).  In 
addition amphetamine, which enhances DA release, worsens positive symptoms 
of schizophrenia patients (Angrist et al., 1974) and induces schizophrenia-like 
symptoms  in  unaffected  individuals  (Janowsky  &  Risch,  1979).    From  these 
studies it is thought that over-activity of subcortical dopamine DA systems is 
responsible for the positive symptoms of schizophrenia.  Moreover a series of 
studies have shown increased D2 receptor binding in mesolimbic regions of the 
brains  of  schizophrenia  patients  (MacKay  et  al.,  1982;  Seeman  et  al.,  1984; 
Crawley et al., 1986) 
 
In contrast, D1 receptors are predominantly expressed in cortical regions (Davis 
et al.,  1991).  It is thought that a hypodopaminergic state in this prefrontal 
cortical region may be responsible for the cognitive deficits of schizophrenia, as 6 
D1-mediated  transmission  is  required  for  optimal  PFC  activity  and  thus 
performance in cognitive tests (Goldman-Rakic, 2000).  This is supported by the 
fact  that  current  antipsychotic  treatments,  which  predominantly  act  by 
antagonising  D2  receptors  have  little  efficacy  in  the  treatment  of  cognitive 
deficits.    The  imbalance  between  mesocortical  dopamine  deficiency  and 
mesolimbic dopamine over-activity may then explain all three symptom domains 
of schizophrenia.  
 
1.2.2  Glutamate hypothesis 
There  is  growing  support  for  the  hypothesis  of  glutamatergic  dysfunction  in 
schizophrenia.  This was primarily proposed due to non-competitive N-Methyl-D-
asparate (NMDA) receptor antagonists, for example ketamine and phencyclidine 
(PCP), producing effects similar to positive, negative and cognitive symptoms of 
schizophrenia in healthy humans (Krystal et al., 1994; Ardler et al., 1999; Lahti 
et  al.,  2001).    Moreover,  administration  of  these  antagonists  can  exacerbate 
symptoms in schizophrenia patients (Luby et al., 1959; Allen et al., 1978; Lahti 
et al., 2001).  In line with these findings, it is thought that schizophrenia may 
involve NMDA receptor hypofunction.  This is supported by evidence for reduced 
NMDA  receptor  subunit  GRIN1  (NR1)  mRNA  levels  in  post-mortem  brains  of 
schizophrenia  patients  (Law  &  Deakin,  2001)  and  reductions  in  markers  for 
glutamate  transport  for  example  vesicular  glutamate  transporter-1 
(SLC32A1/VGAT1) (Reynolds and Harte, 2007).   
 
In agreement with NMDA receptor hypofunction, GABAergic neurotransmission is 
thought  to  be  affected  in  schizophrenia.  NMDA  receptors  are  particularly 
concentrated on parvalbumin-containing GABA interneurones, loss of function of 
these  NMDA  receptors  impacts  GABAergic  dysregulation  (Morris  et  al.,  2005).  
Reductions  in  parvalbumin-positive  GABA-ergic  interneurones  in  frontal  and 
hippocampal regions have been observed in schizophrenia (Benes et al., 2000; 
Reynolds et al., 2004).  Glutamic acid decarboxylase (GAD)-67 (GAD1) an enzyme 
important in the conversion of glutamate to GABA is also thought to be down-
regulated in schizophrenia (Lipska et al., 2003). 
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1.2.3  Other hypotheses 
Other  neurotransmitters  have  also  been  implicated  in  the  pathology  of 
schizophrenia, for example serotonin (5HT).  5-HT involvement in schizophrenia 
was  first  prompted  by  the  observation  that  lysergic  acid  diethylamide  (LSD), 
which binds with high affinity to 5HT receptors, induces psychosis-like symptoms 
(Hemmings & Hemming, 1978).  The serotonin hypothesis was also strengthened 
by the observation that the antipsychotic clozapine, which was found to have 
higher efficacy in treating symptoms, with fewer extra-pyramidal side effects 
(EPS),  had  an  ability  to  block  5HT2A  receptors  (Baldessarini  &  Frankenburg, 
1991).  This implies that schizophrenia may be partly due to an over-activation 
of 5HT receptors. 
 
1.3  Treatments of schizophrenia 
Although there is, as of yet, no cure for schizophrenia, there are drugs available 
for  the  life-long  management  of  positive  symptoms,  and  to  a  lesser  extent 
negative  symptoms.    However,  there  is  to  date  no  significantly  effective 
treatment  for  the  cognitive  deficits.    Some  of  the  earlier  treatments  for 
schizophrenia  resulted  in  unwanted  side  effects;  nevertheless,  with  better 
pharmacological knowledge, more effective, safer antipsychotic drugs are being 
produced. 
 
1.3.1  Typical antipsychotics 
Typical  antipsychotics,  also  referred  to  as  first  generation  antipsychotics, 
include haloperidol, chlorpromazine, thioridazine and flupenthixol.  These drugs 
have a high affinity for D2 receptors and are linked to a number of serious side 
effects.  These side effects include dry mouth, muscle stiffness, tremors and 
extra-pyramidal  symptoms  (EPS).    EPS  are  a  group  of  side  effects  caused  by 
hypodopaminergic  transmission  in  the  nigrostriatal  pathway  and  resemble 
symptoms  of  Parkinson’s  disease.    These  include  dystonia  (muscle  spasms), 
tardive dyskinesia (involuntary movement of muscles, usually in the face) and 
akathisia (restlessness).  Moreover, although there is high D2 receptor blockade, 
some  patients  are  resistant  to  typical  antipsychotic  treatment.  Importantly 8 
these drugs also have no effect on negative symptoms or cognitive deficits (Abi-
Dargham & Laruelle, 2005).   
 
1.3.2 Atypical antipsychotics 
Schizophrenia treatment was revolutionised with the introduction of clozapine in 
the early 1990s.  This drug was found to be better in treating positive symptoms 
in treatment-resistant schizophrenia patients and also produced fewer EPS.  This 
reduction in  EPS  may  be  due  to the drug having  a  different pharmacological 
profile  from  typical  antipsychotics,  with  a  lower  blockade  of  DA  receptors.  
Clozapine however does cause alternative side-effects such as weight gain, and 
more seriously, agranulocytosis.  Therefore it is mainly prescribed to treatment-
resistant  schizophrenia  patients.    Other  atypical  antipsychotics,  such  as 
olanzapine,  risperidone  and  amisulpride,  like  clozapine,  do  not  act  solely  by 
antagonising  D2  receptors,  but  have  a  wide  range  of  affinities  including  5HT 
receptors, other DA receptor subtypes and histamine receptors (Abi-Dargham & 
Laruelle,  2005).    Despite  this  relatively  broad  tropism,  Clinical  Antipsychotic 
Trials of Intervention effectiveness (CATIE) studies and Cost Utility of the Latest 
Antipsychotic  drugs  in  Schizophrenia  Study  (CUtLASS)  failed  to  find  atypical 
antipsychotics significantly more effective than their predecessors (Lieberman et 
al., 2005; Jones et al., 2006).  Furthermore, cognitive deficits are poorly treated 
by atypical antipsychotics.   
 
1.3.3 Developing therapies 
With multiple hypotheses of the potential underlying neurotransmission deficits 
involved  in  schizophrenia  now  generally  accepted,  there  has  been  a  rapid 
development of drugs which target these alternative neurotransmitter systems.  
These  drugs  include  metabotropic  glutamate  receptor  5  (mGluR5/GRM5) 
activators  which  enhance  NMDA  receptor  function.    However,  there  are 
difficulties in producing drugs which act specifically at subtypes of mGluRs, as 
their  binding  sites  are  very  similar.    Due  to  the  complex  genetic  nature  of 
schizophrenia,  which  most  likely  leads  to  the  heterogeneity  observed  in 
symptom severity, it is probable that patients with symptom clusters or specific 
polymorphisms will respond better to more targeted treatments.  However, the 9 
causal  genetics  and  neurotransmitter  impairments  in  schizophrenia  are  too 
poorly understood for the development of such drugs at this time. 
 
1.4  Risk factors implicated in schizophrenia 
Schizophrenia is a very complex disorder and it is thought that there are several 
causative factors that can increase the risk of subsequent development of the 
condition.  However, the complexity of schizophrenia suggests that there is not 
one  individual  underlying  causative  factor.    Instead  it  is  feasible  to  say  that 
additive  or  interactive  effects  between  several  candidate  genes  and  several 
environmental factors are responsible.  
 
1.4.1 Illegal substances 
One  such  risk  factor  associated  with  schizophrenia  is  the  use  of  illegal 
substances, in particular cannabis.  Cannabis use is known to produce effects on 
the CNS that reflect some of the symptoms of schizophrenia such as impairments 
in memory and attention, anxiety and hallucinations.  Moreover, long term heavy 
use of cannabis has been associated with long term cognitive deficits (Hall & 
Solowij,  1998);  however,  this  has  been  the  subject  of  much  debate.  
Furthermore, there is evidence for increased cannabinoid receptor, CB1 (CNR1), 
expression  in  multiple  brain  regions  of  schizophrenia  patients  including  the 
dorsolateral  prefrontal  cortex  (Dean  et  al.,  2001).    There  have  been  many 
studies  investigating  the  link  between  cannabis  use  and  increased  risk  to 
schizophrenia  development;  however  the  results  of  these  studies  have  been 
variable.    In  2005  a  meta-analysis  of  these  studies  showed  that  cannabis 
consumption is related to doubling the risk of schizophrenia (Henquet  et al., 
2005).  It has also been reported that the age of onset of cannabis use affects 
the risk factor.  Arseneault et al., (2002), demonstrated this by reporting that 
people  who  regularly  used  cannabis  by  early  adolescent  years  (15  years  old) 
were  four  times  more  likely  to  be  diagnosed  with  schizophrenia  or  a 
schizophrenia-like-disorder by the age of 26 than controls (people who had never 
used cannabis or had used it once or twice as an adolescent).  
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1.4.2  Environmental factors 
Environmental  risk  factors  have  also  been  associated  with  increased  risk  of 
schizophrenia.    It  has  been  reported  that  risk  of  schizophrenia  is  altered  by 
whether  birth  and  childhood  upbringing  took  place  in  an  urban  or  rural 
environment.  There is an increased risk of schizophrenia in people who are born 
in urban areas, and this risk is increased relative to the length of time spent in 
this environment (Pedersen and Mortensen, 2001).  The reason for this change in 
risk  level  is  unknown;  however,  differences  in  diet,  exposure  to  toxins  and 
infections as well as social class have all been suggested as an explanation.  In 
addition to area of birth, time of birth has been proposed as a risk factor for 
developing  schizophrenia.    It  has  been  shown  in  both  Northern and  Southern 
hemisphere countries that people born in winter and spring months compared to 
other seasons are more likely to develop schizophrenia (Torrey et al., 1997). 
 
1.4.3  Intrauterine environmental factors 
The environment during prenatal life is also an important causative risk factor 
for schizophrenia.  There is an increased risk of schizophrenia in people whose 
mother was malnourished during pregnancy.  A well documented case of this is 
the Dutch Hunger Winter during 1944-45,  where people conceived during the 
famine were later shown to have a two fold higher risk of schizophrenia than 
people conceived in the country in years previous to the famine (Hoek et al., 
1998).  This increase in risk was replicated in another study investigating the 
Chinese famine of 1959-61 (St Clair et al., 2005).  The most accepted reasoning 
behind  this  increase  in  risk  is  that  intrauterine  nutrients  are  necessary  for 
normal  foetal  development  including  development  of  the  brain.    Other 
complications during pregnancy can also lead to the delivered child having an 
increase  in  the  risk  of  developing  schizophrenia,  for  example  obstetric 
complications during labour (Cannon et al., 2001)  and viral infections during 
pregnancy such as Influenza (Limosin et al., 2003), Rubella (Brown et al., 2001) 
and Herpes Simplex (Buka et al., 2001). 
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1.4.4  Genetic factors 
Schizophrenia  is  known  to  be  a  highly  heritable  disorder  and  there  is  a  high 
incidence running through families.  The concordance rate of schizophrenia is 
80%  (Cannon  et  al.,  1998;  Cardno  et  al.,  1999;  Sullivan  et  al.,  2003).    In 
monozygotic  twins,  who  share  100%  genetic  material,  if  one  twin  has 
schizophrenia the other twin has a 40-50% risk of also developing schizophrenia 
(Gottesman et al. 1987; Sullivan et al., 2003).  This risk drops to approximately 
15% in dizygotic twins or siblings who share 50% genetic material (Gottesman et 
al. 1987; Sullivan et al., 2003).  Although the concordance rate of schizophrenia 
is very high, it is not 100%, which suggests schizophrenia is not purely a genetic 
disorder.   
1.4.5 Gene x environment interaction 
It is now widely accepted that other factors other than genes (as described in 
sections  1.4.1,  1.4.2,  1.4.3)  are  capable  of  subtly  increasing  risk  for 
schizophrenia,  and  in  recent  years  attention  has  turned  to  investigating 
potential  interactions  between  genetic  and  environmental  risk  factors.  
However,  these  studies  are  difficult  to  carry  out  due  to  their  longitudinal 
requirements. 
 
To  date  the  most  successful  gene  x  environment  studies  have  been  those 
investigating  the  interaction  between  genes  and  cannabis  use.    One  such 
example of this additive effect is that adolescents who smoke cannabis and have 
a specific single nucleotide polymorphism (SNP) in the gene Catechol-O-methyl 
transferase (COMT), which encodes an enzyme which degrades catecholamines 
(involved in dopamine catabolism), have a greater risk for schizophrenia than an 
adolescent individual that solely smokes cannabis or solely has the COMT gene 
polymorphism (Caspi et al., 2005).  This result however, was not confirmed in a 
similar subsequent study (Zammit  et al., 2007).  Another gene,  Neuregulin 1 
(NRG1),  has  also  been  recently  linked  to  having  a  potential  interaction  with 
cannabis, as mice with a mutation in the Nrg1 gene show a heightened response 
to  the  psychoactive  component  of  cannabis,  -9-tetrahydrocannabinol  (THC) 
(Boucher et al., 2007). 12 
1.5 Identification of schizophrenia candidate genes 
Although it is known that schizophrenia runs in families, it is also known that 
schizophrenia  is  not  inherited  in  a  Mendelian  inheritance  pattern,  and  the 
precise mechanism of inheritance in schizophrenia remains unknown.  Over the 
past  few  decades,  as  advances  in  molecular  biology  have  significantly 
progressed,  many  genes  have  been  identified  that  may  be  associated  with 
increased liability to schizophrenia.  Advances in technology have facilitated the 
identification of these schizophrenia candidate genes. 
 
1.5.1 Structural chromosomal studies 
Several  schizophrenia  candidate  genes  have  been  identified  via  studies 
investigating changes in chromosome structure.   Deletion of the chromosomal 
region 22q11 has been found to lead to velo-cardio-facial-syndrome (VCFS).  This 
microdeletion syndrome is estimated to affect 1:2500-1:4000 live births, and is 
associated with a 30-fold increase in the risk of affected individuals with VCFS to 
develop schizophrenia (Murphy et al., 2002; Gothelf et al., 2007).  Deletion of 
this chromosomal region will affect the expression of multiple genes, however.   
Two of these are of particular interest in terms of schizophrenia.  COMT which 
encodes  an  enzyme  initiating  the  degradation  of  catecholamines  such  as  the 
neurotransmitter  dopamine  by  catalysing  their  methylation,  and  Proline 
dehydrogenase  (PRODH)  which  encodes  an  enzyme  which  initiates  the 
degradation of proline: an amino acid important in the synthesis of glutamate 
(Harrison  &  Weinberger,  2005).    Since  several  aspects  of  schizophrenia  have 
been  linked  to  the  manifestation  of  altered  dopaminergic  and  glutamatergic 
states in specific brain regions, COMT and PRODH are likely candidate genes for 
schizophrenia. 
 
An autosomal balanced translocation involving chromosomes 1q42.1 and 11q14.3 
was identified in a large Scottish family that were found to have a very high 
incidence of schizophrenia, bipolar disorder and major depression (St Clair  et 
al., 1990).  Subsequent sequencing of the 1q42 and 11q14.3 breakpoints led to 
the finding of two novel genes disrupted by the previous mutation, DISC1 and 
DISC2, with only DISC1 having the ability to encode protein (Millar et al., 2000).  13 
DISC1 is a promising schizophrenia candidate gene as it has many functions which 
relate  to  the  pathophysiology  of  the  disorder,  with  Morris  et  al.,  (2003) 
concluding  that  “DISC1  is  a  multifunctional  protein  whose  truncation  may 
contribute to schizophrenia susceptibility by disrupting intracellular transport, 
neurite architecture, and/or neuronal migration”.  
 
More recent studies have shifted from looking at gross chromosomal structural 
changes  to  more  focussed  studies  of  sub-microscopic  copy  number  variants 
(CNVs) - microdeletions or microduplications of small stretches of DNA.  Several 
studies  utilising  genome  wide  searches  for  CNVs  have  found  CNVs  are  more 
abundant in schizophrenia patients (Kirov et al., 2008; Walsh et al., 2008; Xu et 
al., 2008). Genes which appear to be affected by these deletions or duplications 
include those previously implicated in schizophrenia including Neurexin (NRXN1) 
and  ERBB4  (Kirov  et  al.,  2008;  Walsh  et  al.,  2008;  St  Clair,  2009).    These 
chromosomal  aberrations  are  highly  penetrant  variants,  which are  thought to 
exist in combination with other genetic variants to increase the genetic risk for 
schizophrenia. 
 
1.5.2 Linkage studies 
The aim of linkage analysis studies, which are carried out using samples from 
affected families, is to identify regions of the genome which are shared between 
affected  family  members  but  not  among  unaffected  family  members  (I.e. 
inherited genetic variation).  Many linkage studies have implicated “risk regions” 
of the genome that appear to be linked with schizophrenia.  Meta-analyses of 
over 30 schizophrenia linkage studies found that chromosomal regions 8p21-22 
and  22q11-12  are  likely  to  contain  potential  schizophrenia  candidate  genes 
(Badner & Gershon, 2002; Lewis et al., 2003).  Although linkage studies do not 
identify individual candidate genes they do narrow down regions in which these 
genes may be positioned; further studies within these regions can then identify 
individual  genes.  Several  plausible  schizophrenia  candidate  genes  have  been 
identified  from  these  aforementioned  “risk  regions”  such  as  NRG1  which  is 
located on 8p21-22 (see section 1.8).   14 
1.5.3 Association studies 
Unlike  linkage  studies,  association  studies  can  be  carried  out  on  unrelated 
individuals, and aim to investigate if SNPs within a specific gene are associated 
with  disease.    SNPs  represent  common  genetic  variations  which,  individually, 
have low penetrance.  Support for many schizophrenia candidate genes has been 
strengthened by positive findings of association studies, including dystrobrevin 
binding protein (also known as  dysbindin) (DTNBP1) (Straub  et al.,  2002).  A 
useful  resource  for  the  overview  of  association  studies  of  schizophrenia 
candidate  genes  is  SZGene  (www.schizophreniaforum.org/res/sczgene)  which 
lists both positive and negative findings for many genes.  From these findings 
SZGene  composes  a  list  of  the  current  top  schizophrenia  genetic  risk  factors 
(based on genetic evidence only), the top schizophrenia candidate gene as of 
1/12/2010 is PRSS16 which encodes a serine protease.  Often negative findings 
of  previously  positively  associated  genes  are  found,  this  may  be  due  to 
limitations in sample size, ethnicities tested and which SNPs were investigated. 
Genome  wide  association  studies  (GWAS)  utilise  a  similar  approach  to  the 
aforementioned association studies.  However, instead of investigating SNPs in 
an individual gene, genotypes of cases and controls for half a million to a million 
SNPs  are  simultaneously  tested  on  a  chip.    Because  of  the  large  number  of 
statistical comparisons required in such studies, the risk of false positive findings 
is  increased  by  using  this  method.    Therefore  the  threshold  for  a  significant 
finding of a difference in genotype frequency between cases and controls has to 
be  set  much  higher  than  that  of  regular  association  studies.    Several 
schizophrenia  GWAS  scans  have  been  carried  out  since  2007  with  many 
interesting  genes  being  identified,  such  as  the  zinc  finger  gene,  ZNF804A 
(O’Donovan et al., 2008).  However, three meta-analyses of GWAS scans only 
found converging results for the major histocompatibility region on chromosome 
6 being associated with schizophrenia (Purcell  et al.,  2009;  Shi  et al.,  2009; 
Stefansson et al., 2009).  
Although  converging  evidence  is  emerging  for  genetic  risk  factors  for 
schizophrenia, the polygenic nature of the disorder makes the identification of 
the  underlying  genetic  risks  very  complex.    It  has  been  suggested  that  the 15 
complex  genetic  risk  of  schizophrenia  is  due  to  low  penetrance  variations  in 
1000s of individual genes (Purcell et al., 2009).  However, it is also likely that it 
is a combination of multiple common polymorphisms in schizophrenia candidate 
genes and rare de novo mutations that contributes to the risk of schizophrenia.  
With  the  ongoing  development  of  new  technologies,  such  as  next  generation 
sequencing, the genetic burden of schizophrenia will be better understood.    
1.6 Measuring cognition in rodents 
Cognitive  deficits  are  now  considered  to  be  a  core  symptom  domain  of 
schizophrenia,  with  cognitive  performance  being  closely  correlated  with 
functional  outcome  in  patients  (Green,  1996;  Green,  2006).    Unfortunately 
current  antipsychotic  therapies  are  inefficient  at  treating  these  cognitive 
deficits (Harvery & Keefe, 2001; Keefe et al., 2007).  Therefore, an initiative 
was developed to identify the cognitive symptoms that have unmet therapeutic 
need, called the Measurement and Treatment Research to Improve Cognition in 
Schizophrenia (MATRICS) initiative.  This initiative identified seven domains of 
cognition that are affected in schizophrenia 1) attention/vigilance 2)  working 
memory 3) reasoning and problem solving 4) processing speed 5) visual learning 
and memory 6) verbal learning and memory 7) social cognition (Marder et al., 
2004).  
Preclinical assessment that maps onto these symptom domains in rodents may 
allow the discovery and selection of potentially useful therapies for treating the   
cognitive  deficits  of  schizophrenia.    For  example  attention/vigilance  and 
processing speed can be measured in the 5-choice serial reaction time task (5-
CSRTT), a preclinical equivalent to the continuous performance task (CPT) in 
humans (Robbins, 2002). Problem solving and reasoning can be assessed by the 
attentional  set-shifting task which is analogous to the Wisconsin Card Sorting 
Task (WCST) used in humans (Birell & Brown, 2000).  Other tasks such as social 
recognition and social interaction allow assessment of social cognition, whereas 
working memory can be assessed by the radial arm maze and odour span tests 
(Young et al., 2009). 16 
1.7 Animal models 
With the complexity of schizophrenia come limitations to the creation of animal 
models of the disorder.   Although it is unlikely that animal models are capable 
of encapsulating all aspects of the disorder, it is possible to model components 
of schizophrenia.  To date animal models have allowed a better understanding of 
the underlying neurotransmitter systems that are likely to be dysfunctional in 
schizophrenia.  They also allow preclinical testing of potential new therapies for 
schizophrenia.  There are several different mechanisms by which animal models 
of  schizophrenia  have  been  generated,  each  mechanism  generating  models 
reflecting  slightly  different  aspects  of  schizophrenia,  with  their  own  distinct 
advantages and disadvantages.   
1.7.1 Pharmacological models 
Pharmacological  animal  models  of  schizophrenia  are  based  upon  the  current 
knowledge of the alterations in neurotransmitter systems that are thought to 
lead to the symptoms of schizophrenia.  For example, based on the glutamate 
hypothesis of schizophrenia (section 1.2.2), administration of PCP  to rats has 
been shown to result in not only biochemical changes but also behavioral deficits 
that reflect those observed in schizophrenia patients.  Previous studies from our 
laboratory have shown that repeated PCP administration to rats led to reduced 
parvalbumin (Pvalb) mRNA and Kv3.1 (Kcnc1) potassium channel mRNA, which 
are both expressed in GABAergic interneurones (Cochran et al., 2002; Cochran et 
al.,  2003).    Additionally,  PCP  causes  reduced  metabolic  activity  in  PFC  and 
reduces  network  connectivity  (Cochran  et  al.,  2003;  Dawson  et  al.,  2010).  
Furthermore, transcriptome analysis of PFC tissue, from rats chronically treated 
with PCP, showed that PCP treatment altered the expression of many genes with 
functions  related  to the  glutamate  and  GABA  systems  (Catherine  Winchester, 
personal  communication).    These  alterations  included  genes  located  on 
chromosomal  loci  that  have  been  previously  implicated  in  schizophrenia 
including 8p22-21 (Winchester et al., 2007).  In addition PCP treatment in rats 
has resulted in deficits in behaviours that are dysfunctional in schizophrenia, 
including  sensorimotor  gating  (Egerton  et  al.,  2005),  executive  function  as 17 
assessed by set-shifting (Egerton et al., 2003; Egerton et al., 2005; Dawson et 
al., 2010) and attention, vigilance and processing speed (Thomson et al., 2010).  
Other pharmacological substances, including toxins, have also been utilized to 
generate  animals  which  resemble  some  of  the  aspects of  schizophrenia.    For 
example prenatal exposure of rats to the mitotoxin methylazoxymethanol (MAM) 
decreases cortical mass, causes deficits in PPI, heightened locomotor response 
to amphetamine and deficits in working memory (Moore et al., 2006). 
1.7.2 Environmental models 
As described in section 1.4.2, environmental factors have also been implicated 
in increasing the risk to schizophrenia.  Rodents with environmental insults show 
biochemical and behavioral changes that resemble those of schizophrenia.  Rats 
or  mice  that  are  moved  into  social  isolation  post-weaning  show  deficits  in 
prepulse  inhibition,  locomotor  activity  and  object  recognition  (Jones  et  al., 
2010) along with decreased cortical and hippocampal synaptic plasticity (Comery 
et al., 1995; Silva–Gomez et al., 2003). 
1.7.3 Genetic models 
Genetic  association  studies  have  identified  polymorphisms  within  many  genes 
that  increase  risk  for  schizophrenia;  in  addition  numerous  genes  have  been 
identified/hypothesised  as  functional  candidate  genes  based  on  their 
endogenous  roles  within  the  CNS  which  are  known  to  be  dysfunctional  in 
schizophrenia.  However, to date no causative genes have yet been identified.  
Therefore, in order to understand further the functions of these genes and to 
gain  a  better  insight  into  how  they  may  be  potentially  pathophysiological  in 
schizophrenia,  animal  models  have  been  generated  with  altered  forms  of 
schizophrenia candidate genes.   
 
For  example  animal  models  with  deletion  of  chromosome  22q11.2  show 
sensorimotor  gating  and  working  memory  deficits  that  reflect  aspects  of 
schizophrenia  (Paylor  et  al.,  2001).    Targeted  mutation  of  selected 
schizophrenia genes in rodents has permitted a greater understanding of how the 
gene  of  interest  may  play  a  role  in  structural  and  biochemical  changes  of 18 
schizophrenia.  Animal studies of Disc1 show a strong link between the gene and 
schizophrenia.    For  instance  Kamiya  et  al.,  (2005)  demonstrated  that  loss  of 
expression of Disc1 by RNAi (quantified by western blot) resulted in impaired 
cerebral cortex development,  whereas another study demonstrated that Disc1 
dysfunction in schizophrenia may lead to altered glycogen synthase kinase 3 
(GSK3) signalling (Mao et al., 2009).  In addition functions of Nrg1 and Erbb4 
have  been  better  understood  by  animal  models  of  these  genes  (see  section 
1.9.3).   
 
1.8 Neuregulin-Erbb signalling  
1.8.1 Neuregulin 1 (NRG1) nomenclature and structure 
Neuregulins  are  a  family  of  four  growth  factor  genes  (NRG1-4)  that  mediate 
important roles in a number of different organs by activating receptor tyrosine 
kinases.  Human NRG1 (also known as heregulin) was first identified in the early 
1990’s (Holmes et al., 1992), with the identification of NRG2, NRG3 and NRG4 
occurring in subsequent years (Carraway et al., 1997; Zhang et al., 1997; Harari 
et al., 1999).  Of the neuregulins, NRG1 has been most widely studied due to its 
important roles in CNS and cardiac development.  However, recently there has 
been a surge of interest in NRG3 as it is the only neuregulin with expression 
restricted  to  the  brain  and  its  binding  ability  restricted  to  specific  receptor 
tyrosine  kinase  sub-types  (Zhang  et  al.,  1997),  making  NRG3  a  potentially 
attractive molecule to study in terms of neurological disorders.   
 
The structure of the human NRG1 gene has been widely investigated since its 
discovery.  NRG1 is a large gene (1.4 megabases (Mb)) located on chromosome 
8p12.21, and due to multiple promoter transcription start sites and alternative 
splicing there are approximately 31 transcript isoforms (Mei & Xiong, 2008). The 
nomenclature of these isoforms is based upon four structural characteristics: 1) 
The  N-terminal  encoded  sequence  determines  the  “type”  of  NRG1,  with  six 
distinct types of NRG1 (NRG1 type I-VI) having been identified to date.  Types I, 
II,  IV  and  V  are  similar  in  that  they  possess  an  immunoglobulin  (Ig)  domain 
whereas type III possesses a cysteine rich domain (CRD).  Type VI NRG1 lacks the 
exons  that  encode  for  Ig  and  CRD  domain  and  so  little  is  known  about  its 19 
processing and signalling capabilities. 2) All NRG1s contain an epidermal growth 
factor (EGF)-like domain; however there are three types of EGF-like domains 
termed ,  and 3) The linker region between the EGF-like encoding domain 
and  the  C-terminal  transmembrane  encoding  domain  (TMD)  is also  subject  to 
alternative splicing, resulting in four variants (1-4) of the linker region.  4) The 
C-terminal domain can consist of a cytoplasmic tail of type a, b or c (Falls, 2003; 
Mei  &  Xiong,  2008).  These  isoform  defining  characteristics  determine  the 
function and regional expression of NRG1, for example NRG1 isoforms with a 
EGF-like  domain  and  a  type  “a”  cytoplasmic  tail  are  the  most  prominently 
expressed  in  the  brain  (Falls,  2003).    A  simplified  summary  of  the  NRG1 
nomenclature is shown in Figure 1-1.   
 
The NRG1 gene encodes a membrane bound pro-protein which is susceptible to 
cleavage by proteases. Tumour necrosis factor- converting enzyme (ADAM17, 
TACE),  -amyloid  precursor  protein  cleaving  enzyme  (BACE)  and  meltrin   
(ADAM19) act at a juxtamembrane site close to the EGF-like domain (Loeb & 
Fischbach, 1995; Sunnarborg et al., 2002; Yokozeki et al., 2007).  This cleavage 
results in the release of the bioactive extracellular fragment of NRG1 that can 
then  initiate  signalling  cascades  via  binding  to  receptor  tyrosine  kinases 
expressed  on  the  same  cell  type  (autocrine  signalling)  or  other  cell  types 
(paracrine signalling).  Type III NRG1 is unique in that not only is it the only 
NRG1 type to consist of a CRD but also because its transmembrane domain is 
located within the N-terminal domain.  Thus cleavage of the type III pro-protein 
does  not  result  in  release  of  a  bioactive  extracellular  fragment,  but  instead 
exposes the bioactive EGF-domain as a tethered ligand still membrane bound.  
Type III NRG1 isoforms are therefore thought only to be capable of juxtacrine 
signalling.   
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Figure  1.1  Neuregulin-1  isoform  nomenclature.    NRG1  isoforms  arise  from 
combinations of type (I-VI), presence of Ig or CR domain, or EGF domain, 
linker region (1-4), cytoplasmic tail a, b or c.* Type VI Nrg1 does not contain either 
Ig or CR domain.  
# Type III Nrg1 has an additional TMD located within the N-
terminal domain.  Ig: Immunoglobulin, CRD: cysteine rich domain, EGF: epidermal 
growth factor, TMD: transmembrane domain. 
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1.8.2 NRG1 expression in the CNS 
NRG1  is  widely  expressed  in  the  adult  human  brain,  including  the  prefrontal 
cortex, hippocampus, cerebellum and substantia nigra- areas which have been 
linked to being important in schizophrenia (Law et al., 2004; Bernstein et al., 
2006).  Similarly, in the adult rat brain Nrg1 expression has been shown in these 
structures (Chen et al., 1994; Kerber et al., 2003).  NRG1 isoform expression in 
the brain appears to be spatially and temporally controlled.  Where types I, II 
and III NRG1 are expressed in the cortex of adult human and rat brain (Kerber et 
al., 2003; Hashimoto et al., 2004), type IV NRG1 appears to be brain specific and 
is restricted to human expression (Steinhorsdottir et al.,2004; Tan et al., 2007).  
Moreover NRG1 isoform expression changes during development.  Type IV NRG1 
is expressed 3.5 fold times higher in foetal human brain than that of the adult 
(Tan  et  al.,  2007).    Moreover,  in  rodents  Nrg1  protein  expression  in  the 
hippocampus, cerebellum and cortex is lower in adulthood than in foetal tissues 
(Chen et al., 1994).  In mice the first embryonic expression of Nrg1 is type III 
NRG1 expression, which is followed by the expression of type I then type III, 
suggesting  the  isoforms  have  distinct  roles  during  different  stages  of 
development. 
NRG1  mRNA  has  been  shown  to  be  clearly  expressed  in  cortical  pyramidal 
neurons and interneurones of the adult human cortex and hippocampus, and in 
Golgi and Purkinje cells of the cerebellum (Law et al., 2004; Bernstein et al., 
2006).  In agreement,  Kerber  et al.,  (2003)  found Nrg1 protein expression in 
granular  and  Purkinje  cells  of  cerebellum  in  adult  rat  (Kerber  et  al.,  2003).  
Type II NRG1 is expressed in oligodendrocytes, microglia and astrocytes of the 
adult human brain (Cannella et al.,  1999).  Subcellular location of NRG1 has 
been  shown  to  be  predominantly  in  the  neuronal  cell  body  and  synapse  rich 
regions, with clustering at cell membranes (Chaudhury et al., 2003; Law et al., 
2004). 
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1.8.3 ERBB4 nomenclature and structure 
ERBB4 is one of four members of the ERBB receptor tyrosine kinase (RTK) family.  
ERBB1-4 are located on human chromosomes 7, 17, 12 and 2, respectively, and 
encode  type  1  receptor  tyrosine  kinases  ERBB1  (epidermal  growth  factor 
receptor; EGFR), ERBB2, ERBB3 and ERBB4 (Ullrich et al., 1984; Yamamoto et 
al., 1986; Kraus et al., 1989; Plowman et al., 1993).  Human ERBB4, like NRG1, 
is a large gene of approximately 1.15Mb, consisting of 28 exons (Mei & Xiong, 
2008).  The ERBB4 gene is also subject to alternative splicing, and as a result 
four isoforms of ERBB4 have been identified.  JMa ERBB4 isoforms contain exon 
16 but not exon 15, while JMb isoforms contain exon 15 but not 16, consequently 
these  isoforms  differ  structurally  in  their  juxtamembrane  sequence  affecting 
their susceptibility to proteolytic cleavage (Elenius et al., 1997a).  CYT isoforms 
differ in their cytoplasmic tail sequence, with CYT1 isoforms containing exon 26 
and  thus  a  16  amino-acid  sequence  that is  the  binding  site  for  PI3-K.    CYT2 
isoforms  lack  exon  26  and  therefore  activation  of  CYT2  containing  ERBB4 
receptors  by  NRG1  does  not  activate  the  PI3-K  signal  transduction  pathway 
(Elenius et al., 1999). A very recent study has identified novel ERBB4 transcripts 
with alternative splicing of exon 3.  These isoforms have been termed del.3 and 
appear to exist only in CYT2 transcripts (i.e. not containing exon 26) (Tan et al., 
2010).  It is unlikely that these are the only naturally occurring ERBB4 isoforms, 
and indeed further novel isoforms have been identified in rare forms of cancers 
termed JMc and JMd (Gilbertson et al., 2001).  The nomenclature for  ERBB4 
isoforms is diagrammatically shown in Figure 1-2. 
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Figure 1.2 Partial exon structure of ERBB4 isoforms JMa, JMb, CYT1 and 
CYT2 produced by alternative splicing.  JMa and JMb isoforms resulting from 
the inclusion of exon 16 or 15, which in turn renders them sensitive or insensitive 
to  proteolytic  cleavage  by  presenilin  dependent  secretase  respectively.    CYT1 
and CYT2 isoforms result from the inclusion or exclusion of exon 26, respectively, 
resulting  in  the  ability  or  inability  to  activate  the  PI3-K  transduction  pathway.  
Therefore  four  combinations  of  receptor  are  possible,  JMa/CYT1,  JMa/CYT2, 
JMb/CYT1 or JMb/CYT2. Dashed line indicates continuation of exons not shown in 
diagram.  Exons  are  numbered  and  represented  as  boxes,  with  intronic  DNA 
represented by dashed lines (size is not to scale).  
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1.8.4 ERBB4 expression in the CNS 
Human  ERBB4  is  highly  expressed  in  the  heart,  kidney  and  neuronal  tissues 
(Plowman et al., 1993).  The levels of ERBB4 isoform expression appears to be 
tissue  dependant,  with  JMa  isoforms  being  solely  expressed  in  the  kidney, 
whereas the heart only expresses JMb ERBB4 isoforms (Elenius et al., 1997a).  In 
addition ERBB4 CYT2 isoforms are predominantly expressed in neural and renal 
tissues while CYT1 is predominantly expressed in the breast and heart (Elenius et 
al., 1999).  
ERBB4 is expressed in most regions of the adult human brain, and in all cortical 
areas with intense expression specifically in cortical layers II and V (Bernstein et 
al., 2006).  This general expression pattern is also seen in the brains of non-
human primates (Thompson et al., 2007).  To date the regional expression of 
ERBB4 isoforms is unknown, however it has been shown that all four isoforms 
(JMa,  JMb.  CYT1  and  CYT2)  are  expressed  to  some  extent  in  cortical  and 
hippocampal tissues of human brain (Law et al., 2006).  In the adult rat brain 
Erbb4  is  widely  expressed  in  the  cortex,  amygdala,  hippocampus,  reticular 
thalamic nucleus and cerebellum (Steiner et al., 1999; Gerecke et al., 2001).   
All  isoforms  of  ERBB4  including  the  newly  identified  del.3  transcript  are 
expressed in the foetal brain (Tan et al., 2010). Erbb4 expression in rats has 
been  shown  to  increase  with  development  (Mechawar  et  al.,  2007).    The 
subcellular location of Erbb4 has been identified.  In general Erbb4 expression 
has been identified as somatodendritic, with Erbb4 immunoreactivity or mRNA 
expression localising to the cytoplasm and/or plasma membrane (Gerecke et al., 
2001; Mechawar et al., 2007).  However, the expression has also been observed 
within the nucleus of cortical and hippocampal cells (Mechawar  et al., 2007).  
The complex proteolytic processing of ERBB4 may explain this diffuse cellular 
expression. 
Moreover, ERBB4 is expressed in many cell types.  ERBB4 has been identified in 
interneurones in human brain (Bernstein et al., 2006), and rat brain (Steiner et 
al., 1999; Mechawar et al., 2007).  More recently Erbb4 protein expression has 
been shown to be in GABAergic interneurones (Yau et al., 2003; Fishan et al., 
2009; Vullhorst et al., 2009; Neddens & Buonanno, 2010).   ERBB4 has also been 25 
identified in pyramidal neurons (Berstein et al., 2006; Mechawar et al., 2007; 
Thompson  et  al.,  2007).    However,  this  pyramidal  cell  expression  has  been 
subject  to  debate  recently  as  studies  utilising  newly  synthesised  antibodies 
generated against Erbb4 have found no expression of Erbb4 in pyramidal cells of 
the mouse hippocampus (Vullhorst  et al.,  2009;  Neddens & Buonanno,  2010).  
Expression  of  ERBB4  in  glia  is  also  somewhat  unclear  with  studies  showing 
presence (Ma et al., 1999; Bernstein et al., 2006) and absence (Mechawar et al., 
2007) of co-localisation of ERBB4 with glial markers.  Erbb4 has also been shown 
to  be  expressed  in  dopaminergic  neurons  of  the  substantia  nigra  and  ventral 
tegmental area (Steiner et al., 1999).  
1.8.5 NRG-mediated ERBB4 activation 
All ERBB receptors are alike in that they contain four domains; an ectodomain 
containing  two  cysteine  rich  domains,  a  single  transmembrane  domain, 
intracellular juxtamambrane domain and a carboxy-terminal tail (Mei & Xiong, 
2008).  Ligand  binding  to  the  ectodomain  triggers  receptor  dimerisation  and 
subsequent auto and trans-phosphorylation of the intracellular tyrosine kinase 
residues  on  the  receptor,  which  serve  as  docking  sites  for  various  adaptor 
proteins.    These  proteins  then  activate  numerous  intracellular  signalling 
cascades. 
Each  type  of  ERBB  receptor  has  a  distinct  ligand  binding  profile.    There  are 
seven known ligands that bind with high affinity to ERBB4, including three known 
ERBB1  ligands;  betacellulin  (Riese  et  al.,  1996),  heparin  binding  epidermal 
growth factor (Elenius et al., 1997b) and epiregulin (Komurasaki et al., 1997) as 
well as neuregulins 1-4 (NRG1-4) the most potent being NRG1-1 (Tzahar et al., 
1994).  Upon activation, receptor dimerisation can be homodimerisation, where 
two  ERBB  receptors  of  the  same  type  come  together,  or  heterodimerisation, 
where  two  differing  ERBB  receptors  form  a  complex.    ERBB4  receptors  are 
capable  of  homodimerisation  (i.e.  ERBB4/ERBB4),  whereas,  ERBB3  lacks  an 
enzymatically active tyrosine kinase domain and so requires heterodimerisation 
with ERBB2 as a co-receptor for signalling (Guy et al., 1994).  ERBB2 itself is 
thought to be an orphan receptor as no ligands have been identified; instead 
ERBB2 forms heterodimers with the other ERBB receptors, activating signalling as 26 
ERBB2 does have an active tyrosine kinase domain.  ERBB2/ERBB4 heterodimers 
are thought to potentiate ERBB4’s signalling capacity by increasing the affinity 
of the ligand binding site, thus accentuating the signalling response to ligand 
binding (Graus-Porta et al., 1997; Wang et al., 1998; Jones et al., 1999). 
 
Following  ligand  binding  and  ERBB4  dimerisation,  phosphorylation  of  the 
intracellular domains generates docking sites for adapter proteins such as SHC 
(Culouscou et al., 1995) and GRB7 (Fiddes et al., 1998).  This initiates mitogen-
activated protein kinase (MAPK) and phosphoinositide-3 kinase (PI3-K) signalling 
cascades (Puricelli et al., 2002).   
 
Like NRG1, the ERBB4 receptor is susceptible to proteolytic cleavage.  Cleavage 
of  the  juxtamembrane  domain  of  JMa  containing  ERBB4  isoforms  by  TACE 
releases an extracellular fragment containing the ligand binding site (Elenius et 
al., 1997a; Cheng et al., 2003).  This extracellular fragment can then bind to 
pro-protein  membrane  bound  NRG’s  or type  III  NRG1,  to  initiate intracellular 
signalling.    Furthermore,  the  remaining  80kDa  membrane  bound  fragment  of 
ERBB4 can be further cleaved by -secretase to release an intracellular fragment 
(Ni et al., 2001; Vidal et al., 2005).  This intracellular fragment can translocate 
to the nucleus where it has been shown to interact with transcriptional factors 
which may regulate gene expression (Omerovic et al., 2004; Linggi & Carpenter, 
2006).  This backwards signalling has also been proposed for NRG1, which can 
also be cleaved by -secretase.  This intracellular fragment can also translocate 
to the nucleus and has been shown to regulate the promoter of post synaptic 
density 95 (PSD95) (Bao et al., 2004). 
 
1.9 Evidence  for  aberrant  NRG1-ERBB4  signalling  in 
schizophrenia  
NRG1  and  ERBB4  have  both  been  implicated  as  strong  candidate  genes  for 
increasing  the  risk  to  schizophrenia  due  to  evidence  from  studies  of  their 
endogenous functions in the CNS, genetic studies and animal models.  Based on 
the  evidence  from  genetic  studies,  NRG1  is  currently  at  position  26  in  the 
SZGene database. 27 
1.9.1 Biological functions related to schizophrenia 
NRG1 signalling has been shown to have central functions in the regulation and 
development  of  several  organs  including  those  of  the  cardiovascular  system 
(Erickson  et  al.,  1997;  Rentschler  et  al.,  2002;  Kuramochi  et  al.,  2006)  and 
breast tissue (Yang et al., 1995; Jones et al., 1996; Li et al., 2002), however, it 
is  the  important  roles  that  NRG1  plays  in  the  CNS  that  have  linked  it  to 
schizophrenia. 
 
NRG1  plays  central  roles  in  systems  that  are  affected  in  schizophrenia  (for 
example the regulation of oligodendrocytes and myelination, which appears to 
be abnormal in schizophrenia) (Hakak et al., 2001; Hof et al., 2002; Flynn et al., 
2003; Tkachev et al., 2003).  In addition, studies of ERBB4 have identified many 
important functions including mediating axonal navigation between the thalamus 
and  neocortex  (Lopez-Bendito  et  al.,  2006),  regulation  of  neuroblast  chain 
migration,  orientation  and  organisation  (Anton  et  al.,  2004),  promotion  of 
proliferation and organisation of neuronal precursors in the sub ventricular zone 
(Ghashghaei et al., 2006), and regulation of neuronal migration along radial glial 
fibres  (Rio  et  al.,  1997).    These  actions  appear  to  be  dysfunctional  in 
schizophrenia  and  are  a  potential  explanation  for  the  loss  of  synaptic 
connectivity observed in the disease, which could implicate ERBB4’s role in the 
cognitive deficits seen in schizophrenia.   
 
NRG1-ERBB4 signalling has also been implicated in regulating the expression of 
neurotransmitter  receptor  subunits,  indicating  NRG1-ERBB4  signalling 
dysfunction  may  affect  neurotransmitter  systems  that  have  previously  been 
proposed to be altered in schizophrenia.  For example, ERBB4 appears to have 
distinct interactions with GABA receptors: ERBB4 signalling through activation by 
immunoglobulin-domain containing isoforms of Nrg1 increases the expression of 
the GABAA receptor 2 subunit as well as increasing the number of functional 
GABAA receptors in cerebellar granule cells (Rieff et al., 1999).  However, Okada 
et  al.,  (2004),  found  that  Ig-NRG,  which  was  in  close  proximity  to  ERBB4 
receptors,  down-regulated  the  expression  of  GABAA  receptor    subunits  in 
hippocampal  slices.    It  is  probable  to  assume  that  this  effect  of  NRG1, 
hypothetically through ERBB4 receptors, is brain region and/or GABAA subunit 28 
dependent.  Flames et al., (2004), showed that NRG1/ERBB4 signalling has an 
important role in the development and migration of GABAergic interneurons, as 
loss of the functionality of either NRG1 or ERBB4 resulted in a decrease in the 
number  of  GABAergic  interneuron’s  migrating  to  the  cortex.  Therefore  this 
creates  a  direct  link  between  dysfunction  of  NRG1/ERBB4  signalling  and 
defective GABA neurotransmission as seen in schizophrenia (Lewis et al., 2000; 
Benes & Berretta 2001).  In addition NRG1 signalling, particularly through type III 
NRG1, regulated neuronal acetylcholine receptor expression (Yang et al., 1998; 
Liu et al., 2001).  NMDA subunit expression is also regulated by NRG1 (Ozaki et 
al., 1997). 
 
NRG1-ERBB4  signalling  has  been  further  linked  to  regulating  NMDA 
neurotransmission.  Huang et al., (2000) reported that ERBB4 is co-localised with 
PSD95, and more recently it has been shown both NRG1 and ERBB4 bind to PSD95 
through the PDZ domain of their C termini (Fujikawa et al., 2007).  Altering the 
level  of  PSD95,  by  over-expression  or  inhibition,  enhanced  or  attenuated 
activation of ERK by means of NRG1 (Huang et al., 2000).  Furthermore, PSD95, 
ERBB4 and NMDA receptors co-localise at excitatory synapses, offering potential 
that  there  is  an  interaction  between  these  proteins  (Garcia  et  al.,  2000).  
Following  these  studies  Gu  et  al.,  (2005)  found  that  Nrg1  decreased  NMDA 
receptor currents in both cultured rat PFC neurons and rat PFC tissue slices, and 
that  this  decrease  was  attenuated  by  inhibiting  Erbb  receptors  as  well  as 
blockers of downstream molecules.  The authors suggest that the decrease in 
NMDA  receptor  currents  is  due  to  an  increase  in  receptor  internalisation.  
However, as the inhibitors were non-specific for all Erbb receptors, it is unclear 
as to which were responsible.  A direct link between NRG1/ERBB4/PSD95 and 
schizophrenia  was  made  by  Hahn  et  al.,  (2006),  who  showed  that  in  human 
schizophrenic post-mortem prefrontal cortex tissue slices there was an increase 
in PSD95-ERBB4 interaction versus tissue from unaffected individuals.  This study 
also showed that although  there were no significant changes in the levels of 
NRG1 or ERBB4 between groups, there was enhanced NRG1-ERBB4 signalling in 
the tissue from schizophrenic patients and that this enhanced signaling led to a 
greater reduction of NMDA receptor function in schizophrenia.  This observation 
directly  links  with  the  hypothesis  that  NMDA  receptor  function  is  reduced  in 29 
schizophrenia, and thus alterations in NRG1-ERBB4 signalling caused by a genetic 
deficit in schizophrenia may contribute to this hypofunction.   
 
Because of the findings that ERBB4 and NRG1 are enriched at the post synaptic 
density, in recent years the role NRG1-ERBB4 signalling may play in regulating 
synaptic  plasticity  has  been  investigated.    NRG1-ERBB4  has  been  shown 
constitutively  to  regulate  long  term  potentiation  (LTP)  (Kwon  et  al.,  2005; 
Pitcher et al., 2008) through a dopamine dependent mechanism (Kwon et al., 
2008). 
 
Another connecting factor linking NRG1’s biological function to schizophrenia is 
that NRG1 is important in the onset of puberty and sexual development (Toyoda-
Ohno et al., 1999).  Mice that have dysfunctional NRG1 signalling have delayed 
onset of puberty and reproductive development due to levels of reproductive 
hormones being reduced (Prevot et al., 2003).  As these hormones are of utmost 
importance at the time of the onset age of schizophrenia, this indicates that if 
indeed there was a link between schizophrenia and NRG1 signalling dysfunction, 
it could be viable that the neurodevelopmental abnormality is due to a change in 
levels of these critical hormones.   
 
1.9.2 Genetic  evidence  for  NRG1-ERBB4  dysfunction  in 
schizophrenia 
NRG1  and  ERBB4  are  located  at  8p21-22  and  2q33.3-34,  respectively,  regions 
highlighted as risk regions in one or both of the aforementioned meta-analyses 
of linkage studies (Badner & Gershon, 2002; Lewis et al. 2003).  There have been 
several lines of research strengthening the association of both NRG1 and ERBB4 
with  schizophrenia.      A  major  breakthrough  came  from  an  Icelandic  familial 
study when Stefansson et al. (2002) reported that there was significant linkage 
between  a  core  haplotype  of  NRG1,  consisting  of  five  single  nucleotide 
polymorphisms  (SNPs)  and  two  microsatelites,  and  schizophrenia.  This 
association between NRG1 and schizophrenia has been subsequently replicated 
in  20  case  control  studies  and  a  further  9  family  based  studies  in  multiple 
populations including those of European, American and Asian origins. However, 
there have also been several studies finding no association in these populations.  30 
A summary of all of the schizophrenia association studies carried out on NRG1 to 
date  can  be  found  on  SZGene 
(http://www.szgene.org/geneoverview.asp?geneid=311).  
 
Several association studies have strengthened the link of ERBB4 as a risk gene for 
schizophrenia.    In  a  large  case/control  study  from  the  UK  and  Ireland, 
association  was  found  between  variants  in  ERBB4  with  an  increased  risk  of 
schizophrenia,  and  this  association  may  be  through  the  interaction  with  the 
Icelandic NRG1 haplotype (Norton et al., 2006).  This association was replicated 
by two further studies (Silberberg et al., 2006; Law et al., 2007), where both 
found  association  of  three  intronic  SNPs;  rs7598440,  rs839523  and  rs707284, 
which form a core risk haplotype in exon 3 of ERBB4, in linkage disequilibrium in 
three  separate  populations.    Further  association  studies  have  positively 
associated ERBB4 with schizophrenia; however, as with NRG1, negative findings 
have also been documented.  A summary of all of the schizophrenia association 
studies  carried  out  on  ERBB4  to  date  can  be  found  on  SZGene 
(http://www.szgene.org/geneoverview.asp?geneid=273).  In addition, in a study 
of rare structural variants in schizophrenia a novel deletion in ERBB4 was found 
(Walsh et al., 2008). 
  
1.9.3 Biochemical  evidence  for  NRG1-ERBB4  dysfunction  in 
schizophrenia 
A  number  of  studies  in  human  post-mortem  brain  tissue  have  shown  an 
alteration in the expression of NRG1 in schizophrenia.  Hashimoto et al., (2004) 
found that in the human dorsolateral prefrontal cortex (DLPFC) there was a 23% 
increase in NRG1 type I mRNA in tissue from schizophrenia patients compared to 
samples from unaffected individuals,  with no alterations in expression of the 
other NRG1 subtypes.  These findings were also replicated in the hippocampus 
(Law et al., 2006); however this study did not find small decreases in subtype 
ratios  that  were  observed  by  Hashimoto  et  al.,  (2004).    More  recently  NRG1 
protein  levels  were  found  to  be  increased  selectively  within  the  PFC  of 
schizophrenia patients (Chong et al., 2008). Conversely, a study by Hahn and 
colleagues (2006), found no alteration in the expression of NRG1 in the DLPFC of 31 
post-mortem human schizophrenic samples in comparison to unaffected control 
samples.  
  
Furthermore,  there  is  also  evidence  of  altered  expression  of  ERBB4  in 
schizophrenia.  Two studies have found that ERBB4 expression in the DLPFC is 
increased  in  schizophrenia,  and  that  these  increases  are  due  to  significant 
increases in JMa and CYT1 splice isoforms (Silberberg et al., 2006; Law et al., 
2007).    Additionally  Law  et  al.,  (2007)  observed  that  this  increase  was  not 
present in the hippocampus but appeared to be specific to the PFC, and was 
associated with specific SNP allelic expression of ERBB4.  Although no changes in 
ERBB4 protein expression have been identified in one study (Hahn et al., 2006), 
the previous findings of increased ERBB4 in schizophrenia have been supported 
by two recent studies (Chong et al., 2008; Law et al., in press).  
 
It should be noted however, that several studies have suggested that Nrg1 and 
Erbb4 expression is altered in rats chronically treated with anti-psychotic drugs 
(Wang  et  al.,  2008;  Chana  et  al.,  2009),  although  these  results  were  not 
replicated  in  a  recent  study  (Law  et  al.,  in  press).    Therefore,  changes  in 
expression of these genes in schizophrenia may be partly attributable to long-
term exposure to antipsychotic treatments.   
 
1.9.4 Animal models of aberrant Nrg1-Erbb4 signalling 
In addition to the association and expression studies, animal models have also 
provided positive evidence for NRG1 and ERBB4 as functional candidate genes for 
schizophrenia.    Heterozygous  Nrg1  knockout  mice  have  shown  open  field 
hyperactivity (Gerlai et al., 2000; Stefansson et al., 2002; O’Tuathaigh et al., 
2005; Karl et al., 2007).  However, with the complexity of the NRG1 gene it is 
not surprising that this behavioural phenotype was not observed in other mouse 
models  with  mutated  Nrg1  (Rimer  et  al.,  2005;  Erlichman  et  al.,  2009).  
Sensorimotor gating has also been shown as dysfunctional in some Nrg1 mouse 
models (Stefansson et al., 2002; Chen et al., 2008; Deakin et al., 2009) but not 
in others (Erlichman et al., 2009).  Other behaviours more representative of the 
cognitive deficits have been observed in Nrg1 mouse models, such as disrupted 32 
latent  inhibition  (Rimer  et  al.,  2005),  fear  conditioning  and  novel  object 
recognition (Duffy et al., 2010).   
 
In agreement that NRG1 signalling is dysfunctional in schizophrenia, mutations in 
the  Erbb4  gene  in  mice  result  in  similar  behavioural  deficits  reflective  of 
schizophrenia.  These behaviours include hyperactivity (Stefansson et al., 2002; 
Golub  et  al.,  2004;  Wen  et  al.,  2010),  dysfunctional  pre-pulse  inhibition 
(Stefansson et al., 2002; Wen et al., 2010), social interaction (Roy et al., 2007) 
and  working  memory  deficits  (Golub  et  al.,  2004;  Wen  et  al.,  2010). 
Furthermore,  Gerlai  et  al.,  (2000)  showed  that  the  schizophrenia-related 
behavioural phenotype seen in heterozygous Erbb4 rodents was specific and not 
observed in heterozygous mutants of Erbb2 or Erbb3.  Although there has been a 
recent advance in animal modelling of these two genes, to date these studies 
have  been  limited  to  mice,  and  investigate  the  effect  of  gene  dysfunction 
throughout the entire brain.  
 
As well as behavioural changes, animal models of Nrg1 and Erbb4 have allowed 
the elucidation of other neurobiological roles of these genes within the CNS.  For 
example  Nrg1  mutant  mice  have  impaired  short  and  long  term  potentiation 
(Bjarnadottir et al., 2007) and alterations in the expression of serotonin-related 
genes  (Dean  et  al.,  2008).    Moreover  mice  with  alterations  in  Erbb4  show 
reduced  dendritic  spine  density  (Barros  et  al.,  2009)  and  altered  GABAergic 
neurotransmission (Wen et al., 2010).  
 
1.10   Regulating gene expression 
For several decades the genetic composition of rodents has been manipulated to 
allow  the  understanding  of  the  underlying  function  of  the  targeted  genes.  
Knockout  animals  have  been  successfully  bred  and  are  an  invaluable  tool  in 
scientific research; however, as in the case of Nrg1 and Erbb4 homozygous mice, 
knockout  can  be  lethal  (Gassmann  et  al.,  1995;  Seshadri  et  al.,  2010).  
Heterozygous “knockouts” of schizophrenia candidate genes are commonly bred 
where  only  one  copy  of  the  endogenous  gene  is  deleted  or  manipulated, 
permitting  the  gene  expression  to  be  significantly  reduced  but  still  allowing 
viability of the animal.  One of the major problems with knockout animals is that 33 
the  effect  of  the  mutation  is  not  regional  but  is  widespread  throughout  the 
entire body.  In the past 10 years it has come to light that there are alternative 
approaches  to  regulating  the  expression  levels  of  specific  genes.    One  such 
approach is RNA interference (RNAi).   
 
1.10.1   RNAi 
This  method  of  endogenous  gene  silencing  allows  for  double  stranded  RNA 
(dsRNA)  with  a  sequence  complementary  to  the  gene  of  interest  to  be 
introduced  into  cell  cultures  or  organisms,  where  it  recognises  and  causes 
initiation of the RNAi pathway, knocking down transcription of the target gene.  
The  RNAi  pathway  can  be  effectively  induced  in  vitro  and  in  vivo  by  the 
application of short interfering RNAs (siRNA) or by the expression of short hairpin 
RNAs (shRNA) via viral or non-viral vectors. 
 
The term RNAi was coined in 1998 by Fire and colleagues who discovered that 
injecting  dsRNA  into  the  body  or  gonad  of  nematode  Caenorhabditis  elegans 
resulted  in  silencing  of  a  gene  with  sequence  complementary  to  that  of  the 
dsRNA (Fire et al., 1998).  This phenomenon had already been observed in plants 
(Napoli  et  al.,  1990)  and  fungi  (Romano  and  Macino,  1992),  where  the 
phenomenon observed was termed posttranscriptional gene silencing (PTGS) and 
quelling, respectively.   
 
1.10.2   RNAi pathway 
When  long  dsRNA  enters  the  cell,  it  is  recognised  by  a  dsRNA-specific 
endonuclease called Dicer.  This protein cleaves the dsRNA into short dsRNAs of 
around  21  to  23  nucleotides  with  2  nucleotide  long  3  prime  (3’)  overhangs.  
These siRNAs then form a complex with several proteins including Argonaut, this 
complex is termed the RNAi silencing complex (RISC).  RISC causes unwinding of 
the ds siRNA sequence leaving one single antisense strand of complementary RNA 
bound  to  the  RISC,  which  binds  to  the  target  mRNA  in  a  sequence  specific 
manner.   
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Binding of the siRNA-RISC to the target mRNA results in the target mRNA being 
cleaved  in  the  middle  of  the  siRNA  complementary  sequence.    The  cleaved 
mRNA is recognised by the cell as foreign material and is digested by nucleases. 
mRNA cleavage prevents translation into the target protein thus silencing gene 
function (Hoyer, 2007). 
 
1.10.3   RNAi applications 
RNAi has been used as an effective tool for investigating the function of several 
schizophrenia candidate genes including DISC1, DTNBP1 and CAMK2 (Numakawa 
et al., 2004; Babcock et al., 2005; Duan et al., 2007).  Several studies have 
observed the behavioral outcome following specific knockdown of the gene of 
interest in rodents, for example behavioral testing of: nociception (Tan et al., 
2005),  auditory  processing  and  spatial  learning  (Threlkeld  et  al.,  2007), 
Alzheimer’s  related  behavioural  deficits  (Singer  et  al.,  2005),  exploratory 
behaviour (Babcock et al., 2005) and motor performance deficits (Hommel et 
al., 2003).   
 
1.11 Hypotheses and aims  
It is well established from genetic associations, expression studies, and animal 
models that NRG1 and ERBB4 are promising candidate genes for schizophrenia, 
yet  the  understanding  of  how  these  genes  function  in  distinct  regions  of  the 
brain  in  adulthood,  and  the  relation  of  these  functions  to  cognition  and 
schizophrenia-related behaviors, is poor. Therefore we sought to investigate the 
function of Nrg1-Erbb4 signalling within a distinct brain region of the adult rat, 
the mPFC, by utilising recombinant adeno-associated viral particles designed to 
knockdown the expression of Erbb4. 
We hypothesised that by knocking down expression of Erbb4 within the mPFC of 
rats,  a  brain  region  highly  associated  with  the  cognitive  deficits  of 
schizophrenia,  we  would  initiate  changes  in  schizophrenia-related  behaviours 
and in particular measures of cognition.  In addition, it was also hypothesised 
that  as  ERBB4  signals  as  part  of  a  regulated  signal  transduction  pathway, 
dysregulation of Erbb4 expression would have a knock-on effect on the levels of 35 
other  components  of  this  pathway-which  may  be  reflective  of  biochemical 
changes that are pathophysiological in schizophrenia. 
By  validating  in  vivo  viral-mediated  knockdown  of  Erbb4  and  measuring  the 
downstream effects of this knockdown on behavioural and biochemical function 
in rats, we aimed to gain a greater knowledge of the function of Erbb4 within 
the mPFC in adulthood, and overcome the spatial and temporal restrictions of 
previous  animal  models  of  Nrg1-Erbb4  dysfunction.    We  propose  that 
investigating Nrg1-Erbb4 signalling in this way will potentially lead to a greater 
understanding of how Nrg1-Erbb4 may be pathophysiological in schizophrenia, 
and could give a greater insight in to prospective therapeutic targets for treating 
the cognitive deficits of schizophrenia.   
In  addition  we  also  aimed  to  validate  a  neuronal  cell  line  NG108-15  as  a 
potential  in  vitro  model  for  investigating  Nrg1-Erbb4  signalling.    Thus  as  an 
alternative to in vivo studies this model system would allow a reduction in the 
numbers of animals required, and also enable validation of recombinant adeno-
associated viral particles to be tested on a cell line before being utilised in more 
physiologically relevant tissues.   
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2  Materials and Methods 
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2.1 Materials 
Recombinant  adeno-associated  viral  particles  (rAAVs)  were  produced  by  the 
University of Pennsylvania, Penn Vector Core facility, USA. Three types of rAAVs 
were supplied expressing either: enhanced green fluorescent protein (eGFP) only 
(rAAV.eGFP),  eGFP  and  a  hairpin  sequence  corresponding  to  rat  Erbb4 
(rAAV.shErbb4.eGFP) or eGFP and a scrambled version of the hairpin sequence 
corresponding  to  rat  Erbb4  which  does  not  correspond  to  any  known  gene 
(rAAV.scr.eGFP).    The  shErbb4  sequence  specifically  targets  a  19  nucleotide 
sequence  of  exon  28  of  the  rat  Erbb4  gene:  TGG  AGA  CCT  TCA  AGC  TTT  A 
whereas the scrambled hairpin sequence: AGT TCA TGA GTG TCA CAT C is not 
known to target any gene.  In brief, the recombinant replication deficient AAV 
vectors were produced by the co-transfection of HEK293 cells with plasmids that 
encoded 1) shRNA driven by the U6 promoter and/or eGFP driven by the CMV 
promoter 2) AAV ori proteins of serotype 2 and rep and cap proteins of serotype 
9 and 3) adenoviral “helper” proteins VA, E2a and E4.  The constructs encoded 
additional elements to aid viral packaging and transduction properties including 
the SV40 intron, woodchuck posttranscriptional regulatory element (WPRE) and 
bovine growth hormone polyadenylation signal. The viral particles were supplied 
with titres quantified as genome copies (gc)/ml. 
 
Phencyclidine hydrochloride (PCP) and d-amphetamine sulphate were purchased 
from Sigma-Aldrich, Poole, UK.  Human recombinant NRG1 was purchased from 
R&D Systems, Abingdon, UK and reconstituted in 0.1% BSA (w/v)/1xPBS.  0.5M 
ethylenediaminetetraacetic  acid  (EDTA,  C10H16N2O8)  solution  pH8  and  all  cell 
culture media (Neurobasal, Dulbecco’s Modified Eagle Medium (DMEM, 4500mg/L 
D-Glucose), Minimum Essential Medium (MEM) and Opti-MEM® I Reduced Serum 
Medium) were purchased from GIBCO®, Invitrogen, Paisley, UK.   
Several chemicals were routinely used in the preparation of buffers described 
within this section.  Table 1 lists these routinely used chemicals and the source 
from  which  they  were  purchased.    The  source  of  all  other  materials  and 
equipment used in this study is stated in brackets in the appropriate section of 
the description of methods. 38 
Ringers solution was composed by diluting one quarter-strength Ringers Solution 
tablet (Oxoid, Cambridge, UK) in 500ml distilled H2O.  10x Phosphate Buffered 
Saline  (PBS)  consisted  of a  final concentration  of  1.3M  NaCl,  70mM  Na2HPO4, 
30mM  NaH2PO4.2H2O  in  diethylpyrocarbonate  (DEPC)  treated-H2O,  and  was 
diluted to a 1x solution in distilled H2O before use.   
Table 2-1 List of chemicals routinely used and their source  
Chemical  Chemical formula  Source 
Potassium phosphate  KH2PO4  Fisher Scientific, Leicestershire, 
UK  Sulphuric acid  H2SO4 
Tris Base  C4H11NO3 
Glycerol  C3H8O3 
BDH, Poole, UK  Potassium chloride  KCl 
Sodium chloride  NaCl 
Sodium hydrogen phosphate  Na2HPO4 
Calcium chloride dihydrate  CaCl2.2H2O 
Sigma-Aldrich, Poole, UK 
D-Glucose  C6H12O6 
Magnesium sulphate 
heptahydrate 
MgSO4.7H20 
Methanol  CH3OH 
Sodium azide  NaN3 
Sodium bicarbonate  NaHCO3 
Sodium deoxycholate  C24H39NaO4 
Sodium dodecyl sulphate 
(SDS) 
CH3(CH2)11OSO3N
a 
Sodium orthovanadate  Na3VO4 
Sodium phosphate dihydrate  NaH2PO4.2H2O 
Triton® X-100  (C4H4O)nC14H22O 
Tween®-20  C58H114O26 
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2.2 Cell culture 
2.2.1 NG108-15 cell culture 
Mouse neuroblastoma x rat glioma NG108-15 cells (European Collection of Cell 
Cultures, ECACC) were maintained in DMEM (4500mg/L D-Glucose) supplemented 
with 10% (v/v) Foetal Bovine serum (FBS, Sigma-Aldrich), 100 units/ml penicillin 
and 0.1mg/ml streptomycin (Invitrogen).  Cells were grown in 25cm
2/75cm
2 flat 
bottomed plates (Corning® CoStar®, Sigma-Aldrich) and incubated at a constant 
temperature of 37˚C in air containing 5% C02.  Once cells were at approximately 
75-80% confluency they were detached from the plate surface with 0.05% (v/v) 
trypsin/ 1xEDTA (Sigma-Aldrich) and resuspended in fresh supplemented DMEM.  
The  cells  were  then  replated  into  75cm
2  plates  or  counted  using  a 
haemocytometer and plated at a specific density into 6/12 well flat bottomed 
plates (Corning® CoStar®, Sigma-Aldrich). 
 
2.2.2 Primary dissociated cortical cultures 
Dissociated  cortical  cultures  were  prepared  from  postnatal  day  1/2  rat  pups 
using  a  dissection  surface  and  surgical  equipment  sterilised  with  70%  (v/v) 
ethanol.  The pups were euthanised by a 100l intraperitoneal (i.p.) injection of 
Euthatal  (Merial,  Harlow,  UK),  followed  by  decapitation.    The  brains  were 
removed and placed in MEM that had been chilled to 4°C, the hemispheres were 
separated and the cortical tissue dissected out.  The cortical tissue was then cut 
with a size 10 scalpel blade into small pieces and incubated in 1.5mg/ml papain 
(Sigma-Aldrich)/preparation  buffer  (116mM  NaCl,  5.4mM  KCl,  26mM  NaHCO3, 
1.3mM NaH2PO4.2H2O,   1mM  MgSO4.7H2O,  1mM CaCl2.2H2O,  0.5mM EDTA pH8, 
25mM  D-Glucose)  for  30  minutes  at  37°C  to  disrupt  the  cortical  tissue 
enzymatically. 
The  cortical  tissue  was  then  removed  from  the  papain  and  transferred  into 
10mg/ml  BSA  (Sigma-Aldrich)/  preparation  buffer  pre-warmed  to  37°C.    The 
tissue  was  then  gently  triturated  using  a  plastic  Pasteur  pipette.    Next,  the 
dissociated  tissue  was  centrifuged  in  a  Sigma  2K15  refrigerated  centrifuge 
(Sigma-Aldrich) at 4°C, 2000rpm for 3 minutes, the supernatant removed and 40 
the tissue resuspended in Neurobasal® media supplemented with 2% (v/v) B27 
(Invitrogen), 100 units/ml penicillin and 0.1mg/ml streptomycin (Invitrogen) and 
2mM  L-Glutamine  (Invitrogen).    The  cells  were  then  plated  out  into  8-well 
chamber slides or 6/12 well flat bottom plates pre-coated with 4mg/ml poly-D-
lysine  (Sigma-Aldrich)/DEPC  treated  H2O.    Two  days  after  plating  half  the 
medium was removed from the wells to remove any dead cells or debris and 
replaced with fresh supplemented Neurobasal® medium. 
The cells were then left to culture for a further 4 days before any treatments 
were carried out.   
2.2.3 NRG1 stimulation 
NG108-15 cells were grown in 6-well flat bottom plates as described in section 
2.2.1 for 24 hours before their cell culture media was removed and replaced 
with serum free DMEM.  The cells were left to culture for a further 24 hours 
before  being  treated  with  vehicle  (0.1%  BSA  (w/v)/1xPBS)  or  NRG1  at  final 
concentrations ranging from 10ng/ml-200ng/ml.  The cells were then incubated 
for 10, 30 or 60 minutes at a constant temperature of 37˚C in air containing 5% 
C02 before protein was isolated (section 2.12) from the cells.  Phosphorylated 
ERBB4  levels  or  levels  of  other  proteins  of  interest  were  assessed  by  ELISA 
(section 2.14) or western blotting (section 2.13) respectively, following NRG1 
application. 
2.3 RNAi in vitro 
2.3.1 siRNA transfection 
NG108-15 cells at a density of 1.5x10
5 cells/ml were plated into 6 or 12 well flat 
bottomed  plates (Corning® CoStar®, Sigma-Aldrich) and incubated at a constant 
temperature of 37˚C in air containing 5% C02 for 24 hours before transfection 
with  siRNAs.    Lipofectamine™  RNAiMAX  transfection  reagent  (Invitrogen)  was 
allowed to come to room temperature and then diluted in Opti-MEM® I reduced 
serum  medium  according  to  the  manufacturer’s  protocol.  Custom  Silencer® 
select siRNA for mouse Erbb4 and Silencer® siRNA for Gapdh and a non-targeting 41 
sequence (Ambion, Austin, TX, USA) were diluted to required concentrations in 
Opti-MEM® I and incubated at room temperature for 5 minutes.  Equal volumes 
of diluted Lipofectamine™ RNAiMAX and diluted siRNA were incubated together 
at  room  temperature  for  20  minutes  to  allow  complexes  to  form.    Following 
incubation,  the  siRNA/transfection  reagent  complex  was  added  to  the  plated 
NG108-15  cells.    For  each  experiment  control  wells  were  included  which 
contained untreated NG108-15 cells (no transfection reagent or siRNA) and cells 
treated with transfection reagent only (mock transfection, no siRNA). Cells were 
incubated  at  a  temperature  of  37˚C  in  air  containing  5%  C02  until  further 
processing.   
The target sequence of the Erbb4 siRNA was the mouse equivalent of the hairpin 
sequence used in the shErbb4 recombinant adeno-associated viral particles.   
2.3.2 rAAV transfection 
24 hours (NG108-15 cells) or 4 days (dissociated cortical cultures) after plating, 
cells  were  treated  with  recombinant  adeno-associated  viral  particles.    Viral 
particles were allowed to thaw on ice before being diluted in the appropriate 
cell  culture  media  (DMEM  or  Neurobasal®).    The  correct  volumes  of  diluted 
particles  were  applied  directly  into  the  well  to  give  the  desired  amount  of 
genome copies (gc).  For each experiment wells were included that were treated 
with  3%  (w/v)  sucrose/PBS  to  control  for  the  effect  of  viral  particles  alone.  
Following rAAV treatment, cells were incubated at a temperature of 37˚C in air 
containing 5% C02 until further processing.   
2.4 In vivo studies 
2.4.1 Animals 
All experimental procedures were carried out in accordance with the UK Animal 
(Scientific Procedures) Act, 1986.  Male Hooded Lister rats (Harlan, UK) weighing 
260-280g  upon  arrival  were  dual  housed  at  a  maintained  temperature  and 
humidity of 20-22˚C and 55%, respectively.  Following a one week quarantine 42 
period the rats were ready to begin training or undergo surgery as described in 
the following sections.  Three individual in vivo studies were performed.   
1)  9 rats were used to study the location of injection sites and at which titre 
to use rAAV particles.  There were two treatment groups in this study: the 
first group of 3 rats received a 2l injection into the medial prefrontal 
cortex (mPFC) of vehicle (3% (w/v) sucrose/PBS) in one hemisphere and a 
2l injection of “high titre” 1x10
9gc/l rAAV.eGFP into the contralateral 
hemisphere.  The second group of 6 rats received a 2l injection into the 
mPFC of “low titre” 1x10
8gc/l rAAV.eGFP in one hemisphere and a 2l 
injection  of  “high  titre”  1x10
9gc/l  rAAV.eGFP  into  the  contralateral 
hemisphere  (surgeries  were  performed  as  described  in  section  2.4.2).  
Rats then underwent transcardial perfusion (see section 2.4.3) at 1, 3 or 8 
weeks following surgery (1 veh/high titre rat and 2 low/high titre rats at 
each time point).  The prefrontal cortex (PFC) was sectioned and then 
stained to detect the presence of multiple proteins (see section 2.15.2) 
2)  24 rats were used to study the effect of viral particles on schizophrenia-
related behaviours and to quantify mRNA and protein levels of members 
of the Nrg1-Erbb4 signalling pathway.  This study included 3 treatment 
groups of 8 rats receiving 2l bilateral injections into the mPFC of vehicle 
(3%  (w/v)  sucrose/PBS),  1x10
9gc/l  rAAV.scr.eGFP  or  1x10
9gc/l 
rAAV.shErbb4.eGFP  (surgeries  were  performed  as  described  in  section 
2.4.2).  Rats were then allowed to recover for one week before being 
tested in the open field and prepulse inhibition (PPI) behavioural tasks (as 
described in sections 2.5 and 2.6, respectively).  The tasks were repeated 
at  3  weeks  and  5  weeks  post-surgery,  after  which  the  rats  were 
euthanised  by  cervical  dislocation  and  the  PFC  tissue  collected  (see 
section 2.4.4).  The mRNA expression of genes of interest was analysed in 
this  tissue  by  qRT-PCR  (see  section  2.11),  while  protein  expression  of 
members of the Nrg1-Erbb4 signalling pathway was analysed by western 
blot and ELISA (see sections 2.13 and 2.14, respectively). 
3)  36 rats were used to study the effect of viral particles on performance in 
the 5-choice serial reaction time task.  First rats were trained in the task 43 
(see  section  2.7.3)  then  split  into  three  treatment  groups  based  on 
performance at baseline testing (see section 2.7.4).  This study included 
three treatment groups of 12 rats receiving 2l bilateral injections into 
the mPFC of vehicle (3% (w/v) sucrose/PBS), 1x10
9gc/l rAAV.scr.eGFP or 
1x10
9gc/l rAAV.shErbb4.eGFP (surgeries were performed as described in 
section 2.4.2).  At one, three and five weeks post-surgery the rats were 
tested in the task (see section 2.7.5). 
2.4.2 Stereotaxic surgery 
Rats were initially anaesthetised in a clear acrylic chamber via the inhalation of 
isoflurane  (Isoflo®,  Abbot  Animal  Health,  Maidenhead,  UK)  set  at  level  5.  
Oxygen and nitrous oxide were continuously supplied at 0.3L/min and 0.7L/min, 
respectively, throughout the duration of the surgical procedure.  Once no pedal 
or corneal reflexes were present the fur from the level of the eyes to muscular 
band of the neck was shaved using a small set of clippers.  Next, the rat was 
transferred  to  a  heat  mat  (Fine  Science  Tools,  Inc,  Cambridge,  UK)  and 
positioned in front of the stereotaxic frame (David Kopf Instruments, Tujunga, 
CA,  USA).    The  level  of  anaesthesia  was  reduced  to  3  and  the  rat  was  then 
secured into the frame using atraumatic ear bars (David Kopf Instruments), the 
incisor bar was set to 3.3mm below the ear bars to achieve flat skull position 
(Paxinos & Watson, 2007).   
The shaved area was swabbed with 70% (v/v) ethanol and a single incision was 
made with a sterile scalpel from between the eyes to between the ears.  Next, 
the skull was exposed by blunt dissection and Bregma located.  The flat skull 
position  was  confirmed  by  checking  the  dorso-ventral  (DV)  co-ordinates  of 
Bregma and Lambda were the same, if not the incisor bar was adjusted.  From 
Bregma the location of the prelimbic area of the mPFC (prL) in each hemisphere 
was identified and marked on the skull using the co-ordinates +3.2mm anterior-
posterior (AP), +/- 2mm medio-lateral (ML) (Paxinos & Watson, 2007).  Using a 
dental  drill  with  a  small  1mm  dental  burr  attached  (Royem  Scientific  Ltd, 
Bedfordshire, UK) small burr holes were made at these co-ordinates.  Next the 
5l Hamilton syringes fitted with Hamilton needles (Hamilton Company, Reno, 
NV, USA) were secured to both arms of the stereotaxic frame at an angle of 20°, 44 
and  lowered  through  the  burr  holes  to  4mm  below  the  surface  of  the  skull 
(injections were performed at an angle to reduce the chance of disturbing blood 
vessels  running  along  the  midline  of  the  brain).    2µl  bilateral  injections  of 
vehicle  (PBS/3%  (w/v)  sucrose),  rAAV.eGFP,  rAAV.scr.eGFP  or 
rAAV.shErbb4.eGFP  were  then  performed  over  a  10  minute  time  period; 
following completion of the injection the needle was left in place for a further 5 
minutes to reduce the chance of back-flow of injected material.  The needle 
was slowly retracted and the incision site closed using Vicryl™ sutures (Ethicon® 
coated Vicryl™ 4.0, Dunlop Veterinary Supplies, Dumfries, UK). 
Following surgery the rats were removed from the stereotaxic frame and placed 
single housed in one warmed paper-lined cage per rat.  The following day the 
cage bedding was changed back to sawdust and the rats were kept separate for a 
further 48 hours to prevent damage to the incision wound.  The rats’ were then 
re-housed with their cage mates from before surgery and allowed to recover for 
another  4  days  before  any  further  experimental  procedures  were  performed.  
Rats’ weights were closely monitored to check for post-surgical weight changes.   
2.4.3 Transcardial perfusion 
Rats were removed from their home cage and given a lethal i.p. injection of 
Euthatal (Merial).  Once no pedal or corneal reflexes were present the chest 
cavity  was  exposed  and  a  needle  was  inserted  into  the  left  ventricle  of  the 
heart.  The right atrium was then cut and 1x Ringer’s/PBS solution was then 
pumped into the heart until the liver had paled.  250ml freshly made 4% (w/v) 
paraformaldehyde  (PFA,  prilled  form,  Sigma-Adrich)/PBS  was  then  pumped 
through  the  heart,  at  a  slow  rate  until  complete  fixation  had  taken  place 
(approximately 30 minutes).  The whole brain was then dissected out and placed 
in 20% (w/v) sucrose/PBS and stored at 4°C for cryoprotection purposes.   
2.4.4 Cervical dislocation and PFC dissection 
Rats that were involved in studies 2 and 3 (see section 2.4.1) were euthanised by 
cervical  dislocation.      The  whole  brain  was  immediately  removed  and  brains 
from  rats  in  study  3  were  snap  frozen  in isopentane  (VWR  International  Ltd, 
Poole,  UK)  cooled  to  -42°C  on  dry  ice  and  stored  at  -80°C  until  further 45 
processing  (data  not  shown  in  thesis).    Brains  from  rats  in  study  2  were 
transferred to an ice cold tile and the whole PFC dissected out.  The PFC tissue 
was exposed by the initial removal of the olfactory bulb tissue; a coronal slice of 
approximately 1.5mm was then collected.  Diagonal cuts were then made with a 
size 10 scalpel blade through the cingulum of this coronal slice, isolating the 
prefrontal  cortical  tissue.  All  dissections  were  carried  out  by  the  same 
individual  to  minimise  variation  in  sample  collection.  Each  hemisphere  was 
individually stored in ribolyser tubes (Lysing Matrix D, Qbiogene, Cambride, UK) 
at -80°C until being used for mRNA or protein expression analysis. 
2.5 Open Field 
2.5.1 Open field apparatus 
The  open  field  test  apparatus  consisted  of  two  100cmx100cmx40cm  infra-red 
translucent acrylic plastic arenas situated on top of infra-red light boxes and 
positioned  directly  under  a  ceiling  mounted  infra-red  sensitive  camera.    The 
camera was linked to a computer in an adjacent room where distance travelled 
was analysed using EthoVision Pro, Version 3.0 video tracking software (Noldus 
Information  Technology,  The  Netherlands).    All  locomotor  experiments  were 
carried out in the same room with lighting level fixed at 190 Lux. 
2.5.2 Habituation to open field 
Rats were removed from their home cages and individually housed in the room 
where the locomotor activity was to be assessed.  The rats were habituated to 
the open field arenas for 30 minutes prior to locomotor activity assessment. 
2.5.3 Amphetamine challenge 
The effect of an amphetamine challenge on locomotor activity was assessed in 
the rats  that  had  previously  undergone  stereotaxic  surgery.     In  a  cross-over 
design rats received subcutaneous injections in the flank of vehicle (0.9% (w/v) 
saline)  or  d-amphetamine  sulphate  (1mg/kg)  on  the  first  day  of  locomotor 
testing.  The following day the alternative treatment was administered to the 46 
rats (e.g. vehicle day 1, amphetamine day 2).  In brief, the rats were removed 
from the arena following the 30 minute habituation period and administered the 
appropriate drug treatment. They were then immediately placed back into the 
same arena as where the habituation had been monitored to assess locomotor 
activity  over  a  60  minute  period.    Arenas  were  cleaned  with  disinfectant 
between rats. 
2.6 Prepulse inhibition 
2.6.1 PPI apparatus 
The effect of stereotaxic surgery on PPI was carried out using three identical 
sound-attenuated  chambers  (MED  Associates,  St.  Albans,  VT,  USA)  and  the 
magnitude  of  startle  responses  recorded  by  MED  Associates  Startle  Software 
(SOF-825).  
2.6.2 Habituation to PPI 
The day prior to the PPI testing (and at least 2 hours after locomotor activity 
assessment)  rats  were  habituated  to  the  PPI  procedure.    PPI  experimental 
procedure  was  as  follows,  rats  were  placed  into  restrainers  connected  to  a 
platform measuring the extent of movement.  The restrained rats were firstly 
acclimatised for 5 minutes to a background noise of 65 decibels (dB).  They were 
then tested in three blocks of trials, in all of which the interval between trials 
was on average 15 seconds.  Blocks 1 and 3 consisted of 6 stimulus-alone trials of 
120 dB pulses of white noise lasting 40 milliseconds (ms).  Block 2 consisted of 52 
trials 12 of which were stimulus alone trials, 10 of which were 40ms trials of 
background  noise  (no-stimulus),  and  30  of  which  were  40ms  120  dB  pulses 
preceded  by  a  20ms  lower  amplitude  "pre-pulse"    of  4,  8  or  16dB  above 
background noise 100ms before the stimulus.    Each pre-pulse intensity was 
presented 10 times in a pseudorandom order.   47 
2.6.3 PPI testing 
The next day (day 2) the rats were again exposed to this PPI procedure, this 
time the test data were acquired and PPI calculated from the trials in Block 2 for 
each pre-pulse amplitude using the following equation:  % PPI= 100x ((stimulus 
alone  response)-(pre-pulse  +  stimulus  response))/  (stimulus  alone  response).  
Startle per se was taken from the startle response to stimulus alone.    
2.7 5-choice serial reaction time task 
2.7.1 Animals 
36 Male Hooded Lister rats (Harlan) weighing 260-280g upon arrival were dual 
housed  at  a  maintained  temperature  and  humidity  of  20-22˚C  and  55%, 
respectively.  Following a one week quarantine period the rats were maintained 
at 85% of their free feeding weight by a strict daily food restriction regime of 25-
30g standard rat chow per cage.  All animals were allowed water ad libitum, 
except during the 30 minute training/testing periods.  The rats’ weights were 
monitored three times a week throughout the duration of the study (except the 
period following surgery, where the rats’ weights were monitored daily for a 
week).  This study was carried out in accordance with the UK animals (scientific 
procedures) Act 1986.   
 
2.7.2 Habituation phase 
For three days prior to the habituation to the apparatus, each rat was handled 
daily for approximately 5 minutes to allow familiarisation to being handled.  The 
day prior to the rats being introduced to the apparatus for the first time reward 
pellets (45mg, Sandown Scientific, Middlesex, UK) were placed in each cage to 
familiarise the rats to the rewards and thus prevent  neophobia.   
 
On the first day of habituation to the apparatus, the rats were placed within the 
operant box with reward pellets in the food hopper.  This purpose of this was 
two-fold  1)  To  accustom  the  rat  to  the  operant  box  and  2)  To  build  the 
association between the food hopper and reward collection.  This association 48 
was  strengthened  on  the  second  habituation  day  where  reward  pellets  were 
again available in the food hopper, in addition each aperture was baited with a 
reward pellet to build the association between nose poking and food reward.    
 
2.7.3 Training of the 5-choice serial reaction time task  
Once the rats were familiarised with the apparatus and food rewards, training of 
the task began.  The rats were placed into the operant box and a nose-poke into 
the food hopper initiated the beginning of the task.  After a 5 second inter-trial 
interval (ITI) one of the five open apertures illuminated for a fixed period of 
time (stimulus duration, SD).  Responses into this illuminated aperture during 
the SD or within a specified duration of time afterwards (limited hold, LH) the 
rat would be rewarded with a food reward and a correct response was recorded.  
Responses into an incorrect aperture during SD or LH periods would be recorded 
as an incorrect response and the rat would be punished by a time out period of 
darkness of 5 seconds.  Time out punishments were also initiated if the rat made 
an omission - no response into any aperture during SD or LH, or a premature 
response – a response in an aperture within the ITI period.  The next trial was 
again initiated by a nose-poke in the food hopper.  This was repeated for 100 
trials or 30 minutes, whichever was completed first.   
 
Training of the five choice serial reaction time task was performed on weekdays.  
Training  of  the  task  initially  involved  the  stimulus  duration  and  limited  hold 
being set at 60 seconds; these durations were gradually reduced once the rat 
had performed the task to criteria at that training level with an accuracy of 80% 
or  more  with  less  than  20%  omissions.    Each  rat  was  trained to  the  level  of 
performing  the  task  with  an  accuracy  of  80%  or  more  with  less  than  20% 
omissions with a stimulus duration of 0.6 seconds and limited hold duration of 5 
seconds.  As not all rats met criteria at level 12 at the same time, the rats that 
had  met  criteria  at  level  12  were  reduced  to  3  training  sessions  a  week  to 
prevent over-training.  The training levels are summarised in Table 2.    
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2.7.4 Baseline testing   
Once all rats had reached criteria at training level 12 their performance in 3 
variations of the 5-choice serial reaction time task was assessed.  Parameters of 
these  tasks  are  summarised  in  Table  3.    Performance  in  the  basic  task  was 
assessed on Monday, Tuesday and Thursday and an average performance over 
the three days was calculated.  Performance in the variable inter-trial interval 
task and variable stimulus duration task were assessed on Wednesday and Friday, 
respectively.  The rats were split into 3 groups of 12 with equal performance in 
all  three  task  types  based  on  the  baseline  testing  period  to  ensure  any 
differences following surgery was due to the surgical treatment carried out.   
2.7.5 Post-surgical testing 
Rats were re-tested in all three task types 1,  3 and 5 weeks post-surgery as 
described  in  Table  4.  Again,  an  average  performance  in  the  basic  task  was 
calculated  from  three  basic  task  sessions  at  each  time  point.    In  the  weeks 
between testing (weeks 2 and 4), the rats were exposed to the basic task three 
times a week to maintain their performance.   
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Table 2-2 Summary of 5-choice serial reaction time task training levels.  s, 
seconds 
Training 
level 
Stimulus 
duration (s) 
Inter-trial 
interval (s) 
Limited 
hold (s) 
Time 
out (s) 
1  60  5  60  5 
2  30  5  30  5 
3  20  5  20  5 
4  10  5  10  5 
5  5  5  5  5 
6  2.5  5  5  5 
7  1.5  5  5  5 
8  1  5  5  5 
9  0.9  5  5  5 
10  0.8  5  5  5 
11  0.7  5  5  5 
12  0.6  5  5  5 
 
Table 2-3 5-choice serial reaction time task types.  s, seconds 
Test 
type 
Stimulus 
duration (s) 
Inter-trial 
interval (s) 
Limited 
hold (s) 
Time 
out (s) 
Basic  0.5  5  5  5 
vITI  0.5  5 / 7 / 10 / 12  5  5 
vSD  0.5 / 0.4 / 0.2 / 0.1  5  5  5 
 
Table  2-4  Summary  of  5-choice  serial  reaction  time  task  testing  post-
surgery. 
Day  5-choice test type  Treatment 
0  - 
Stereotaxic injections into 
mPFC 
veh/scr.rAAV/shErbb4.rAAV 
W
E
E
K
 
1
  7  Basic  - 
8  Basic  - 
9  vITI  - 
10  Basic  - 
11  vSD  - 
W
E
E
K
 
3
  21  Basic  - 
22  Basic  - 
23  vITI  - 
24  Basic  - 
25  vSD  - 
W
E
E
K
 
5
  35  Basic  - 
36  Basic  - 
37  vITI  - 
38  Basic  - 
39  vSD  - 
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2.8 Total RNA isolation 
2.8.1 RNA isolation from cultured cells 
RNA was isolated from NG108-15 cells or dissociated cortical cultures 24 hours 
and 4 days, respectively after transfection using RNeasy mini kit (Qiagen, West 
Sussex, UK) according to the manufacturer’s protocol.  First the medium was 
removed  from  the  wells  and  cells  were  subsequently  washed  with  ice-cold 
Dulbecco’s phosphate-buffered saline (D-PBS, Invitrogen).  NG108-15 cells were 
then  detached  from  the  well  surface  using  0.05%  (w/v)  trypsin/  1xEDTA  pH8 
(Sigma-Aldrich)  which  was  inactivated  with  DMEM.    The  detached  cells  were 
transferred to an Eppendorf tube and pelleted by centrifugation in a Boeco M-24 
desktop  centrifuge  (Boeco,  Germany)  at  10,000rpm  for  5  minutes  at  room 
temperature. The cell pellet was washed with ice cold D-PBS and centrifuged 
again at 10,000rpm for 5 minutes at room temperature.   
 
The cells were lysed (either directly in the plate for dissociated cortical cultures 
or as a cell pellet for NG108-15 cells) with 350µl buffer RDD+-mercaptoethanol 
(Sigma-Aldrich).  Lysed cells were then  transferred to a ribolyser tube (Lysing 
Matrix D, Qbiogene) and disrupted mechanically for 20 seconds at 6.5g (Hybaid 
Ribolyser, Hybaid Ltd, Middlesex, UK).  An equal volume of 70% (v/v) ethanol 
was then added to the lysed cells which were transferred to an RNeasy column 
and centrifuged at 10,000rpm for 15 seconds at room temperature. The total 
RNA, bound to the column matrix was washed with the kit wash buffers and 
treated with DNase to remove any genomic DNA from the sample.  Total RNA 
was eluted from the column with 30µl RNase free water.  Table 5 summarises 
the steps involved in total RNA isolation. 
 
2.8.2 RNA isolation from PFC tissue 
Total RNA was isolated from the PFC tissue (one hemisphere) using RNeasy mini 
kit (Qiagen) as described above with the following modifications.  Tissue was 
lysed with 350µl buffer RDD+-mercaptoethanol (Sigma-Aldrich) directly in the 
ribolyser  tube  and  total  RNA  eluted  with  50l  RNase  free  H2O  (Ambion).   52 
Samples were stored at -80°C until further processing.  Table 5 summarises the 
steps involved in total RNA isolation. 
 
Table 2-5 Steps involved in total RNA isolation from cultured cells and PFC 
tissue. 
Step  Buffer  Volume  Spin cycle 
1  RW1  350µl  15s, 10,000rpm 
2  RDD+DNase I*  80µl  ----- 
3  RW1  350µl  15s, 10,000rpm 
4  RPE  500µl  15s, 10,000rpm 
5  RPE  500µl  2min, 10,000rpm 
6  -  -  1min, 13,000rpm 
7  RNase free H2O  30/50l  1min, 10,000rpm 
 
  
2.8.3 Qualification and quantification of total RNA 
1.5µl isolated total RNA was used to quantify the concentration of total RNA in 
each  sample  by  NanoDrop™  1000  (Thermo  Scientific,  Leicestershire,  UK)  and 
quality of RNA in selected samples was checked using the RNA6000 Nano Chip Kit 
on the Bioanalyser 2100 (Agilent Technologies, Berkshire, UK). 
 
2.9 First strand cDNA synthesis 
First strand cDNA was synthesised from up to 2µg total RNA isolated from NG108-
15 cells, dissociated cortical culture cells, rat PFC tissue or rat and mouse brain 
total  RNA  (Ambion)  using  SuperScript®VILO™  cDNA  synthesis  kit  (Invitrogen) 
according  to  the  manufacturers  instructions.    In  a  final  volume  of  20l  first 
strand cDNA was synthesised using up to 2g total RNA 1xVILO™ reaction mix, 
1xSuperScript®  III  reverse  transcriptase  enzyme  and  nuclease  free  water 
(Ambion).    First  strand  cDNA  was  then  generated  by  incubating  the  tube 
contents  at  25˚C  for  25  minutes,  42˚C  for  60  minutes  then  terminating  the 
reaction  at  85˚C  for  5  minutes  (Veriti™  96-well  Thermal  Cycler,  Applied 53 
Biosystems, Foster City, CA, USA).  Samples were stored at -20°C until they were 
further processed. 
2.10 Reverse  transcriptase  polymerase  chain  reaction 
(RT-PCR) 
2.10.1  Primer design 
RT-PCR primers specific for Erbb4 were purchased from Sigma-Genosys (Poole, 
UK).    Primers  were  designed  so  that  the  forward  and  reverse  primers  were 
located in different exons and therefore any product amplified from genomic 
DNA would have a much bigger amplicon length than that of a product amplified 
from intronless mRNA.  Mouse and rat Erbb4 exon sequences were taken from 
ENSEMBL (www.ensembl.org).  PCR primers were designed so that the resulting 
product amplified would include differences in sequence between rat and mouse 
Erbb4 or differences between Erbb4 isoforms.  Specificity of primers to Erbb4 
was confirmed by ensuring the primer sequences had no sequence identity to 
any  other  known  genes  using  the  Basic  Local  Alignment  Tool 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). 
Sequences of PCR primers used in this study are shown in table 6.  It also shows 
the species and isoform specificity of the primers.   
2.10.2  Polymerase chain reaction 
KOD Hot Start DNA polymerase enzyme mixture (Novagen, Merck Chemical Ltd, 
Nottingham, UK) was used to amplify up to 2g 1
st strand cDNA synthesised from 
NG108-15 cell RNA or total RNA from rat or mouse brain (Ambion).  A reaction 
mix  was  prepared containing  a  final  concentration of:  1x  KOD  Hot  Start PCR 
Buffer,  0.2mM dNTP mixture,  1mM MgSO4,  0.3M forward and reverse primer 
mix, 1-2l cDNA, 1U KOD Hot Start DNA polymerase, RNase free H2O up to 50l). 
The  reaction  mix  was  incubated  in  a  thermocycler  (Veriti™  96-well  Thermal 
Cycler, Applied Biosystems) 95°C for 2 minutes, followed by 35-40 cycles of 95°C 
for 20 seconds, 62-67°C for 10 seconds, 70°C for 10 seconds.   54 
5-20l  of  PCR  products  were  loaded  with  BlueJuice™  gel  loading  buffer 
(Invitrogen)  into  2.5%  (w/v)  agarose  gels  stained  with  0.01%  (v/v)  GelStar® 
Nucleic Acid Gel Stain (Lonza, Slough, UK) and electrophoresed at a constant 
supply  of  80volts.    Products  were  then  viewed  by  ultraviolet  light  and  size 
confirmed by comparison to 1kb Plus DNA ladder (Invitrogen).   
 
2.10.3  Extraction and purification of PCR products 
The PCR product was then carefully cut out of the gel and the DNA fragments 
were  extracted  and  purified  using  QIAquick  Gel  Extraction  Kit  (Qiagen)  as 
recommended  by  the  manufacturer’s  protocol.    In  brief,  the  product  was 
weighed and added to an eppendorf tube with 6x v/w of buffer QG, the sample 
was heated at 50˚C for 10 minutes with brief vortexing every three minutes.  
Next  an  equal  volume  to  product  weight  of  isopropanol  was  added  and  the 
sample applied to spin column in 800µl intervals and centrifuged in a Boeco M-24 
desktop centrifuge (Boeco, Germany) at 13,000rpm/1min until the entire sample 
was used.  Next 500µl buffer QG was applied to the column and centrifuged 
again  at  13,000rpm/1min.    750µl  buffer  PE  was  pipetted  directly  onto  the 
column  and  incubated  at  room  temperature  for  1  minute  before  being 
centrifuged at 13,000rpm/1min.  The purified product was then eluted from the 
spin column with 30µl RNase free H20.  A small amount of the purified product 
was then electrophoresed on a 2.5% (w/v) agarose gel to ensure correct size was 
maintained.   
 
2.10.4  PCR product sequencing and sequence analysis 
Purified  PCR  products  were  sequenced  using  3.2µM  forward  and  reverse  PCR 
primers (GeneService, Nottingham).   
 
The  resulting  sequence  of  the  PCR  product  was  analysed  by  aligning  against 
human,  mouse  and  rat  genomes  and  transcripts  (BLAST, 
http://blast.ncbi.nlm.nih.gov/Blast.cgi).   
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Table 2-6 Summary of RT-PCR primers used 
Primer ID  Primer sequence (5’-3’) 
Species 
specificity 
Isoform 
specificity 
Exon location 
FwdM1  AGGCTACATGACTCCAATGC  Mouse  All  27 
FwdR1  AGGCTACATGACTCCCATGC  Rat  All  27 
RevRM1  TTCCAGTAGTCGGGGTTGTC  Rat/Mouse  All  28 
M/R JMa/b Fwd  CCACCCTTGCCATCCAAA  Rat/Mouse  JMa/JMb  14 
M/R JMa/b Rev  CCAATGACTCCGGCTGCAATCA  Rat/Mouse  JMa/JMb  17 
M CYT1/2 Fwd  CAACATACCTCCTCCCATCTACAC  Mouse  CYT1/2  25 
M CYT1/2 Rev  GCATTCCTTGTTGTGTAGCAAA  Mouse  CYT1/2  27 56 
2.11 Quantitative real time RT-PCR (qRT-PCR) 
2.11.1  Plate set-up 
qRT-PCR was carried out using TaqMan® based chemistry (Applied Biosystems) in 
MicroAmp™  optical  96-well  reaction  plates  (Applied  Biosystems).  Each 
experimental  well  contained  up  to  125ng  1
st  strand  cDNA,  1x  TaqMan®Gene 
Expression Master Mix (Applied Biosystems), 1x Gene expression assay (Applied 
Biosystems) and RNase free H2O in a final volume of 25l.  In each experiment, 
wells containing RNase free H2O instead of template were included to monitor 
for  contamination.    Each  sample  or  non-template  control  was  performed  in 
triplicate.    The  reaction  plate  was  then  sealed  with  a  piece  of  MicroAmp™ 
optical adhesion film (Applied Biosystems) and briefly centrifuged.  cDNA was 
amplified for 40 cycles of 95˚C/2min, 95˚/15sec, 60˚/1min using an ABI PRISM® 
7000 Sequence Detection System (Applied Biosystems).  Simultaneously, levels of 
gene  expression  were  quantified  in  real  time  from  the  levels  of  excited 
fluorescent  probe  incorporated  into  the  gene  expression  assay.    The  gene 
expression assays used in this study are listed in table 7.   
Table 2-7 TaqMan
® gene expression assays used in this study 
Gene expression assay  Target gene  Species 
Rn00665492_m1  Erbb4  Rat 
Mm01256803_m1  Erbb4  Mouse 
Mm00437762_m1  -2-m  Mouse 
Mm99999915_g1  Gapdh  Mouse 
Hs99999901_s1  r18s  Human/rat/mouse 
Rn01482168_m1  Nrg1  Rat 
Rn00583646_m1  Akt1  Rat 
Mm00433800_m1  Grin1  Mouse 
 
 
2.11.2  Gene expression quantification 
The  Comparative  CT  Method  (CT  Method  -  where  the  amount  of  target  is 
normalised to an endogenous reference then expressed relative to a calibrator 
sample)  was  used  to  quantify  changes  gene  expression.    The  cycle  at  which 57 
amplification  begins  was  set  as  the  end  cycle  of  the  baseline;  this  was 
determined for each gene expression assay in each experiment performed.  The 
threshold level of fluorescence was set to 0.3 in all experiments. The cycle at 
which  the  amount  of  fluorescence  emitted  from  a  given  sample  crosses  the 
threshold value is recorded as that sample’s CT value.  The CT value of the non-
template wells was checked to ensure any amplification in experimental samples 
was  not  due  to  contamination,  the  CT  values  of  each  triplicate  of  each 
experimental sample were averaged (outliers were removed if the CT value was 
notably different from the other two replicates).   
The CT was calculated by subtracting the mean CT value of the endogenous 
control gene from the mean CT value of target gene.  For each sample, the CT 
value of a calibrator sample (e.g. untreated cells or vehicle treated rats) was 
then subtracted from the CT value of the test sample to give the CT value. 
The antilog (2
-C
T) of this value was then calculated to give a fold change in 
gene expression of the target gene. 
   
2.11.3  Gene expression assay validation 
To ensure the validity of using the Comparative CT Method (CT method), the 
amplification  efficiencies  of  the  TaqMan®  Gene  expression  Assays  used  for 
endogenous control genes and target genes in this study were tested.  To test if 
the amplification efficiencies were relatively equivalent (and therefore valid for 
CT analysis) the amplification of endogenous control genes and target genes 
was quantified over a range of dilutions of template cDNA.   
cDNA synthesised from 200ng, 100ng, 40ng, 20ng, 10ng, 4ng and 2ng of rat brain 
or mouse brain total RNA (Ambion) using the protocol described in section 2.9 
was diluted 1/2.5 in RNase free H2O (Ambion).  The experiment was set-up as 
described  in  the  previous  section  with  the  appropriate  gene  expression  assay 
being used.  The  CT was calculated for the target gene as described in the 
previous section.  An XY scatter plot was then created plotting  CT for each 
sample against template amount, a linear regression was applied to this data to 
calculate the value of the slope.  If the value of the slope is less than 0.1 then it 58 
is evident that the efficiency of the two assays tested were of equal efficiency 
and  therefore  the  CT  Method  can  be  used  to  quantify  changes  in  gene 
expression.   
2.12 Protein isolation 
2.12.1  Protein lysate isolation from cultured cells 
48 hours to 8 days post-treatment protein lysates were isolated from NG108-15 
cells  and  dissociated  cortical  cultures.    On  ice  the  cell  culture  medium  was 
removed from the wells and cells were washed with ice cold D-PBS.  125l-250l 
ice cold RIPA buffer (10mM Tris, pH7.4, 100mM NaCl, 1mM EDTA, 1mM EGTA, 
0.1% (w/v) SDS, 0.5% (w/v) sodium deoxycholate, 1% (v/v) Triton® X-100, 10% 
(v/v) glycerol)  supplemented with 10µl/ml protease inhibitor cocktail (Sigma-
Aldrich), 1mM NaF and 2mM Na3VO4 was added to each well and incubated on ice 
for 5 minutes.  Lysed cells were scraped from the wells and transferred to an ice 
cold  eppendorf  tube and centrifuged  in  a Sigma  2K15  refrigerated  centrifuge 
(Sigma-Aldrich)    at  4˚C  for  10  minutes  at  10,000rpm.    The  supernatant  was 
collected and stored at -80°C until further processing.  
2.12.2  Protein lysate isolation from PFC tissue 
The tissue from one hemisphere of the PFC, weighing 25-60mg, was allowed to 
thaw  on  ice.    Once  thawed,  500l  ice  cold  RIPA  buffer  supplemented  with 
10µl/ml protease inhibitor cocktail (Sigma-Aldrich), 1mM NaF and 2mM Na3VO4 
was added to each sample.  The tissue was then mechanically disrupted and 
cells lysed three times at 3.5g for 20 seconds (Hybaid Ribolyser).  The lysates 
were then centrifuged in a Sigma 2K15 refrigerated centrifuge (Sigma-Aldrich)  
at 4°C for 10 minutes at 10,000rpm, before the supernatant was collected and 
stored at -80°C until further processing.   
2.12.3  Protein quantification 
The  concentration  of  protein  in  each  sample  was  determined  using  the 
Bradford’s colorimetric assay (Bradford, 1976).  In brief, BSA (Sigma-Aldrich) was 59 
diluted in H2O to known concentrations of 250µg/ml, 125 µg/ml, 62.5 µg/ml and 
31.25µg/ml.  Each protein lysate sample (from cells or tissue) was diluted in H2O 
so that its concentration would be within the range of that of the BSA standards 
used (generally 1/10 or 1/20 dilution). As a standard for 0g/ml protein RIPA 
buffer  was  diluted  to  the  same  factor  as  the  samples.      10µl  of  each  BSA 
standard, lysis buffer and sample were pipetted, in triplicate, into a flat bottom 
96 well plate (Corning® CoStar®, Sigma-Aldrich).  200µl 5x Bradford’s reagent 
(BioRad, Hemel Hemstead, UK) diluted 1:4 in H2O was then added to each well 
and incubated at room temperature for 10 minutes to allow the dye to bind to 
protein and to convert colour.  
The plate was then inserted into a MRX microplate reader (Dynex Technologies, 
Ashford, UK) and the optical density of each well was measured at 630nm.  Using 
Revelation  software  v3.01  a  linear  regression  of  optical  density  vs.  protein 
concentration was calculated using the optical density value from lysis buffer to 
represent  0µg/ml  protein  and  the  serial  dilution  of  BSA  as  known  protein 
concentration standards. The concentration of each sample was then calculated 
from  the  linear  regression  curve.  The  concentration  of  each  sample  was 
multiplied by the dilution factor (10 or 20) to give the final concentration.   
2.13 Western blotting 
2.13.1  Sample preparation 
Protein lysates from cells or tissue were prepared for western blotting by the 
addition  of  4x  NuPAGE®  LDS  sample  buffer  (Invitrogen)  and  10x  NuPAGE® 
reducing agent (Invitrogen) to the lysate sample.  This was then denatured at 
70°C for 10 minutes.  As the samples were further diluted by the addition of the 
sample  buffer  and  reducing  agent,  the  protein  concentration  quantified  by 
Bradford’s assay was adjusted by multiplying by 0.65.  This final concentration 
was then used to determine the volume of sample required to give a desired 
amount  of  protein,  so  that  the  same  amount  of  protein  was  used  for  each 
sample.  60 
2.13.2  Electrophoresis 
Separation of proteins by molecular weight was achieved using 10% NuPAGE® 
Novex® Bis-Tris gels (Invitrogen).  In brief, the NuPAGE® gels were secured into 
the  XCell  SureLock®  Mini-Cell  system  (Invitrogen)  and  the  inner  and  outer 
chambers  filled  with  1x  NuPAGE®  SDS  MES  Running  Buffer  (Invitrogen).    The 
inner  chamber  was  supplemented  with  NuPAGE®  Antioxidant  (Invitrogen)  to 
maintain  the  state  of  the  protein  samples  during  electrophoresis.    Next,  the 
correct  volumes  of  the  protein  samples  were  pipetted  into  the  wells  of  the 
NuPAGE® gel, in each experiment at least one well of each gel contained 5l 
Precision Plus Kailedescope™ ladder (BioRad) as a colorimetric marker of protein 
molecular weights.   
Samples were then electrophoresed at 200V for 35 minutes or until the loading 
dye had visibly reached the bottom of the gel. 
2.13.3  Protein transfer 
Following electrophoresis, the protein samples were then transferred to PVDF 
membrane (0.2m pore size, Invitrogen).  First, sponges, PVDF membranes (pre-
wet  in  100%  Methanol)  and  filter  papers  were  pre-soaked  in  1x  NuPAGE® 
Transfer  Buffer/  10%  (v/v)  methanol/  NuPAGE®  Antioxidant.    The  gels  were 
carefully removed from their cassettes and assembled on top of a piece of pre-
wet filter paper, and the pre-wet PVDF membrane was then placed on top of the 
gel and this was topped by another piece of pre-wet filter paper.  This gel-
membrane  “sandwich”  was  then  secured  into  the  XCell  II™  Blot  Module 
(Invitrogen) with enough pre-wet sponges under the “sandwich” (on the cathode 
core) and on top of the “sandwich” (the anode core) until there was a tight fit 
and any trapped air bubbles were removed.   
The blot module was then filled with 1x NuPAGE® Transfer Buffer/ 10% (v/v) 
methanol/  NuPAGE®  Antioxidant  and  the  outer  chamber  filled  with  H2O  to 
dissipate any heat during the transfer process. A supply of 30V was then passed 
through the blot module (from the cathode core to the anode core) for 1 hour to 
transfer proteins from the gel onto the PVDF membrane.   61 
2.13.4  Antibody incubations 
Detection of proteins of interest was performed using several blocking, washes 
and antibody incubation steps. Initially, the PVDF membrane were incubated in 
TBS (20mM Tris, 137mM NaCl, pH 7.6)/ 0.1% (v/v) Tween-20/ 5% (w/v) dried milk 
powder (Marvel) for 2 hours at room temperature with agitation to block non-
specific  binding  of  antibodies.    Next,  the  membrane  was  washed  5  times  in 
TBS/0.1% (v/v) Tween®-20 for 5 minutes per wash at room temperature with 
agitation before being incubated in the appropriate primary antibody diluted to 
the correct concentration in TBS/0.1% (v/v) Tween®-20/ 5% (w/v) dried milk 
overnight at 4°C with agitation.  The list of antibodies and dilutions used are 
shown in table 8.   
The following day the membrane was washed as before, with an additional 10 
minute final wash.  The membrane was then incubated for 1-2 hours at room 
temperature  with  agitation  in  the  appropriate  HRP-conjugated  secondary 
antibody diluted to the correct concentration in TBS/0.1% (v/v) Tween®-20/ 5% 
(w/v) dried milk.  When multiple proteins of different sizes were being detected 
from the same sample two primary and, if necessary, secondary antibodies were 
used in conjunction.  When the primary antibody was already conjugated to HRP 
and  no  secondary  antibody  necessary  (e.g.  Actin-HRP  antibody),  overnight 
incubation was not necessary, the membrane was simply incubated for 1-2 hours 
at  room  temperature  in  diluted  HRP  antibody  then  processed  as  if  after 
secondary  antibody  incubation  had  taken  place.    Next,  the  membranes  were 
washed as before, with an additional 10 minute final wash. 
2.13.5  Visualisation and quantification of proteins 
The proteins were then detected using enhanced chemiluminescence (ECL) Plus 
reagents (Amersham, GE Healthcare, Buckinghamshire, UK).  The reagents were 
allowed  to  come  to  room  temperature  and  then  diluted  as  described  in  the 
manufacturer’s instructions (1ml Solution A + 50l Solution B per membrane) this 
was  then  pipetted  onto  the  PVDF  membrane  and  allowed  to  incubate  for  5 
minutes  at  room  temperature.    Next,  the  PVDF  membrane  was  wrapped  in 
Clingfilm,  ensuring  no  air  bubbles  were  present  and  taped  inside  an  x-ray 62 
cassette.  In complete darkness x-ray film (ECL Plus Hyperfilm, Amersham, GE 
Healthcare  or  Kodak)  were  placed  against  the  membrane  and  exposed  for  5 
seconds to 1 hour.  The film was then developed (X-O MAT) and protein levels in 
each sample were quantified by measuring the optical density of each sample 
(ImageJ, NIH, Bethesda, MD, USA). 
Each sample’s optical density was expressed as normalised to the optical density 
of  actin,  a  protein  for  which  the  expression  should  not  change  with  the 
treatments used in this study, and therefore can serve as a control for variations 
in the amount of sample initially loaded.  The same membrane was used several 
times to identify the levels of multiple proteins in the same sample.  To do this 
the antibodies were stripped from the membranes by incubating the membrane 
in pre-warmed stripping buffer (62.5mM Tris HCL (pH 6.7), 2% (w/v), 100mM -
mercaptoethanol) for 30 minutes at 50°C.  Membranes were then washed twice 
in TBS/0.1% (v/v) Tween-20 for 10 minutes before undergoing blocking, washes 
and antibody incubations as described above. 
2.14 Enzyme linked immunosorbant assay (ELISA) 
2.14.1  Plate preparation 
Protein levels of total ERBB4 (tERBB4) and phosphorylated ERBB4 (pERBB4) were 
quantified using DuoSet® IC Human total-ERBB4 ELISA and DuoSet® IC Human 
Phospho-ERBB4 ELISA (R&D Systems).  Firstly, wells of high bind polystyrene flat 
bottom  96-well  microplates  (R&D  Systems)  were  coated  with  100l  1g/ml 
(pERBB4)  or  4g/ml  (tERBB4)  capture  antibody  diluted  in  PBS  (137mM  NaCl, 
2.7mM KCl, 8.1mM Na2HPO4, 1.5mM KH2PO4, pH 7.2) overnight at 4°C.   
2.14.2  Sample and Standard application 
The following day wells were washed five times with wash buffer (PBS, 0.05% 
(v/v)  Tween®-20)  then  non-specific  antibody  binding  was  blocked  with  300l 
blocking buffer (PBS, 1% (w/v) BSA, 0.05% (w/v) NaN3 pH 7.2) for 2 hours at 
room temperature after which the wells were washed again (as before). Next, 
Human tERBB4 standards of known concentration (31.25pg/ml-4000pg/ml) and 63 
Human  pERBB4  standards  of  known  concentrations  (46.875pg/ml-6000pg/ml) 
were diluted in IC Diluent#12 (R&D Systems) and pipetted in triplicate into the 
96-well plate.  NG108-15 cell, dissociated cortical cell or rat PFC tissue lysates 
were diluted 1/2 (for tERBB4 ELISA) or 1/4 (for pERBB4 ELISA) in IC Diluent#12 
(R&D  Systems)  and  pipetted in duplicate or  triplicate  into the 96-well  plate.  
Standards and samples were incubated at room temperature for 2 hours.  For 
each experiment triplicates of RIPA buffer diluted to the same factor as samples 
were included to serve as a 0pg/ml standard.  Wells including capture antibody 
only or detection antibody only were included to ensure specificity of antibodies 
(no optical densities were observed with these treatments).   
2.14.3  Antibody incubations 
The  wells  were  again  washed  (as  before)  and  then  incubated  with  detection 
antibody (1x phosphotyrosine-HRP for pERBB4 ELISA or 1g/ml tERBB4 detection 
antibody)  diluted  in  IC  Diluent#14  (R&D  Systems)  for  2  hours  at  room 
temperature.  For the tERBB4 ELISA an additional antibody incubation step of 20 
minutes  in  1x  streptavidin-HRP  diluted  in  IC  Diluent#14  was  required  as  the 
detection antibody used in this ELISA was not HRP-conjugated.   
2.14.4  Detection and quantification of proteins 
Following antibody incubations the wells underwent a final wash step (as before) 
then  were  incubated  in  Substrate  solution  (1:1  Solution  A  :  Solution  B,  R&D 
Systems)  for  30  minutes  at  room  temperature.    The  enzymatic  reaction  was 
stopped by the addition of 50% (v/v) H2SO4 to each well. The optical density of 
each well was measured on a MRX microplate reader (Dynex Technologies) at 
450nM.  A standard curve of the standards was generated plotting mean optical 
of each standard against standard concentration (pg/ml).  The levels of tERBB4 
or pERBB4 in the samples were then determined from this using linear regression 
analysis. 64 
2.15 Immuno-fluorescent staining 
2.15.1  Immuno-fluorescent staining in cultured cells 
Cell culture media was removed from the wells of an 8-well chamber slide and 
cells were fixed in ice-cold 4% (w/v) PFA (prilled form, Sigma-Aldrich)/PBS for 20 
minutes  at  4°C.    Following  fixation,  cells  were  washed  twice  in  PBS  for  3 
minutes  at  room  temperature  before  being  permeablised  in  PBS/0.5%  (v/v) 
Triton® X-100.  Non-specific antibody binding was then prevented by incubating 
the cells in blocking buffer (PBS/15% (v/v) donkey serum) for 1 hour at room 
temperature.  The cells were then incubated in the correct primary antibody 
diluted in PBS/3% (v/v) donkey serum/0.5% (v/v) Triton-X-100 overnight at 4°C.   
The  following  day,  the  cells  were  washed  three  times  in  PBS  before  being 
incubated  with  the  appropriate  Alexa-Fluor  conjugated  secondary  antibody 
diluted in 1xPBS/5% (v/v) donkey serum for 1 hour at room temperature.  The 
cells were again washed three times in PBS, the chamber removed from the slide 
and a coverslip being applied with VECTASHIELD® Mounting Medium with DAPI 
(Vector Laboratories, Burlingame, CA, USA).   
Immunofluorescent staining was then observed using the correct filter on a Nikon 
Eclipse  E600  epifluorescent  microscope  and  images  were  taken  using a  Nikon 
CoolPix 4500 camera mounted to the microscope.   
2.15.2  Immuno-fluorescent staining in PFC brain sections 
Once the brains from the transcardially perfused rats had sunk to the bottom of 
the  20%  (w/v)  sucrose/PBS  solution  they  were  believed  to  be  cryoprotected.   
The brains were then snap frozen in isopentane (VWR International Ltd) cooled 
to -42°C on dry ice, then placed in the cryostat (Leica CM1850) to equilibrate to 
-20°C.  The brains were then cut into 20µm sections and mounted onto poly-L-
lysine  (0.01%,  Sigma-Aldrich)  coated  slides.    Using  a  hydrophobic  barrier  pen 
(Vector Laboratories), boundaries were drawn around each brain section.   
Firstly the sections were dehydrated in 50% (v/v) ethanol for 30 minutes at room 
temperature.  Next sections underwent three 10 minute washes in wash buffer 65 
(2.5mM NaH2PO4.2H2O, 7mM Na2HPO4 , 0.3M NaCl) before being incubated in the 
correct  primary  antibody  diluted  in  wash  buffer/0.3%  (v/v)  Triton®-  X-100 
overnight at 4°C.  The next day the sections were washed again 3 times for 10 
minutes in wash buffer before being incubated in the appropriate Alexa Fluor 
conjugated secondary antibody diluted in buffer/0.3% (v/v) Triton®- X-100 for 
two  hours  at  room  temperature.    For  co-localisation  studies  combinations  of 
primary and secondary antibodies were used together in the incubation stages, 
ensuring  that  the  antibodies  were  raised  in  different  species.    The  list  of 
antibodies used is shown in table 8.  After another series of washes (as before) 
the  sections  were  allowed  to  air-dry  then  coverslips  were  mounted  onto  the 
slides with VECTASHIELD® Mounting Medium with DAPI. 
Immunofluorescent staining was then observed using the correct filter on a Nikon 
Eclipse  E600  epifluorescent  microscope  and  images  were  taken  using a  Nikon 
CoolPix 4500 camera mounted to the microscope.  For co-localisation studies 
further  images  were  taken  using  a  Leica  TCS  S-P5  laser  scanning  confocal 
microscope.  Images were merged using ImageJ (NIH, Bethesda, MD, USA). 
2.16 Statistical analysis 
All statistical analyses were carried out using Minitab version 13.1.  For data to 
be assessed by parametric statistical tests (ANOVA, followed by Tukey’s post hoc 
pair-wise comparisons  tests  or  Student’s  t-test)  all  data  sets  were tested  for 
normal distribution using the Anderson Darling normality test.  Where data were 
not  normally  distributed  they  were  transformed  by  Box-Cox  transformation.  
Non-parametric  tests  were  utilised  where  transformed  data  did  not  result  in 
normal  distribution  (Mann-Whitney  or  Wilcoxon-rank  tests).    Statistical 
significance was set at p<0.05.  Data were expressed as mean ± standard error of 
the mean (SEM).   
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Table  2-8  Summary  of  antibodies  and  dilutions  used  for 
immunofluorescence and western blotting experiments 
Antibody  Supplier  Cat No.  Species  Dilution 
Primary antibodies         
         
-Erbb4  Santa Cruz  sc-283  Rabbit  1:1000 
-Nrg1  Santa Cruz  sc-348  Rabbit  1:1000 
-Actin-HRP  Santa Cruz  sc-1616  Rabbit  1:2000-1:7000 
-GFP  Serotec  4745-1051  Sheep  1:1000-1:3000 
-GFAP  Autogen Bioclear  AB-J158  Mouse  1:400-1:500 
-Akt  Cell Signalling  #9272  Rabbit  1:1000 
-phospho-Akt  Cell Signalling  #4058  Rabbit  1:1000 
-Erk  Cell Signalling  #4696  Mouse  1:2000 
-phospho-Erk  Cell Signalling  #4377  Rabbit  1:1000 
-N200  Sigma-Aldrich  N 0142  Mouse  1:400 
-Parvalbumin  Swant  PV 235  Mouse  1:5000 
         
Secondary 
antibodies         
         
-sheep-HRP  Santa Cruz  sc-2473  Donkey  1:1000-1:2000 
-mouse-HRP  Santa Cruz  sc-2306  Donkey  1:1000-1:2000 
- rabbit-HRP  Santa Cruz  sc-2305  Donkey  1:1000-1:2000 
Alexa Fluor
® 488 -
sheep IgG 
Invitrogen 
Molecular 
Probes® 
 
A-11015  Donkey  1:1000 
Alexa Fluor
® 594 -
mouse IgG 
Invitrogen 
Molecular 
Probes® 
A-11005  Goat  1:200 
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3  Validation of the NG108-15 cell line as a tool for 
researching Erbb4 
 
 
 
 
 
 
 
 
 
 
 68 
3.1 Introduction 
3.1.1 Neuronal cell lines as a tool for investigating CNS systems 
Cell lines can serve as effective models for investigating several aspects of the 
CNS, such as researching pharmacological responses to new therapeutics before 
in  vivo  testing  and  exploring  mechanisms  of  receptor  mediated  signalling.  
Although  it  is  unlikely  cell  lines  encapsulate  the  entire  complex  neuronal 
network  system  of  the  CNS,  they  are  useful  in  determining  roles  of  specific 
proteins in different cell types by utilising cell lines of different cellular origins; 
for  example  C6  and  JS1  cells  for  investigating  glial  cells  or  Schwann  cells, 
respectively.  Moreover,  the  use  of  cell  lines  can  help  reduce  the  amount  of 
animals required for neuroscience research.   
In addition, neuronal-like cell lines are generally easy to maintain  in culture, 
and  although  optimisation  is  required,  they  can  be  manipulated  more  simply 
than primary cultured cells.  Much research has been performed in neuronal and 
non-neuronal cell lines to investigate proteins potentially involved in neuronal 
disorders.  However, many studies over-express genes of interest in these cell 
lines  without  prior  determination  of  whether  the  gene  is  endogenously 
expressed.    It  is  important  to  characterise  which  genes/proteins  are 
endogenously expressed in neuronal cell lines,  as this will allow the study of 
processes that may be involved in disorders of the CNS in an environment where 
the cell has complete control over the expression of all components involved.  
Manipulation of gene expression i.e. by over-expression systems, may thus take 
over the endogenous control the cell has over these components of the process 
being investigated, and may lead to potentially unnatural interactions.   
3.1.2 NG108-15 cell line 
The NG108-15 cell line is a hybrid clonal cell line formed by Sendai virus-induced 
fusion of the mouse neuroblastoma cell clone N18TG-2 and the rat glioma cell 
clone C6 BV-1 (Klee & Nirenberg, 1974).  This cell line has been widely used to 
investigate many aspects of the CNS and is known to express genes/proteins of 
multiple neuronal signalling systems endogenously.  A large proportion of studies 69 
utilising  NG108-15  cells  have  been  to  research  the  renin-angiotensin  system 
(Gendron  et  al.,  2003;  Kilian  et  al.,  2008)  and  -opioid  receptor  signalling 
(Eisinger & Ammer, 2011).  
NG108-15 cells express multiple important neurotransmitter receptors including 
5HT3 receptors (Emerit et al., 1995; Matsushima et al., 2010), NMDA receptors 
(Ohkuma  et  al.,  1994),  glutamate  receptors  (Tanaka  et  al.,  2010)  and 
acetylcholine  receptors  (both  muscarinic  and  nicotinic)  (Hamprecht,  1985).  
NG108-15  cells  also  express  the  inhibitory  neurotransmitter  GABA  and  its 
synthesising enzyme GAD (Searles & Singer, 1988).  Since NG108-15 cells express 
aspects of these neurotransmitter systems,  which have also been linked with 
Nrg1-Erbb4  function,  it  is  likely  that  this  signalling  pathway  is  expressed  in 
NG108-15 cells but this hypothesis requires confirmation.  
 
 
 
 
 
 
 
 
 
 70 
3.2 Aims 
The aims of this chapter were to validate the neuronal cell line NG108-15, as a 
potential tool for exploring the Nrg1-Erbb4 signalling pathway by investigating 
the mRNA and protein expression of Erbb4 in this cell line, and to determine if 
Erbb4 levels could be altered by siRNA mediated RNA interference and to study 
the consequences of such knockdown.  In addition, the functionality of the Erbb4 
receptors in NG108-15 cells was studied to explore if Nrg1-Erbb4 signalling in this 
cell line was a relevant model of Nrg1-Erbb4 signalling within the CNS.   
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3.3 Results 
3.3.1 Expression of Erbb4 mRNA in NG108-15 cells 
RT-PCR carried out on total RNA isolated from NG108-15 cells (sections 2.8.1 and 
2.9)  confirmed  that  Erbb4  mRNA  is  expressed  in  this  cell  line  (Figure  3.1).  
Species-specific PCR primers were utilised (section 2.10.2) as the genome of this 
cell  line  contains  rat  and  mouse  chromosomes  and  therefore  potentially  rat 
and/or mouse Erbb4 transcripts.  An amplicon of the predicted molecular weight 
(approximately 300bp) was obtained using a mouse specific forward PCR primer 
(FwdM1, section 2.10.1) in combination with a universal reverse primer (RevRM1, 
section 2.10.1) (Figure 3.1, lane 3) indicating that mouse Erbb4 transcripts are 
expressed  in  this  cell  line.  However  no  amplicons  were  obtained  using  a  rat 
specific  forward  PCR  primer  (FwdR1,  section  2.10.1)  in  combination  with  a 
universal reverse primer (RevRM1, section 2.10.1) (Figure 3.1, lane 5).  These 
data suggest that the Erbb4 transcripts in NG108-15 cells are of mouse origin. 
To  confirm  that  the  NG108-15  Erbb4  PCR  product  obtained  with  the  mouse 
specific  primers  (Figure  3.1,  lane  3)  was  indeed  derived  from  mouse 
chromosomes in the hybrid cell line, the DNA sequence of this amplicon was 
obtained (sections 2.10.3 and 2.10.4).  Bioinformatic analyses (section 2.10.4) 
showed that there was 100% sequence identity with this amplicon and mouse 
Erbb4 mRNA (Figure 3.2A) and that no matches were found with any other mouse 
or rat transcripts or genomic DNA or sequences from other species, suggesting 
that this Erbb4 PCR product was indeed of mouse origin.  Furthermore, when the 
sequence  of  the  PCR  product  was  aligned  with  the  288bp  rat  Erbb4  mRNA 
sequence  there  were  multiple  differences  between  the  two  sequences, 
confirming that the sequenced amplicon was not of rat origin (Figure 3.2B).  
These data showed that Erbb4 mRNA was expressed in the NG108-15 cell line 
and that it was likely to be solely of mouse origin. However the lack of a rat PCR 
product could be a technical artefact and therefore further PCR analyses were 
carried out.  RT-PCR was performed on total RNA isolated from rat and mouse 
brains (sections 2.10.2) using the rat specific primers (FwdR1 and RevRM1). An 
amplicon of the correct molecular weight (approximately 300bp) was obtained 72 
from  the rat  brain  cDNA  (Figure  3.3A,  lane  4),  confirming  that  the technical 
conditions employed could amplify a rat Erbb4 transcript if it was present in the 
NG108-15 sample.  However, no amplicon was obtained from the mouse brain 
cDNA using the rat primers suggesting that the rat primers were indeed specific 
for the rat Erbb4 mRNA (Figure 3.3A, lane 3). The species specificity of the PCR 
primers was confirmed when the mouse specific primers (FwdM1 and RevRM1) 
were used for RT-PCR on total RNA isolated from rat and mouse brains (sections 
2.10.2).  The mouse specific primers used to amplify an Erbb4 product in NG108-
15 cells (Figure 3.1, lane 3) were able to generate an amplicon from mouse brain 
cDNA (Figure 3.3B, lane 3) but not from rat brain cDNA (Figure 3.3B, lane 4). 
Moreover,  analysis  of  the  DNA  sequence  of  the  PCR  product  produced  from 
amplifying  rat  brain cDNA  with  the  rat  specific  primers  (FwdR1  and  RevRM1) 
showed 100% sequence identity with rat Erbb4 mRNA (Figure 3.4A).  In addition 
there were no 100% identity matches with transcripts or genomic DNA from other 
species  with.    Furthermore,  when  the  sequence  of  the  rat  brain  cDNA  PCR 
product  was  aligned  with  mouse  Erbb4  mRNA  sequence  there  were  multiple 
differences in the nucleotide sequence (Figure 3.4B) whereas alignment of the 
PCR  product  with  the  expected  rat  Erbb4  amplicon  sequence  showed  100% 
sequence identity.  
In  addition  as  the  correct  molecular  weight  of  the  expected  amplicon  was 
achieved in all reactions, along with the 100% sequence identity of mouse Erbb4 
in NG108-15 PCR products and rat Erbb4 in rat brain PCR products and that the 
resultant sequences of these PCR products showed two exons of Erbb4 confirm 
that the PCR products are very unlikely to be due to a genomic artefact.  In 
summary, these data show that Erbb4 is expressed in the NG108-15 cell line and 
despite these cells being a hybridoma of rat and mouse chromosomes, Erbb4 is 
expressed from mouse chromosomes only.  
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Figure 3.1  Expression of Erbb4 in NG108-15 cells.  Analysis of 30% (v/v) of 
RT-PCR  products  in  a  2.5%  (w/v)  agarose  gel  visualised  by  ethidium  bromide 
DNA stain under ultraviolet light. The molecular weight marker (lane 1) is 0.1g 
1Kb+ DNA ladder (Invitrogen).  Lanes 2 and 3 contain products from using mouse 
specific primers (mouse exon 27 forward primer FwdM1 and exon 28 rat/mouse 
universal primer) in water (lane 2) and NG108-15 cell cDNA (lane 3).  Lanes 4 and 
5  contain  products from  using  rat  specific primers (rat  exon  27  forward  primer 
FwdR1 and exon 28 rat/mouse universal primer) in water (lane 4) and NG108-15 
cell cDNA (lane 5). There are no amplicons from reactions using  water as the 
template or using rat specific primers. A band of approximately 300bp, consistent 
with the predicted molecular weight, was obtained with mouse specific primers in 
cDNA from the NG108-15 cells. 
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 NG Product         1                                                ATC      3 
                                                                    ||| 
 Rat Erbb4          1 AGGCTACATGACTCCCATGCATGACAAGCCAAAACAAGAATATCTGAATC     50 
 
 NG Product         4 CTGTGGAAGAGAACCCTTTTGTGTCCCGAAGGAAGAATGGAGATCTTCAA     53 
                      ||||||||||||||||||||||||||||.||||||||||||||.|||||| 
 Rat Erbb4         51 CTGTGGAAGAGAACCCTTTTGTGTCCCGGAGGAAGAATGGAGACCTTCAA    100 
 
 NG Product        54 GCTTTAGATAATCCGGAGTATCACAGTGCTTCCAGCGGTCCACCCAAGGC    103 
                      ||||||||||||||.|||||||||||.||||||||||||||.|||||||| 
 Rat Erbb4        101 GCTTTAGATAATCCAGAGTATCACAGCGCTTCCAGCGGTCCCCCCAAGGC    150 
 
 NG Product       104 GGAGGATGAATACGTGAATGAGCCTCTATACCTCAACACCTTCGCCAATG    153 
                      .||||||||.||||||||||||||.||.||.||||||||||||.||||.| 
 Rat Erbb4        151 AGAGGATGAGTACGTGAATGAGCCCCTTTATCTCAACACCTTCACCAACG    200 
 
 NG Product       154 CCTTGGGGAGTGCAGAGTACATGAAAAACAGTGTACTGTCTGTGCCAGAG    203 
                      |||||||.|.|||||||||||||||||||||..||||||||||||||||| 
 Rat Erbb4        201 CCTTGGGAAATGCAGAGTACATGAAAAACAGCTTACTGTCTGTGCCAGAG    250 
 
 NG Product       204 AAAGCCAAGAAAGCATTTGACAACCCCGACTACTGGAA                241 
                      ||||||||||||||||||||||||||||||||||||||  
 Rat Erbb4        251 AAAGCCAAGAAAGCATTTGACAACCCCGACTACTGGAA                288 
 
Figure 3.2  Sequence analyses of the NG108-15 cell mouse specific Erbb4 
PCR product.  (A) BLAST analysis (section 2.10.4) of the DNA sequence of the 
Erbb4  amplicon  generated  with  mouse  specific  PCR  primers  (section  2.10.1). 
Query  =  NG108-15  cell  PCR  product  sequence,  Sbjct  =  mouse  Erbb4  mRNA 
sequence.    The  alignment  of  the  Erbb4  PCR  product  sequence  (Query)  with 
mouse Erbb4 mRNA (Sbjct) shows 100% sequence identity, confirming that this 
amplicon is of mouse origin.   Gene name and sequence identity are highlighted 
by red boxes.  (B) Alignment of the DNA sequence of the Erbb4 amplicon (NG 
product)  generated  with  mouse  specific  PCR  primers  with  rat  Erbb4  mRNA 
sequence.  Sequence identity was 93% indicating that this was not a rat transcript. 
The nucleotides that did not match between the two sequences are highlighted in 
red. 75 
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Figure 3.3 Validation of mouse and rat Erbb4 PCR primers.  Analysis of 10% 
(v/v)  of  RT-PCR  products  in  a  2.5%  (w/v)  agarose  gel  visualised  by  ethidium 
bromide DNA stain under ultraviolet light. The molecular weight marker (lane 1) is 
0.1g 1Kb+ DNA ladder (Invitrogen). (A) Lanes 2, 3 and 4 contain products from 
using  rat  specific  primers  (rat  exon  27  forward  primer  FwdR1  and  exon  28 
rat/mouse universal primer) in water (lane 2), mouse brain cDNA (lane 3) and rat 
brain cDNA (lane 4).  (B)  Lanes 2,3 and 4 contain products from using mouse 
specific primers (mouse exon 27 forward primer FwdM1 and exon 28 rat/mouse 
universal primer) in water (lane 2), mouse brain cDNA (lane 3) and rat brain cDNA 
(lane 4). There are no amplicons from reactions using water as the template or 
using rat specific primers with mouse brain cDNA or using mouse specific primers 
with  rat  specific  primers.    A  band  of  approximately  300bp,  consistent  with  the 
predicted molecular weight, was obtained with mouse specific primers in cDNA 
from mouse brain and with rat specific primers in cDNA from rat brain. 
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B 
Rat product         GAACCCTTTTGTGTCCCGGAGGAAGAATGGAGACCTTCAAGCTTTAGATAATCCAGAGTA 77 
 
Mouse Erbb4         GAACCCTTTTGTGTCCCGAAGGAAGAATGGAGATCTTCAAGCTTTAGATAATCCGGAGTA 120 
                    ****************** ************** ******************** ***** 
Rat product         TCACAGCGCTTCCAGCGGTCCCCCCAAGGCAGAGGATGAGTACGTGAATGAGCCCCTTTA 137 
 
Mouse Erbb4         TCACAGTGCTTCCAGCGGTCCACCCAAGGCGGAGGATGAATACGTGAATGAGCCTCTATA 180 
                    ****** ************** ******** ******** ************** ** ** 
 
Rat product         TCTCAACACCTTCACCAACGCCTTGGGAAATGCAGAGTACATGAAAAACAGCTTACTGTC 197 
 
Mouse Erbb4         CCTCAACACCTTCGCCAATGCCTTGGGGAGTGCAGAGTACATGAAAAACAGTGTACTGTC 240 
                     ************ **** ******** * *********************  ******* 
 
Rat product         TGTGCCAGAGAAAGCCAAGAAAGCATTTGACAACCCCGACTACTGGAA             245 
 
Mouse Erbb4         TGTGCCAGAGAAAGCCAAGAAAGCATTTGACAACCCCGACTACTGGAA             286 
                    ************************************************   
 
Figure 3.4 Sequence analyses of rat brain PCR product.  (A) BLAST analysis 
(section 2.10.4) of the DNA sequence of the Erbb4 amplicon generated with rat 
specific PCR primers (section 2.10.1).  Query = rat brain PCR product sequence, 
Sbjct = rat Erbb4 mRNA sequence.  The alignment of the rat brain PCR product 
sequence (Query) with rat Erbb4 mRNA (Sbjct) shows 100% sequence identity, 
confirming that this amplicon is of rat origin.   Gene name and sequence identity 
are highlighted by red boxes.  (B) Alignment of the DNA sequence of the Erbb4 
amplicon (rat brain product) generated with rat specific PCR primers with mouse 
Erbb4 mRNA sequence.  Sequence identity was 93% indicating that this was not a 
mouse transcript. The nucleotides that did not match between the two sequences 
are highlighted in red. 
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3.3.2 Expression of Erbb4 isoforms in NG108-15 cells 
The splicing pattern of Erbb4 is complex (Elenius  et al., 1997; Elenius et al., 
1999; Tan et al., 2010) and so having confirmed that Erbb4 is expressed in the 
NG108-15  cells,  it  was  necessary  to  determine  which  splice  variants  are 
expressed.  Isoform  specific  primers  were  designed  that  would  distinguish 
between  the  JMa  and  JMb  isoforms  and  also  between  the  CYT1  and  CYT2 
isoforms (JMa/b isoforms: exon 14, M/R JMa/b Fwd primer and exon 17, M/R 
JMa/b Rev primer and CYT1/2 isoforms: exon 25, M CYT1/2 Fwd and exon 27, M 
CYT1/2 Rev).   
An  amplicon  of  the  predicted  molecular  weight  for  the  Erbb4  JMa  isoform 
(approximately 140bp) was detected in the NG108-15 cells (Figure 3.5A, lane 3) 
but  there  was  no  amplicon  for  the  predicted  molecular  weight  of  the  JMb 
isoform. The presence of a product with an amplicon of 140bp but not 100bp in 
the NG108-15 cell sample indicates that NG108-15 cells express the mouse JMa 
Erbb4 isoform only.  The RT-PCR conditions were tested using total RNA isolated 
from  mouse  brain,  in  which  Erbb4  seems  to  be  more  highly  expressed.  
Amplicons were obtained for JMa (140bp) and JMb (100bp) in the mouse brain 
cDNA (Figure 3.5B, lane 3), indicating that if the JMb Isoform is expressed in the 
NG108-15 cells it would have been detected.  
Amplicons  of  the  predicted  molecular  weight  of  the  Erbb4  CYT1  and  CYT2 
isoforms (approximately 100 bp and 150bp, respectively) were detected in the 
NG108-15 cell cDNA (Figure 3.6A, lane 4).  Again, the RT-PCR conditions were 
tested using total RNA isolated from mouse brain, in which Erbb4 seems to be 
more highly expressed.  Amplicons were obtained for both Erbb4 CYT1 and CYT2 
isoforms  (Figure  3.6B,  lane  3).    The  presence  of  products  with  amplicons  of 
100bp  and  150bp  in  the  NG108-15  cell  sample  indicates  that  NG108-15  cells 
express the mouse CYT1 and CYT2 Erbb4 isoforms.     
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Figure 3.5 Investigation of Erbb4 JMa/JMb isoform expression in NG108-15 
cells.  Analysis of RT-PCR products in a 2.5% (w/v) agarose gel visualised by 
ethidium bromide DNA stain under ultraviolet light. The molecular weight marker 
(lane 1) is 0.1g 1Kb+ DNA ladder (Invitrogen). (A) Lanes 2, and 3 contain 40% 
(v/v) PCR products from using primers designed to detect JMa/JMb isoforms with 
expected amplicon lengths of 135bp and 103bp, respectively (mouse/rat exon 14 
forward primer M/R JMa/b Fwd and mouse/rat exon 17 reverse primer JMa/b Rev) 
in water (lane 2), and NG108-15 cell cDNA (lane 3).  (B)  Lanes 2, and 3 contain 
20% (v/v) PCR products from using primers designed to detect JMa/JMb isoforms 
with expected amplicon lengths of 135bp and 103bp, respectively (mouse/rat exon 
14 forward primer M/R JMa/b Fwd and mouse/rat exon 17 reverse primer JMa/b 
Rev) in water (lane 2), and mouse brain cDNA (lane 3).  There are no amplicons 
from  reactions  using  water  as  the  template.    A  band  of  approximately  140bp, 
consistent with the predicted molecular weight of JMa, was obtained with JMa/b 
specific primers in cDNA from NG108-15 cell, two bands of approximately 100bp 
and 140bp, consistent with the predicted molecular weight of JMa and JMb, were 
obtained with JMa/b specific primers in cDNA from mouse brain. 
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Figure  3.6  Investigation  of  CYT1/2  isoform  expression  in  NG108-15  cells.  
Analysis of RT-PCR products in a 2.5% (w/v) agarose gel visualised by ethidium 
bromide DNA stain under ultraviolet light. The molecular weight marker (lane 1) is 
0.1g 1Kb+ DNA ladder (Invitrogen). (A) Lanes 2, and 4 contain 40% (v/v) PCR 
products  from  using  primers  designed  to  detect  CYT1/CYT2  isoforms  with 
expected  amplicon  lengths  of  149bp  and  101bp,  respectively  (mouse  exon  25 
forward primer M CYT1/2 Fwd and mouse exon 27 reverse primer M CYT1/2 Rev) 
in water (lane 2), and NG108-15 cell cDNA (lane 4).  (B)  Lanes 2, and 3 contain 
20%  (v/v)  PCR  products  from  using  primers  designed  to  detect  CYT1/CYT2 
isoforms with expected amplicon lengths of 149bp and 101bp, respectively (mouse 
exon 25 forward primer M CYT1/2 Fwd and mouse exon 27 reverse primer M 
CYT1/2 Rev) in water (lane 2), and mouse brain cDNA (lane 3).  There are no 
amplicons from reactions using water as the template.  Bands of approximately 
100bp and 150bp, consistent with the predicted molecular weight of CYT1 and 
CYT2, were obtained with CYT1/2 specific primers in cDNA from NG108-15 cell 
and cDNA from mouse brain. 
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3.3.3 Expression of Erbb4 and Nrg1 protein in NG108-15 cells 
Western  blotting  was  carried  out  to  determine  whether  the  Erbb4  mRNA  is 
translated to protein and whether Nrg1 protein is expressed in NG108-15 cells 
(Section 2.13) and also to determine if expression of these proteins is similar to 
other neural tissues.   
Erbb4 immunoreactive bands of approximately 180kDa, 150kDa, and 60kDa were 
observed in the NG108-15 cell sample.  All of these immunoreactive bands were 
also present in rat and mouse brain samples with faint bands at 100kDa also 
present (Figure 3.7).  The 180kDa band corresponds to the predicted full length 
molecular  weight  of  Erbb4,  whereas  the  lower  molecular  weight  bands 
correspond to predicted molecular weights of cleaved and truncated forms of 
Erbb4.  To compare the expression of Erbb4 in neuronal tissue (rat and mouse 
brain)  and  neuronal-like  cells  (NG108-15)  with  a  peripheral  tissue, 
immunoreactive bands of Erbb4 in rat heart tissue were also examined.  Very 
similar immunoreactive bands were observed in the rat heart lysate than that of 
the  NG108-15  cells,  rat  and  mouse  brain,  but  there  was  no  60kDa 
immunoreactive  band  in  the  rat  heart  sample.    To  achieve  the  180kDa 
immunoreactive band, predicted to represent full length Erbb4, 45g of NG108-
15  cell  lysate  was  required  whereas  15g  of  the  brain  and  heart  tissue  was 
enough tissue to give prominent immunoreactive bands.  This is suggestive that 
the expression of Erbb4 in NG108-15 cells is relatively low compared to cardiac 
or neuronal tissue.   
Nrg1  immunoreactive  bands  of  approximately  150kDa,  100kDa,  80kDa,  55kDa, 
53kDa and 48kDa were observed in the NG108-15 cell sample (Figure 3.8).  All 
these  immunoreactive  bands  were  also  present  in  the  rat  and  mouse  brain 
samples with additional lower molecular weight bands of less than 48kDa also 
present (Figure 3.8).  These bands represent both full length and cleaved forms 
of  Nrg1.    The  intensities  of  the  immunoreactive  bands  did  differ  between 
samples, with the NG108-15 cell sample having a much lower intensity of the 
100kDa  immunoreactive  band  than  the  brain  samples  despite  the  amount  of 
NG108-15 cell total protein lysate analysed being much greater than that of the 
brain samples (45g from the NG108-15 cells and 15g from the brain samples).  83 
The  NG108-15  cells  did  however  appear  to  have  a  greater  abundance  of  the 
48kDa immunoreactive band.    
In  summary,  the  western  blot  analysis  of  NG108-15  cell  total  protein  lysates 
showed that multiple Erbb4 and Nrg1 protein isoforms, including the full length 
proteins, are expressed in NG108-15 cells. 
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Figure 3.7 Comparison of the expression of Erbb4 protein in NG108-15 cells 
with neuronal and non-neuronal tissue.  Representative western blots of 45g 
NG108-15 cell (lane 1), 15g rat brain (lane 2), 15g mouse brain (lane 3) and 
15g  rat  heart  (lane  4)  total  protein  lysates  depicting  immunoreactive  Erbb4 
protein. 
 
 
Figure 3.8 Comparison of the expression of Nrg1 protein in NG108-15 cells 
with  neuronal tissue  Representative western blots of 45g NG108-15 cell (lane 
1), 15g rat brain (lane 2) and 15g mouse brain (lane 3) total protein lysates 
depicting immunoreactive Nrg1 protein. 
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3.3.4 Optimisation of siRNA mediated Erbb4 knockdown 
Confirmation  of  the  expression  of  Erbb4  at  the  mRNA  and  protein  levels 
indicated that this cell line could be used as an in vitro tool for validating Erbb4 
function  in  a  critical  signalling  pathway  for  schizophrenia  by  utilising  siRNA 
(section 2.3.1) to knockdown expression and for validating viral vectors for in 
vivo analyses (methods section 2.3.2 and results section 4.3.1).   Successful gene 
expression knockdown requires optimisation of key factors such as concentration 
of the siRNA and the cell transfection reagent. Optimisation experiments were 
conducted in which three concentrations of mouse Erbb4 siRNA (5nM, 10nM and 
20nM)  were  tested  in  conjunction  with  two  volumes  of  transfection  reagent 
(3.75l and 7.5l) (section 2.3.1).  Knockdown of Erbb4 mRNA was measured in 
the NG108-15 cells 24 hours post-siRNA application using qRT-PCR (section 2.11).  
Treatment of the cells with all three concentrations of Erbb4 siRNA and both 
volumes  of  transfection  reagent  resulted  in  Erbb4  mRNA  knockdown  (Figure 
3.9A).  Although there was no overall significant effect of transfection reagent 
volume on Erbb4 expression (F (1, 33) =0.15 p>0.05), cells transfected with the 
Erbb4  siRNA  and  the  higher  volume  of  transfection  reagent  (7.5l 
Lipofectamine™ RNAiMAX), reduced Erbb4 expression to a greater extent than 
those transfected with the lower volume (3.75l Lipofectamine™ RNAiMAX) when 
compared to cells treated with non-targeting siRNA (Figure3.9A). NG108-15 cells 
had up to 77% knockdown in Erbb4 expression following Erbb4 siRNA treatment.  
All concentrations of Erbb4 siRNA with 7.5l transfection reagent significantly 
reduced Erbb4 expression compared to untreated cells, cells treated with non-
targeting siRNA and cells treated with Gapdh siRNA.  Importantly there was no 
difference in Erbb4 expression between the control treatment groups (untreated 
cells,  non-targeting  siRNA  treated  cells  and  Gapdh  siRNA  treated  cells).  
Measurement of the expression of a house-keeping gene, -2-microglobulin, was 
utilised to determine if the volume of transfection reagent or the Erbb4 siRNA 
had off-target effects.  There was no significant effect of treatment (F (10, 39) 
=0.33 p>0.05) or transfection reagent volume (F (1, 33) =0.01 p>0.05) on -2-
microglobulin expression. (Figure 3.9B) 
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Figure  3.9  Optimisation  of  the  concentration  of  Erbb4  siRNA  and 
transfection reagent volume to produce significant knockdown of Erbb4 in 
NG108-15 cell transfections.  (A) % expression remaining of Erbb4 relative to 
Erbb4 expression in non-targeting siRNA treated NG108-15 cells (B) % expression 
remaining  of  -2-microglobulin  relative  to  -2-microglobulin  expression  in  non-
targeting  siRNA  treated  NG108-15  cells.    low  lipofectamine  =  3.75l 
Lipofectamine™  RNAiMAX  transfection  reagent,  high  lipofectamine  =  7.5l 
Lipofectamine™ RNAiMAX transfection reagent.   qRT-PCR  was performed on 
total RNA isolated from Untreated = untreated NG108-15 cells, non-targeting = 
NG108-15 cells transfected with non-targeting siRNA, siGapdh = NG108-15 cells 
transfected with a Gapdh siRNA, siErbb4 = NG108-15 cells transfected with the 
Erbb4 siRNA at a concentration of 5nM, 10nM and 20nM. Data represent mean ± 
SE  expressed  as  a  percentage  of  the  Erbb4  or  -2-microglobulin  expression 
remaining in cells transfected with non-targeting siRNA at equivalent lipofectamine 
volumes.  n=3-6/treatment group.  ### p<0.001 vs. Erbb4 expression in NG108-15 
cells  transfected  with  Gapdh  siRNA  at  equivalent  lipofectamine  volume,  *** 
p<0.001 vs. Erbb4 expression in NG108-15 cells transfected with non-targeting 
siRNA treated samples at equivalent lipofectamine volume, @ p<0.05, @@p<0.01 
vs. Erbb4 expression in untreated NG108-15 cells using two-way ANOVA followed 
by Tukey’s test for multiple comparisons. 
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Concurrently  NG108-15  cells  were  transfected  with  a  siRNA  for  the  house-
keeping gene Gapdh, to act as a positive control for the procedure. Knockdown 
of  Gapdh  mRNA  was  measured  in  the  NG108-15  cells  24  hours  post-siRNA 
application  using  qRT-PCR.  Gapdh  expression  was  significantly  affected  by 
treatment (F (5,17)=41.59 p<0.001)  with  post hoc comparisons revealing cells 
transfected with Gapdh siRNA had significantly less Gapdh expression than all 
other  treatment  groups  (p<0.001)  (Figure  3.10).    Gapdh  expression  was  also 
measured to check for off-target effects of the Erbb4 siRNA, in addition to the 
measurement  of  -2-microglobulin.  Importantly  Gapdh  expression  did  not 
change under any of the conditions that the cells were transfected with Erbb4 
siRNA (Figure 3.10).   
In  summary,  transfection  of  NG108-15  cells  with  the  Erbb4  siRNA  produced 
significant  knockdown  of  Erbb4  mRNA  but  not  Gapdh  or  -2-microglobulin, 
suggesting knockdown specificity. 
These data showed that transfection of NG108-15 cells with 20nM Erbb4 siRNA 
using 7.5l Lipofectamine™ RNAiMAX  led to a 77% knockdown of Erbb4 mRNA 
without affecting the expression of Gapdh or -2-microglobulin. Therefore these 
conditions were chosen to investigate if reduced Erbb4 protein levels could be 
achieved and detected.   
Although  real  time  PCR  analysis  showed  that  at  24  hours  post-Erbb4  siRNA 
treatment there was significant Erbb4 mRNA knockdown, protein levels of Erbb4 
at 24 hours post-Erbb4 siRNA treatment remain comparable to untreated cells 
and  non-targeting  siRNA  treated  cells.    Erbb4  protein  levels  were  also  not 
knocked down using 20nM Erbb4 siRNA treatment 48 hours, 72 hours or 96 hours 
post-siRNA  application  (Figure  3.11  top  panel).    Gapdh  siRNA  application 
however resulted in Gapdh protein knockdown 48 hours post-siRNA application 
(Figure 3.11 middle panel).  Unfortunately, Erbb4 expression in NG108-15 cells 
was below the detection levels of the ERBB4 ELISA, therefore Erbb4 levels post-
siRNA treatment could not be quantified using this method. 
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Figure 3.10 Effects on Gapdh expression in NG108-15 cells transfected with 
siRNA.   % expression remaining of Gapdh.   qRT-PCR was performed on total 
RNA isolated from Untreated = untreated NG108-15 cells, non-targeting = NG108-
15  cells  transfected  with  non-targeting  siRNA,  siGapdh  =  NG108-15  cells 
transfected with a Gapdh siRNA, siErbb4 = NG108-15 cells transfected with the 
Erbb4 siRNA at a concentration of 5nM, 10nM and 20nM.  Data represent mean ± 
SE  expressed  as  a  percentage  of  the  Gapdh  expression  remaining  in  cells 
transfected  with  non-targeting  siRNA.    n=3/treatment  group.    ###  p<0.001  vs. 
Gapdh  expression  in  NG108-15  cells  transfected  with  Erbb4  siRNA  at  all 
concentrations  tested,  ***  p<0.001  vs.  Gapdh  expression  in  NG108-15  cells 
transfected  with  non-targeting  siRNA,  @@@  p<0.001  vs.  Gapdh  expression  in 
untreated  NG108-15  cells  using  two-way  ANOVA  followed  by  Tukey’s  test  for 
multiple comparisons. 
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Figure  3.11  Erbb4  protein  expression  in  NG108-15  cells  following  siRNA 
treatment.  Representative western blots of 45g NG108-15 cell lysates depicting 
immunoreactive protein levels of Erbb4 at 180kDa, Gapdh at 37kDa and Actin at 
42kDa  at  24  hours,  48  hours,  72  hours  and  96  hours  following  application  of 
siRNA.    Untreated=  untreated  NG108-15  cells,  non-targeting=  NG108-15  cells 
transfected with non-targeting siRNA, siGapdh= NG108-15 cell transfected with 
Gapdh  siRNA,  siErbb4=  NG108-15  cells  transfected  with  Erbb4  siRNA.  
Immunoblots are representative results of n=4 at each condition. 
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3.3.5 Effect of siRNA-mediated knockdown of Erbb4 in NG-108-15 
cells on the expression of related genes 
Having obtained Erbb4 knockdown in NG108-15, expression of genes in the Erbb4 
signalling  pathway  was  assessed.  Real-time  PCR  was  used  to  quantify  the 
expression of Akt and Grin1.  Akt expression was not significantly affected by 
transfection  of  the  cells  with  siRNA  (F  (5,  32)  =2.19  p>0.05)  (Figure  3.12).  
Conversely, Grin1 expression was significantly affected in cells transfected with 
non-targeting siRNA (F (5, 32) =11.22 p<0.001) (Figure 3.13).  However, there 
were no differences in Grin1 expression in cells transfected with Erbb4 siRNA. 
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Figure  3.12  Effects  on  Akt  expression  in  NG108-15  cells  transfected  with 
siRNA.  % expression remaining of Akt.   qRT-PCR was performed on total RNA 
isolated from Untreated = untreated NG108-15 cells, non-targeting = NG108-15 
cells transfected with non-targeting siRNA, siGapdh = NG108-15 cells transfected 
with a Gapdh siRNA, siErbb4 = NG108-15 cells transfected with the Erbb4 siRNA 
at  a  concentration  of  5nM,  10nM  and  20nM.    Data  represent  mean  ±  SE 
expressed as a percentage of the Akt expression remaining in cells transfected 
with non-targeting siRNA.  n=3/treatment group.  
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Figure 3.13 Effects on Grin1 expression in NG108-15 cells transfected with 
siRNA.  % expression remaining of Grin1.   qRT-PCR was performed on total 
RNA isolated from Untreated = untreated NG108-15 cells, non-targeting = NG108-
15  cells  transfected  with  non-targeting  siRNA,  siGapdh  =  NG108-15  cells 
transfected with a Gapdh siRNA, siErbb4 = NG108-15 cells transfected with the 
Erbb4 siRNA at a concentration of 5nM, 10nM and 20nM.  Data represent mean ± 
SE  expressed  as  a  percentage  of  the  Grin1  expression  remaining  in  cells 
transfected with non-targeting siRNA n=3/treatment group. ### p<0.001 vs. Grin1 
expression in NG108-15 cells transfected with Erbb4 siRNA at all concentrations 
tested, *** p<0.001 vs. Grin1 expression in NG108-15 cells transfected with Gapdh 
siRNA, @@@ p<0.001 vs. Grin1 expression in untreated NG108-15 cells using 
two-way ANOVA followed by Tukey’s test for multiple comparisons. 
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3.3.6 Assessment  of  the  functionality  of  Erbb4  receptors  in 
NG108-15 cells 
Having shown that Erbb4 receptors are expressed in NG108-15 cells, it was of 
great interest to assess if the receptors were actually functional.  Therefore, 
Erbb4 phosphorylation following NRG1 application (section 2.2.3) was measured 
as a marker of activity and hence functionality.  Phosphorylated Erbb4 (pERBB4) 
was  determined  using  the  phosphoERBB4  ELISA  (section  2.14)  following  the  
application of a range of NRG1 concentrations (10ng/ml-200ng/ml) or vehicle 
treatment  (PBS/0.1%  (w/v)  BSA)  for  varying  amounts  of  time  (10,  30  or  60 
minutes) on NG108-15 cells (Figure 3.14).  NRG1 treatment had a very variable 
effect on NG108-15 cells, which is seen as quite large error bars in each group.  
Although  individual  Mann-Whitney  tests  comparing  the  effects  of  NRG1 
treatments compared to vehicle treatment at any particular time-point did not 
reveal  any  significant  changes  in  pERBB4  levels  following  NRG1  treatment, 
there was a general trend that 10 minute stimulation with NRG1 resulted in 
higher phosphorylation levels than 30 minute or 60 minute stimulation durations.  
When the levels of pERBB4 in NRG1 treated cells relative to vehicle treated 
cells were analysed by Wilcoxon Rank Test, 10 minute NRG1 stimulation at the 
highest concentration (200ng/ml) significantly increased pERBB4 levels (p<0.05) 
(Figure 3.14). 
To assess if the minimal change in pERBB4 expression observed in NG108-15 cells 
was due to a sensitivity problem  with the pERBB4 ELISA kit, primary cortical 
cultures  were  treated  with  200ng/ml  NRG1  or  vehicle  for  10  minutes  then 
pERBB4 levels assessed by ELISA.  NRG1 stimulation led to a 5 fold increase in 
pERBB4 expression compared to vehicle treated cells (p<0.001) (Figure 3.15). 95 
 
Figure  3.14  Effect  of  NRG1  stimulation  on  pERBB4  levels  in  NG108-15 
cells.  pERBB4 expression in NG108-15 cells analysed by ELISA following 10, 30 
or 60 minute stimulation with vehicle (PBS/0.1% (w/v) BSA), 10ng/ml, 25ng/ml, 
50ng/ml, 100ng/ml or 200ng/ml NRG1Data represent mean optical density ± SE 
relative  to  vehicle  treated  NG108-15  cells.    n=2-5/treatment  group.    *  p<0.05 
greater than 1 using Wilcoxon Rank Sum Test.  
 
 
Figure 3.15 Effect of NRG1 stimulation on pERBB4 levels in primary cortical 
cells.  pERBB4 expression in primary cortical cells analysed by ELISA following 
10  minute  stimulation  with  vehicle  (veh)    (PBS/0.1%  (w/v)  BSA),  or  200ng/ml 
NRG1Data  represent  mean  optical  density  ±  SE  relative  to  vehicle  treated 
primary cortical cells.  n=4-5/treatment group.  *** p<0.001 vs. vehicle treated cells 
using unpaired Students t test. 
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To assess if NRG1 stimulation of Erbb4 in NG108-15 cells resulted in activation 
of downstream Nrg1-Erbb4 signalling pathways, levels of phosphorylated Gsk3, 
Akt and Erk2 were measured by western blot analysis (Figure 3.16).  As with 
pERBB4 levels, levels of phosphorylated Gsk3, Akt and Erk2 in NG108-15 cells 
were very variable following NRG1 stimulation.  However, Wilcoxon Rank Sum 
Tests revealed applications of 10ng/ml and 25ng/ml NRG1 on NG108-15 cells 
for  10  minutes,  significantly  increased  pGSK3  levels  compared  to  vehicle 
treated cells (p<0.05) (Figure 3.16).  Phosphorylation of Akt or Erk2 in NG108-15 
cells was not significantly changed at any concentration of NRG1.   
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Figure  3.16  Effect  of  NRG1  stimulation  on  the  activation  of  Nrg1-Erbb4 
signalling pathways.  pGSK3, pAkt and pErk expression normalised to Actin 
levels  in  NG108-15  cells  as  analysed  by  western  blot  following  10  minute 
stimulation  with  vehicle  (PBS/0.1%  (w/v)  BSA)  or  10ng/ml,  25ng/ml,  50ng/ml, 
100ng/ml or 200ng/ml NRG1Data represent mean optical density ± SE relative 
to vehicle treated NG108-15 cells.  n=2-5/treatment group.  * p<0.05 greater than 
1 using Wilcoxon Rank Sum Test. 
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3.4 Discussion 
3.4.1 Expression of Erbb4 in NG108-15 cells 
A pinnacle finding of this study was that Erbb4 mRNA and protein are expressed 
in NG108-15 cells, as shown by RT-PCR and western blotting.  This is the first 
study which has specifically looked at Erbb4 expression in this neuronal cell line 
and is in agreement with a previous study which showed that NG108-15 cells 
expressed the Erbb4 ligand Nrg1 (Pun et al., 1997), which is also confirmed at 
the protein level in this current study.  This suggests that Nrg1-Erbb4 signalling 
is present in NG108-15 cells and that this cell line may serve as a good in vitro 
model for investigating this signalling pathway.    
A previous study by Schulz and colleagues (2005) suggested that Erbb receptors 
are  not  endogenously  expressed  by  NG108-15  cells.    The  conflict  in  findings 
between this study and that of Schulz et al., (2005) may be due to differences in 
methodology, as an antibody for Erbb1 and a non-specific Erbb inhibitor were 
used by Schulz et al.,.  However, in the present study primers and antibodies 
specific for Erbb4 were used.  In addition, previous studies of Erbb4 expression 
in other cell lines have led to contradictory results.  For example, endogenous 
Erbb4 expression has been shown in HEK293 cells (Yang et al., 2005); whereas 
other studies have concluded there is no endogenous Erbb4 expression in this 
cell  line  (Deb  et  al.,  2008).    Other  neuronal  cell  lines  have  been  shown  to 
express Erbb4 endogenously including the human SK-N-MC neuroblastoma, rat C6 
glioma and human U251 glioma cell lines (Ritch et al., 2003; Fallon et al., 2004).  
Interestingly, many neuronal cell lines express either or both Erbb2 and Erbb3, 
but lack endogenous expression of Erbb4 (Vaskovsky et al., 2000; Frohnert et 
al., 2003; Gambarotta et al., 2004; Fallon et al., 2004; Croslan et al., 2008).  
The  specificity  of  the  RT-PCR  primers  designed  for  Erbb4  in  this  study  was 
thoroughly  checked  and  bioinformatic  testing  confirmed  no  other  transcripts 
were detected by these primers.  It is therefore unlikely that they detected any 
of the other Erbb receptor mRNAs. 
From the RT-PCR results seen with “pan”  Erbb4 primers and isoform specific 
Erbb4  primers,  endogenous  Erbb4  expression  in  NG108-15  cells  is  low  but 99 
detectable, when compared to the levels of Erbb4 expression in mouse and rat 
brain.  Other studies of endogenous Erbb4 expression in cell lines have found 
similar low levels, such as in the mouse epithelial cell line YAMC (Frey et al., 
2009).  In addition, many studies of endogenous Erbb4 expression in cell lines 
may wrongly assume lack of expression if the same amount of template RNA or 
cell lysate is used for quantification of multiple Erbb family members, as it has 
been shown that in some cell lines such as L6 skeletal muscle cell line Erbb4 
expression is 50-fold less than that of Erbb3 (Zhu et al., 1995).  The amount of 
NG108-15 cell lysate used in this study is consistent with a previous study in 
which similar amounts of cell lysate as used to visualise Erbb4 immunoreactive 
bands (Fallon et al., 2004).  However it should be noted that faint PCR products 
or  western  blots  may  be  partly  due  to  technical  artefacts,  such  as  a  poorly 
designed PCR primer.  However, it is unlikely that the low levels of Erbb4 mRNA 
and protein detected in the present study are due to technical artefacts as qRT-
PCR experiments showed the cycle number at which the level of fluorescence 
overcame threshold levels was much higher in NG108-15 cell samples than that 
of samples from brain tissue (data not shown) emphasising a lower expression in 
the cell line than neuronal tissue.     
As NG108-15 cells are a hybrid cell line derived from mouse and rat cell clones, 
it was of interest to determine the origin of Erbb4, in order to specify which 
sequence  should  be  the  target  of  downstream  applications  i.e.  siRNA  target 
sequence and qRT-PCR assay specificity.  As NG108-15 cell cDNA only amplified 
with PCR primers specifically designed to recognise mouse Erbb4, and resulting 
sequencing  confirmed  NG108-15  PCR  products  were  mouse  Erbb4  it  can  be 
concluded that the endogenous Erbb4 in NG108-15 cells is expressed from the 
mouse genome.  This finding is perhaps not surprising as a previous study found 
NG108-15 cells predominantly consist of mouse chromosomes, with an expected 
ratio of mouse:rat chromosomes of 1.9:1 (Ajiro et al., 1982).  Other studies have 
also found that their genes of interest were endogenously expressed in NG108-15 
cells and originate from the mouse genome (LaFlamme et al., 1998; Gorzalka et 
al., 2005).  On the other hand, other studies investigating NG108-15 cells have 
found genes deriving from the rat genome (LaFlamme et al., 1998).  Moreover, 
NG108-15 cells can express both mouse and rat cDNA transcripts of the same 100 
gene (Ajiro et al., 1982; Ho & Zhao, 1996).  It can’t be ruled out therefore that 
other Erbb receptors or Nrg1 in NG108-15 cells derive from the rat genome.  
It should be noted that the NG108-15 cells used here were not differentiated.  
These cells can be differentiated into a more “neuron-like” phenotype using a 
variety of agents, resulting in the appearance of neuron-specific markers, and 
the extensions of neurites (Ma et al., 1998; Nagasawa et al., 2009).  Had more 
time  been  available  it  would  be  of  interest  to  determine  how  Nrg1/Erbb4 
expression alters during the process of differentiation.   
3.4.2 Isoform specific expression of Erbb4 in NG108-15 cells  
Following the finding that NG108-15 cells express mouse Erbb4 mRNA, further 
exploration  using  RT-PCR  primers  designed  to  specifically  recognise  selected 
isoforms  of  Erbb4  showed  that  NG108-15  cells  express  JMa,  CYT1  and  CYT2 
containing isoforms of Erbb4, which are also abundantly expressed in the human 
and rodent prefrontal cortex (Law et al., 2007).  The expression of CYT1 and 
CYT2 isoforms in NG108-15 cells suggests that activation of Erbb4 in NG108-15 
cells could lead to the cascade of Mapk or PI3k signalling.  The expression of the 
JMa but not JMb containing isoforms in NG108-15 cells suggests that all of the 
Erbb4 receptors present in this cell line are susceptible to cleavage by presenilin 
-secretase.    The  presence  of  the  expression  of  JMa  and  CYT1  containing 
isoforms in the NG108-15 cells is of great interest in terms of the validity of this 
cell line in investigating the role of Erbb4 in schizophrenia, as it is specifically 
the  JMa/CYT1  isoform  which  has  been  implicated  in  the  pathophysiology  of 
schizophrenia (Silberberg et al., 2006; Law et al., 2007).  Unfortunately, it is 
not possible to compare this isoform specific expression of Erbb4 in NG108-15 
cells  with  other  cell  lines  as  the  investigation  of  endogenous  Erbb4  isoform 
specific expression has not been carried out.   
Also of great interest is that, like NG108-15 cells, human B lymphoblastoid cells 
which are widely used to study receptor tyrosine kinase signalling and as a model 
of investigating schizophrenia genes, exclusively express the JMa transcripts i.e. 
JMa/CYT1 and JMa/CYT2 (Law et al., in press). 101 
3.4.3  Protein expression of Erbb4 and Nrg1 in NG108-15 cells 
Subsequent to finding Erbb4 mRNA expression, protein expression of Erbb4 and 
Nrg1 was investigated in NG108-15 cells.  Furthermore to validate the neuronal-
like properties of the cell line the expression of Nrg1 and Erbb4 in NG108-15 
cells  was  compared  to  that  of  neuronal  and  non-neuronal  tissues.    The 
immunoreactive banding pattern produced from the Nrg1 and Erbb4 antibodies 
was very similar to that of previous studies of human, non-primate and rodent 
that have utilised the same antibody as in this present study (Thompson et al., 
2007; Chong et al., 2008; Feng et al., 2010).  Multiple immunoreactive bands 
were observed in all of these studies and the lower molecular weight bands are 
thought to represent cleavage products.  The observation that there was a very 
strong immunoreactive band at ~60kDa in NG108-15 cells is in keeping with the 
finding  that  NG108-15  cells  express  the  JMa  isoform  which  is  susceptible  to 
cleavage by proteases. 
Furthermore, the immunoreactive banding pattern in NG108-15 cells for both 
Nrg1 and Erbb4 are very similar to that observed for the rat and mouse brain 
samples, further validating the NG108-15 cell line as a good in vitro neuronal 
model.    NG108-15  cell,  rat  and  mouse  brain  samples  did  have  a  different 
immunoreactive  banding  pattern  than  rat  heart  which  could  be  explained  by 
cardiac tissue lacking expression of JMa isoform of Erbb4 (Elenius et al., 1997a). 
3.4.4 Optimisation of Erbb4 knockdown in NG108-15 cells 
Knockdown of genes utilising siRNA mediated RNA interference has been widely 
used to investigate the function of genes/proteins of interest in many different 
cell  lines  and  also  in  vivo.    It  was  therefore  of  great  interest  to  determine 
whether Erbb4 could be knocked down in NG108-15 cells to validate the use of 
this cell line further to investigate the Nrg1-Erbb4 signalling pathway.  Moreover, 
knockdown of Erbb4 expression utilising this Erbb4 siRNA which has the same 
sequence as that of the rAAV particles validates that this 19 nucleotide sequence 
complementary  to  Erbb4  is  proficient  in  activating  the  RNAi  pathway  and 
generating significant knockdown of  Erbb4 expression.  Although Erbb4 mRNA 
expression  was  low  it  was  still  possible  to  detect up  to  a  77%  knockdown  in 102 
NG108-15  cells,  following  optimisation  of  the  concentration  of  siRNA  and 
transfection volume.   
The knockdown of Erbb4 and Gapdh in NG108-15 cells following the application 
of siRNAs targeting the respective genes suggests that the transfection reagent 
used  (Lipofectamine™  RNAiMAX)  was  efficient  in  transducing  NG108-15  cells.  
Lipofectamine based transfection reagent has been previously shown to be very 
effective  in  transducing  NG108-15  cells  (Martin-Montanez  et  al.,  2010).    In 
addition, the approach taken to optimise siRNA mediated knockdown was similar 
to  previous  studies  utilising  siRNAs  to  knockdown  Erbb4  (Zscheppang  et  al., 
2007).    Normally  multiple  target  sequences  are  tested  for  siRNA  studies.  
However, only one was tested in the present study as the target sequence of the 
siRNA was designed to be the same sequence as that of the shRNA used in the 
following viral mediated Erbb4 knockdown studies.  As the knockdown of Erbb4 
appeared not to change level of Gapdh, Akt or -2-microglobulin it is unlikely 
the knockdown of Erbb4 following Erbb4 siRNA is an off target effect. 
As  Erbb4  signals  through  the  PI3k  signalling  cascade  which  involves  Akt,  the 
expression of Akt following Erbb4 knockdown was assessed.  There appeared to 
be no knockdown of  Akt expression even though Erbb4 in these samples was 
significantly knocked down. This might be explained by the fact that previous 
studies have shown that when Erbb4 signalling is altered it is Akt activity rather 
than Akt expression that is altered (Hahn et al., 2006; Horie et al., 2010).   
Furthermore,  the  expression  of  another  gene  which  has  also  been  linked  to 
Erbb4 signalling was tested following Erbb4 knockdown.  Both the Erbb4 receptor 
and the NMDA receptor are associated with the PSD95 complex, and therefore 
the signalling of the two receptors has been linked.  For that reason expression 
of  the  NMDA  receptor  gene  Grin1  was  measured.    Unfortunately,  Grin1 
expression appeared to be affected by the non-targeting siRNA.  Although the 
sequence  of  the  non-targeting  siRNA  was  unknown,  the  supplier  ensures  the 
sequence of this siRNA is does not have sequence identity to any known gene.  
As  there  appears  to  be  no  effect  of  either  Gapdh  or  Erbb4  siRNAs  on  Grin1 
expression, partial recognition of the non-targeting siRNA to Grin1 is the most 
likely  explanation  of  this  unexpected  knockdown.    In  all  of  the  previous 
experiments the level of the gene expression in untreated cells was very similar 103 
to  non-targeting  siRNA  treated  cells;  therefore  comparison  of  Erbb4  siRNA 
treated  cells  to  untreated  should  give  an  indication  of  changes  in  Grin1 
expression  following  Erbb4  knockdown.  Previous  studies  have  shown  that 
changes in Erbb4 signalling capabilities result in altered NMDA receptor activity 
rather than NMDA receptor expression (Hahn et al., 2006; Li et al., 2007). 
In  addition,  although  non-targeting  siRNA  was  the  most  appropriate  negative 
control of the treatments used in this study as it encompasses effects of both 
transfection reagent and siRNA, the best negative control to use in such studies 
is  an  siRNA  that  contains  a  scrambled  version  of  the  gene  of  interest.  
Nonetheless,  non-targeting  siRNAs  are  widely  and  successfully  used  in  siRNA 
studies. 
Although  there  was  a  significant  knockdown  of  Erbb4  at  the  mRNA  level  in 
NG108-15  cells  at  24  hours  post-siRNA  application,  there  was  no  quantifiable 
Erbb4 protein knockdown at this time point.  Furthermore, there was lack of 
Erbb4  protein  knockdown  at  48,  72  and  96  hours  post-siRNA  application, 
however, since Erbb4 mRNA expression was not assessed at these additional time 
points it cannot be determined if the Erbb4 mRNA knockdown quantified at 24 
hours was still present at the later time points.  The lack of protein knockdown 
may be due to several reasons including further optimisation of concentration 
and  time  point  post-siRNA  application  needed.    The  NG108-15  cells  were 
successfully  transduced  and  the  quantification  of  protein  valid  as  Gapdh 
expression  was  successfully  knocked  down.    Other  studies  have  been  more 
successful in achieving Erbb4 protein knockdown (albeit not in NG108-15 cells) 
(Sharif et al., 2009; Frey et al., 2010; Horie et al., 2010). This divergence of 
results may be due to several technical differences, such as the  Erbb4 siRNA 
target  sequence,  cell  type  transfected  and  transfection  reagent  used.  
Interestingly,  one  study  utilised  a  double  transfection  protocol  to  achieve 
significant  Erbb4  protein  knockdown,  and  thus  an  alternative  transfection 
protocol in NG08-15 cells may achieve significant Erbb4 knockdown (Zscheppang 
et  al.,  2007).    An  important  point  to  note  is  that  the  half-life  of  the  Erbb4 
receptor in NG108-15 cells is unknown therefore it is very difficult to interpret 
at which time-point to measure Erbb4 expression.  The half-life of Erbb4 has 
been shown to dependent upon ligand stimulation (Yang et al., 2005), therefore 
it is possible that if in NG108-15 cells the expression of Nrg1 is endogenously 104 
very high, the half-life of the Erbb4 receptor may be very short and thus difficult 
to measure changes in expression.   
3.4.5 Functionality of Erbb4 receptors in NG108-15 cells 
Although the expression of Erbb4 in NG108-15 cells was not within the range of 
detection by the total ERBB4 ELISA kit, the levels of phosphorylated Erbb4 were 
detectable  by  the  phophoERBB4  ELISA  kit.    To  determine  if  Erbb4  receptor 
expressed in NG108-15 cells was functional and thus provides a valid  in vitro 
model in which to investigate Nrg1-Erbb4 signalling, the NG108-15 cells were 
stimulated  with  NRG1  and  the  activity  of  Erbb4  and  downstream  signalling 
partners were measured.  Even though multiple concentrations of NRG1 were 
used  (ranging  from  10ng/ml  to  200ng/ml)  and  stimulation  durations  of  15 
minutes, 30 minutes and 60 minutes were analysed, very minimal activation of 
any of the molecules was observed.  PErbb4 levels were significantly higher in 
NG108-15 cells following 10 minute stimulation with 200ng/ml NRG1; however, 
in  general  the  phosphorylation  levels  of  Erbb4  (and  the  other  molecules 
measured) were very variable.  This variability may be due to changes in levels 
of  Erbb4  or  Nrg1  in different  passages  of  the  NG108-15  cells.    Moreover  this 
variability was not observed in rat primary cortical cultures which were used as 
a positive control.  Also it was clear from the cortical cultures that the pERBB4 
ELISA was able to detect larger changes in pErbb4 expression than that observed 
in the NG108-15 levels.  Similar concentrations of Nrg1 isoforms have been used 
in previous studies to increase phosphorylation of Erbb4 or other Erbb receptors 
significantly (Hahn et al., 2006; Lok et al., 2009).   
Since  NG108-15  cells  expressed  both  CYT1  and  CYT2  isoforms  of  Erbb4, 
stimulation of the cells with NRG1 could possibly lead to the activation of PI3k 
and MAPK signalling cascades.  NRG1 application however only led to minimal 
activation of Gsk3 and had no effect on pAkt or pErk.  pAkt and pErk expression 
has been  shown to be increased following Nrg1 or  application in multiple 
studies, utilising multiple cell types (Flores et al., 2000; Li et al., 2001; Chae et 
al., 2005; Hahn et al., 2006; Hellyer et al., 2006; Sei et al., 2007; Keri et al., 
2009).    In  addition  previous  studies  utilising  NG108-15  cells  have  shown  that 105 
activation of Akt and Erk is achievable with other ligands such as opioids (Heiss 
et al., 2009).   
Schulz et al. (2005) found that in NG108-15 cells application of epidermal growth 
factor  did  not  result  in  activation  of  Erk,  but  a  reason  for  the  lack  of 
phosphorylation  may  be  the  low  level  of  Erbb4  expression  in  the  cell  line.  
Conversely, another explanation for the low response in NG108-15 cell to NRG1 
is that NG108-15 cells already express NRG1 (Pun et al., 1997) and therefore 
the  basal  levels  of  activation  and  thus  phosphorylation  of  Erbb4  and  its 
downstream  signalling  partners  are  constitutively  high  and  cannot  be  further 
increased.      Interestingly,  one  study  has  showed  that  levels  of  Erbb4 
phosphorylation are dependent upon the ratio of Erbb4 isoforms expressed; with 
JMa/CYT2 isoforms of Erbb4 being highly constitutively phosphorylated (Määttä 
et al., 2006).  Although the ratio of Erbb4 isoforms were not quantified in the 
present study, it was confirmed JMa and CYT2 were expressed, so it is plausible 
phosphorylation  of  Erbb4  was  at  its  maximum  pre-NRG1  application.  
Furthermore, JMa expression was confirmed by RT-PCR and a high expression of 
Erbb4 cleavage products observed by western blot suggesting Erbb4 in NG108-15 
cells  may  be  predominantly  in  the  form  of  intracellular  forms.    Therefore 
NRG1may not be able to bind to the receptor and activate dimerisation and 
thus phosphorylation. 
In addition, the minimal effect of NRG1 on NG108-15 cell activation of Erbb4 
signalling should not be hastily interpreted as lack of functionality of the Erbb4 
receptor in this cell line for the reasons described above, and also because there 
are multiple other ligands of the Erbb4 receptor that have not been investigated 
in this study such as Nrg3 and betacellulin (Zhang et al., 1997).  Finally as noted 
above,  it  should  be  noted  that  these  studies  have  been  carried  out  in 
undifferentiated NG108-15 cells, and therefore the activity or expression of the 
Erbb4 receptor in the cell line may change following differentiation.  Previous 
studies  have  shown  that  receptor  number  increases  following  NG108-15  cell 
differentiation,  such  as  the  muscarinic  acetylcholine  receptors  (Ghahary  & 
Cheng, 1989).  106 
3.5  Conclusions 
In  this  chapter  data  has  been  presented  that  validates  NG108-15  cells  as  a 
suitable in vitro model for studying Erbb4.  Confirmation of the expression of 
Erbb4 in NG108-15 cells was carried out using RT-PCR and western blot.  mRNA 
analysis  displayed  that  NG108-15  cells  express  a  low  but  detectable  level  of 
Erbb4 that originates from the mouse genome, specifically the JMa/CYT1 and 
JMa/CYT2  isoforms.  Furthermore  this  mRNA  expression  of  Erbb4  in  NG108-15 
cells can be knocked down by the use of an optimised Erbb4 siRNA.   
Akin to these findings Erbb4 is expressed at the protein level in NG108-15 cells 
and  the  resultant  receptors  can  be  activated  by  NRG1  and  become 
phosphorylated, activating selected downstream molecules. 
Not only is the finding that NG108-15 cells express Erbb4 endogenously in terms 
of a novel model of investigating Nrg1-Erbb4 signalling, but also because the 
validation  of  this  cell  line  confirms  its  potential  use  for  the  initial  in  vitro 
validation of adeno-associated viral particle studies.   
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4.1 Introduction 
4.1.1 Viral mediated gene manipulation 
Manipulation  of  gene  expression  in  vivo  has  become  an  increasingly  popular 
method  for  investigating  gene  function,  to  allow  a  greater  knowledge  of  the 
pathophysiology of diseases and identification of potential therapeutic targets, 
since the production of the first transgenic mouse in 1989. Nonetheless, there 
are  several  limitations  to  the  use  of  genetically  modified  rodents  for 
translational  research;  often  gross  manipulation  of  genes  is  lethal  during 
embryonic development, and the gene manipulation is not spatially controlled 
and therefore behavioural phenotypes can arise that are due to manipulation of 
the  genes  in  tissues  other  than  the  region  of  interest.    In  addition  gene 
manipulation  is  present  during  neurodevelopment  and  thus  can  lead  to 
compensatory changes resulting in altered behavioural and/or pharmacology in 
adulthood that are not representative of the actual gene function in adulthood.  
However,  recent  technological  advances  have  allowed  the  production  of 
“conditional”  transgenics  through  which  the  advanced  knowledge  of  systems 
such as Cre-Lox recombinase and cell type specific promoters have led to control 
of gene expression at specific time-points in the animals development and in 
which  cells  this  gene  manipulation  will  occur.    Yet  the  production  of  these 
rodents  is  very  expensive  and  generation  of  a  stable  colony  of  genetically 
manipulated  rodents  can  take  years  depending  on  the  strain  used  and  gene 
targeted.   
In  vivo  viral  mediated  gene  manipulation  allows  superior  control  of  gene 
manipulation to that of transgenic laboratory animals due to strict spatial and 
temporal regulation of over expression or knockdown of genes of interest.  In 
particular in the brain where no cell types are definitively specific to a distinct 
brain region,  viral mediated gene manipulation allows spatial control of viral 
injection and thus gene manipulation in specific brain regions.  Furthermore, 
multiple genes can be targeted over several brain regions simultaneously and 
this can be carried out at any time point throughout the rodent’s life-span from 
in  utero  to  adulthood.    Moreover,  although  this  technique  requires  a  skilled 
surgical procedure and the production and optimisation of viral particles can be 109 
problematic,  genetically  manipulated  animals  can  be  quickly  generated 
(Seshadri et al., 2009).  
Several  types  of  viruses  are  commonly  utilised  for  viral  mediated  gene 
manipulation in vivo including adenovirus, lentivirus and adeno associated virus 
(AAV). 
4.1.2 Adeno-associated gene manipulation 
The discovery of the human AAV was fortuitous as it was found as a contaminant 
of  an  adenovirus  preparation  (Atchison,  1965).    Since  their  discovery  AAV 
research has established that the viral particles are small, non-enveloped with a 
single stranded DNA (ssDNA) genome.  AAVs are highly suited for use in viral 
mediated gene manipulation as they are not associated with any known disease 
in humans and moreover they cannot replicate independently, but instead rely 
on  co-infection  with  adenovirus  or  exposure  to  genotoxic  or  UV  radiation  to 
remove the virus from its latent to lytic phase (Meyers et al., 2000).  The wild 
type AAV genome contains rep and cap genes which encode proteins responsible 
for viral replication and encapsulation, respectively.  These genes are flanked by 
inverted terminal repeats (ITR) and in recombinant AAVs (rAAV) used for viral 
mediated  gene  manipulation  these  are  the  only  viral  genetic  component 
remaining,  since  the  rep  and  cap  genes  are  removed  to  produce  a  “gutless 
vector”, thus rendering the rAAVs replication incompetent.  The ssDNA genome 
is  instead  manipulated  to  express  or  knockdown  the  expression  of  genes  of 
interest.  Often other elements are additionally engineered into the genome, for 
example for ease of identification of transduced cells a reporter gene is also 
commonly co-expressed.  The woodchuck posttranscriptional regulatory element 
(WPRE) is often included in rAAVs as it is thought to enhance mRNA processing 
and increase the efficiency of mRNA translation (Xu et al., 2001; Lipshutz et al., 
2003).  A study showed inclusion of WPRE in the vector increased expression of a 
reporter  gene  by  6  fold  in  cortical  cultures  and  by  up  to  35  fold  in  the 
hippocampus (Xu et al., 2001). 
RAAVs were first used as a vehicle for gene transfer in 1984 (Hermonat et al., 
1984) and since then have been widely used to investigate gene function due to 
their ability to transduce terminally differentiated cells such as photoreceptor 110 
cells, hepatocytes, bronchial epithelial cells and neurons (Kaplitt et al., 1994; 
Conrad  et  al,.  1996;  Flannery  et  al.,  1997;  Mingozzi  et  al.,  2002).    Unlike 
lentiviruses which readily integrate into multiple sites in the host genome, wild 
type AAVs have a specific integration site in the human genome on chromosome 
19 termed AAVS1 (Kotin et al., 1990).  However integration is dependent upon 
the  rep  gene  and  therefore  rAAVs  cannot  integrate  at  this  site  and  instead 
evidence  suggests  that  rAAVs  generate  their  second  strand  DNA  episomally.  
There  have  been  studies  suggesting  integration  of  AAVs  does  occur,  but it  is 
thought that these integrations occur at pre-existing DNA breaks (Miller et al., 
2004)  and  very  infrequently.    Two  studies  estimated  that  integration  of  AAV 
occurred at one integration event per 10
3-10
4 vector particles (Russell et al., 
1994; Rutledge et al., 1997). 
RAAV  transduction  is  dependent  upon  binding  of  the  viral  particle  to  a  cell 
surface receptor.  The serotype of AAV defines which cell surface receptor it 
binds to and therefore which cell types the AAV can transduce, explaining the 
altered tropism observed amongst the AAV serotypes.  To date 12 AAV serotypes 
have been identified (Muramatsu et al., 1996; Rutledge et al., 1998; Chiorini et 
al., 1999a; Chiorini et al., 1999b; Xiao et al., 1999; Gao et al., 2002; Gao et al., 
2004; Mori et al., 2004; Schmidt et al., 2008).  AAV9 is thought to bind to the 
laminin receptor, as do AAVs 2, 3 and 8 (Akache et al., 2006).  Many studies are 
taking  advantage  of  the  varying  tropism  of  AAV  serotypes  by  producing 
pseudotyped rAAVs which package AAV2 genomes into capsids of other serotypes 
(Grimm et al., 2003).  This approach may be of benefit in reducing antibody 
mediated response to rAAVs, especially in human trials utilising rAAVs for gene 
therapy as approximately 80% of the population have antibodies against AAV2 
(Erles et al., 1999). 
The mechanism of how rAAVs mediate gene manipulation is a multi-step process 
including internalisation of the viral particle into the cell, followed by trafficking 
to the nucleus where the rAAV genome is translated, to over expression of genes 
of interest or hairpin sequences resulting in knockdown of genes of interest.  A 
summary of this process is shown schematically in Figure 4.1.   
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Figure 4.1 Schematic summary of the mechanism of adeno-association viral 
mediated gene manipulation.  1. rAAV binds to specific cells surface receptor. 2. 
rAAV  binding  and  co-receptor  activation  initiates  endocytosis.  3.  rAAV  is 
internalised  via  clathrin  coated  pit.  4.  rAAV  is  transported  to  the  nucleus  by 
endosomal trafficking. 5. rAAV undergoes endosomal release. 6. rAAV enters the 
nucleus via the nuclear pore complex. 7. Viral uncoating releases rAAV ssDNA 
genome. 8. Viral ssDNA remains episomally or integrates into the host genome 
(rare). 9. Second strand cDNA synthesis. 10a. mRNA transcription. 11a. Protein 
translation. 10b. shRNA transcription. 11b. Activation of RNAi pathway – protein 
knockdown.  
Image produced from information from Schultz & Chamberlain, 2008; Goncalves, 
2005 and Ding et al., 2005.   
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4.1.3 AAV mediated gene manipulation in the CNS 
RAAVs have been repeatedly shown to be able to transduce brain tissue following 
intravenous  injection  of  the  virus  (Inagaki  et  al.,  2006;  Foust  et  al.,  2009).  
Local  injection  of  rAAV  into  distinct  brain  regions  has  shown  successful 
transduction of cells specifically within the rodent striatum (Xue et al., 2009), 
hippocampus (Klein et al., 2007; de Backer et al., 2010), cortex (Nathanson et 
al., 2009) and amygdala (de Backer et al., 2010).  The majority of rAAV studies 
in the CNS have made use of promoters for RNA Polymerase II or III promoters 
(Pol II or Pol III, respectively) however, gene promoters specific for the neuronal 
system such as the neuron-specific enolase (NSE), glial fibrillary acidic protein 
(GFAP)  have  been  shown  to  have  increased  efficiency  and  effectiveness  in 
transducing CNS tissue in vitro and in vivo (Xu et al., 2001).   Since the first 
knockdown study using rAAVs in 2003 (Tomar et al., 2003), shRNA expression by 
rAAVs  have  led  to  many  interesting  findings  regarding  genes  implicated  in 
disorders of the CNS. 
Many neurodegenerative disorders have been investigated using viral mediated 
gene manipulation and rAAVs have been successfully utilised for investigating 
the functions of genes in these disorders due to their capability of expressing 
transgenes for long periods of time, with reporter genes being observed up to 5 
months after systemic AAV9 delivery (Duque et al., 2009).  Localised knockdown 
of the ataxin gene in the cerebellum of a mouse model of spinocerebellar ataxia 
type 1 (SCA1) resulted in the reversal of motor deficits in these mice (Xia et al., 
2004).    In  a  study  of  another  polyglutamine  expansion  disease,  Huntington’s 
disease, suppression of the Htt gene in the striatum of R6/1 mice which display 
behavioural  phenotypes  resembling  those  of  Huntington’s  disease  resulted  in 
delayed onset of these behaviour phenotypes (Rodriguez-Lebron et al., 2005).  
As  well  as  reversing  behavioural  deficits,  studies  have  made  use  of  rAAVs  to 
knockdown  genes  to  induce  phenotypes  analogous  to  neurodegenerative 
disorders.    Hommel  and  colleagues  (2003)  induced  motor  deficits  and 
biochemical changes related to Parkinson’s disease by reducing expression of the 
Th  gene which encodes the enzyme tyrosine hydroxylase essential for dopamine 
synthesis.   113 
4.1.4 Viral  mediated  gene  manipulation  to  investigate  potential 
schizophrenia candidate genes 
As  well  as  investigating  genes  associated  with  the  pathophysiology  of 
neurodegenerative  disorders,  rAAVs  have  been  successfully  employed  to 
investigate  genes  that  have  biological  relevance  to  aspects  of  schizophrenia.  
Polymorphisms in the HOMER1 gene have been associated with increased risk for 
schizophrenia (Norton  et al.,  2003;  Spellman  et al.,  2010)  and  the biological 
function  of  HOMER1  in  regulating  glutamate  neurotransmission  make  this  an 
interesting  target  to  investigate  its  role  of  being  potentially  involved  in  the 
pathophysiology of schizophrenia.   RAAV mediated over-expression of specific 
isoforms  of  Homer  1  within  the  PFC  of  Homer  1  knock-out  mice  resulted  in 
isoform specific reversal of working memory and sensorimotor gating deficits as 
well as reversing glutamate deficits seen in the knock-out mice (Lominac et al., 
2005).    RAAV  mediated  over-expression  of  another  gene  with  biological 
relevance  to  schizophrenia,  Snap25  which  regulates  glutamate-dependent 
excitatory synaptic transmission within the dorsal hippocampus of rats, resulted 
in impaired performance in the water maze and fear conditioning, both of which 
are thought to reflect decreased cognition as seen in schizophrenia (McKee et 
al., 2010).  Camk2a knockdown in the rat hippocampus produced impairments in 
performance of the open field and water maze tasks reflective of the important 
roles Camk2a endogenously plays in spatial learning and maintaining neuronal 
plasticity (Babcock et al., 2005).   
As  well  as  AAVs  other  virus  types  have  been  exploited  to  investigate  genes 
potentially implicated in schizophrenia.  Over the past few years investigations 
into the schizophrenia candidate gene DISC1, using in vivo viral mediated gene 
manipulation,  have  shed  some  light into  the  roles  this  gene  may  play  within 
specific  brain  regions  and  how  these  may  relate  to  the  patholophysiology  of 
schizophrenia.  Retroviral-based introduction of shDisc1 into the hippocampus of 
mice has revealed that Disc1 is important in several aspects of cell morphology 
such as soma size and dendritic initiation, as well as maturation and migration of 
newborn neurons in the adult brain (Duan et al., 2007; Faulkner et al., 2008).  A 
more recent study has been the first to use viral mediated investigation of a well 
known schizophrenia candidate gene to investigate behavioural outcomes of the 114 
gene manipulation. Mao and colleagues (2009) targeted the knockdown of Disc1 
in  the  dentate  gyrus  of  adult  mice  using  lentivirus  based  technology  and 
subsequently found that cells from this brain region transduced with lentivirus 
had  reduced BrdU  incorporation indicative  of  decreased cell  proliferation,  an 
effect that was reversed by application of an inhibitor of GSK3.  Moreover the 
authors found that Disc1 knockdown affected selected behaviours that may be 
relevant to schizophrenia, such as alterations in locomotor activity to a novel 
environment and depressive like behaviour in the forced swim test but no effect 
on anxiety related behaviour as measured by performance in the elevated plus 
maze.    Interestingly  performance  in  the  affected  behavioural  tasks  was 
normalised back to control level by application of the GSK3 inhibitor, suggesting 
that Disc1 functioning through the GSK3 pathway is important in regulating cell 
proliferation and subsequent behaviours involving the dentate gyrus (Mao et al., 
2009). 
In  a  very  recent  study,  lentiviral  mediated  knockdown  specifically  within the 
mouse cerebellum was carried out to target D-amino acid oxidase (Dao), a glial 
enzyme  important  in  the  degradation  of  D-amino  acids.    These  amino-acids 
including D-serine, which is a co-activator of NMDA receptor transmission and 
therefore  potentially  of  importance  in  the  NMDA  receptor  hypofunction 
hypothesis  of  schizophrenia.    Not  only  were  protein  and  mRNA  levels  of  Dao 
quantifiably  reduced,  but  expression  of  several  other  components  of  the 
pathway Dao is involved in were altered, including D-serine and Grin2a (NR2A) 
levels  specifically  within  the  cerebellum  (Burnet  et  al.,  2011).    This  study 
emphasised that not only is viral mediated gene manipulation a valid method of 
investigating the functions of a single gene within a distinct brain region, but 
also  to  investigate  downstream effects  on dysregulation  of  discrete  pathways 
which are much more likely to have a greater pathophysiological impact than 
dysregulation of a single gene in such a complex disorder as schizophrenia.   
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4.2 Aims 
The aims of the validation study described in this chapter were three-fold:  
1)  To  test  the  capability  of  rAAV  particles  (eGFP.rAAV,  scr.rAAV  and 
shErbb4.rAAV) to transduce neuronal-like (NG108-15) and neuronal cells (primary 
cortical cultures), to use eGFP expression as a marker of cell transduction and to 
assess if there was quantifiable knockdown of Erbb4 following transduction.  This 
would validate the functionality of the viral particles before using them in  in 
vivo experiments.  
2) To validate the use of rAAV particles (eGFP.rAAV) in vivo by confirming their 
ability to transduce cells within the designated brain region of the rodent mPFC 
at specific time points post-surgery, and to determine which cell types of the 
mPFC  are  transduced  by  the  rAAVs.    This  would  confirm  that,  if  genetic 
modification took place following viral injection, it would be within the correct 
region of the brain and that knockdown could occur within these cell types. 
3) To quantify the effects of stereotaxic injection of shErbb4.rAAV in the rodent 
mPFC on mRNA and protein levels of Erbb4 and related signalling partners.  This 
would assess whether injection of shErbb4 into the mPFC could knockdown Erbb4 
levels, and determine if this knockdown had secondary effects on the expression 
of members of the Nrg1-Erbb4 signalling pathways. 
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4.3 Results 
4.3.1 Validation of the functionality of rAAV particles in vitro 
Prior  to  using  the  rAAV  particles  in  vivo,  assessment  was  carried  out  to 
determine firstly if the viral particles were capable of transducing neuronal like 
cells (NG108-15) and secondly if they were capable of expressing their inserted 
transgenes (eGFP) in these cells.  As the number of genome copies and length of 
time  required  for  eGFP  expression  were  unknown  a  range  of  titres  of  the 
eGFP.rAAV  particles  (section  2.1)  were  used.  EGFP  protein  expression  was 
assessed at multiple time points by epifluorescence with and without the use of 
an eGFP antibody (section 2.15.1).   
This in vitro analysis showed that the eGFP.rAAV particles were indeed capable 
of transducing NG108-15 cells and that the expression of eGFP was visible in a 
time and titre dependent manner (summarised in Table 1).  No eGFP expression 
was visible 1 day after rAAV application with any titre but low levels of eGFP 
expression were visible without the use of an eGFP antibody from 2 days post-
transduction using the highest titre (10
11gc/ml).  With the use of an antibody for 
eGFP  more  eGFP  positive  cells  were  visible  at  lower  titres  (10
9gc/ml  and 
10
10gc/ml) at 2 days post-viral application (Figure 4.2 A1-E1).  At 7 days post-
application,  all  titres  showed  eGFP  positive  cells,  with  the  highest  titre  of  
eGFP.rAAV particles (10
11gc/ml) resulting in very high eGFP expression (Figure 
4.2 A2-E2). 
Table  4-1  Summary  of  eGFP  expression  at  specific  time  points  following 
transduction of NG108-15 cells with increasing titres of eGFP.rAAV.  
– no eGFP expression, + low eGFP expression, ++ moderate eGFP expression, 
+++ high eGFP expression. 
        gc/ml 
Day  10
7  10
8  10
9  10
10  10
11 
1  -  -  -  -  - 
2  -  -  +  ++  ++ 
3  +  +  +  ++  ++ 
7  +  +       ++    +++  ++  +++ 
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A1                                    B1                                     C1                                    D1                                     E1 
 
 
 
 
A2                                    B2                                     C2                                    D2                                     E2                                  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 eGFP expression in NG108-15 cells transduced with eGFP.rAAV.  eGFP expression in NG 108-15 cells transduced with 
eGFP.rAAV at titres of 1x10
11 gc/ml (A), 1x10
10 gc/ml (B), 1x10
9 gc/ml (C), 1x10
8 gc/ml (D), 1x10
7 gc/ml (E).  Images represent positive 
eGFP immunoreactivity 2 days (1) and 7 days (2) post-viral application.  Scale bars represent 20m. 118 
To validate further the use of the viral particles in vitro prior to carrying out in 
vivo  injections,  the  functionality  of  the  viral  particles  (scr.rAAV  and 
shErbb4.rAAV, section 2.1) was assessed further in primary dissociated cortical 
cultures  from  p1/2  rat  pups  to  investigate  a  model  system  closer  to  in  vivo 
conditions  (section  2.2.2).  This  showed  that  application  of  scr.rAAV  and 
shErbb4.rAAV particles at 2.5x10
10gc/ml resulted in prominent eGFP expression 
and at 7 days post-viral application eGFP could clearly be seen without the use 
of an eGFP antibody.  Both scr.rAAV particles (Figure 4.3A) and shErbb4.rAAV 
particles (Figure 4.3B) were capable of transducing cortical cells and producing 
the expression of eGFP in cell bodies and processes.   
In  addition,  analysis  of  the  capability  of  the  shErbb4.rAAV  particles  to 
knockdown the expression of Erbb4 mRNA in primary cortical cells was assessed 
by qRt-PCR (section 2.11).  Again, different titres of viral particles were tested 
to assess this as it was unknown how many viral particles were necessary to 
affect mRNA levels.  qRT-PCR at 4 days post-viral application revealed that 5x10
9 
gc/ml  shErbb4.rAAV particles  were  sufficient  to  knockdown  the  expression  of 
Erbb4 significantly (F(2,14)= 8.64 p<0.01) (Figure 4.4A).  Post hoc comparisons 
exposed  there  was  significantly  less  Erbb4  mRNA  in  cortical  cells  following 
shErbb4.rAAV  treatment  than  cells  treated  with  vehicle  (p<0.05)  or  scr.rAAV 
(p<0.01).    Furthermore,  treating  the  cells  with  slightly  more  viral  particles 
resulted in an even greater Erbb4 knockdown (Figure 4.4B), with 2.5x10
10 gc/ml 
shErbb4.rAAV particles knocking down Erbb4 mRNA levels in cortical cells by 42% 
compared to cells treated with the same amount of scr.rAAV particles.  There 
was no significant difference in Erbb4 expression between vehicle treated cells 
and cells transduced with scr.rAAV at either titre of viral particles tested. 
As there was a significant effect of the shErbb4.rAAV viral particles on  Erbb4 
expression in primary cortical cells the mRNA expression of Erbb4 ligand Nrg1 
was also assessed.  Interestingly, there was a significant effect of treatment on 
Nrg1  expression  (F  (2,11)=10.73  p<0.01),  with  2.5x10
10  gc/ml  shErbb4.rAAV 
treatment increasing the expression of Nrg1 in cortical cells compared to vehicle 
treated  cells  (p<0.01)  and  2.5x10
10  gc/ml  scr.rAAV  (p<0.05)  4  days  post-
treatment (Figure 4.5). 
 119 
  A 
 
  B 
 
Figure  4.3 eGFP expression  in P1/2  rat cortical cells.   eGFP  expression  in 
dissociated  rat  cortical  cultures  visualised  by  epifluorescence  7days  post-
application  of  2.5x10
10gc/ml  scr.rAAV  (A)  or  shErbb4.rAAV  (B)  viral  particles.  
Scale bar represents 20m. 
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Figure 4.4 Effect of rAAV treatment on Erbb4 expression in primary cortical 
cells.  % ErbB4 mRNA expression remaining in primary cortical cells 4 days post-
transduction  of  vehicle  =  veh  (n=4),  scr  =  scr.rAAV  (n=4-5)  or  shErbb4  = 
shErbb4.rAAV (n=4-6) at titres of 5x10
9gc/ml (A) or 2.5x10
10gc/ml (B) Quantified 
by qRT-PCR using the 
2-CT method (section 2.11.2).  Data represent mean ± 
S.E. relative to vehicle treated samples. * p<0.05, ** p<0.01 analysed using one-
way ANOVA followed by Tukey’s post hoc test for multiple comparisons. 121 
 
Figure 4.5 Effect of rAAV treatment on Nrg1 expression in primary cortical 
cells.  % Nrg1 mRNA expression remaining in primary cortical cells 4 days post-
transduction  of  vehicle  =  veh  (n=4),  scr  =  scr.rAAV  (n=4)  or  shErbb4  = 
shErbb4.rAAV (n=4) at a titre of 2.5x10
10gc/ml quantified by qRT-PCR using the 
2-
CT method.  Data represent mean ± S.E. relative to vehicle treated samples. * 
p<0.05, ** p<0.01 analysed using one-way ANOVA followed by Tukey’s post hoc 
test for multiple comparisons. 
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4.3.2 Validation of the injection of rAAV particles in vivo 
Following the in vitro validation of the eGFP.rAAV, scr.rAAV and shErbb4.rAAV 
rAAV particles, the location of the injections to confirm targeting of the rodent 
mPFC, along with the number of viral particles, and the length of time post-
surgery necessary for eGFP expression were assessed.   First the injection site to 
be used for targeting Erbb4 knockdown specifically to the mPFC was confirmed 
using injections of cresyl violet dye into the brain at co-ordinates according to 
Paxinos & Watson (2007).  Injection of 2l of cresyl violet dye at a 20° angle 
4mm into the brain at 3.2mm anterior and 2mm lateral to Bregma resulted in 
localised dye remaining within the region of the prelimbic area of the mPFC 
(Figure 4.6A, left hemisphere), whereas insertion of the needle without injection 
resulted in very localised tissue damage at the cortex surface at the entrance 
site of the injection  (see 2.4.2) (Figure 4.6A,  right hemisphere).   The region 
where cresyl violet dye was observed was equivalent to the prelimbic (PrL) area 
(Figure 4.6B).   
After validating the injection site, injections of 2l of eGFP.rAAV at 1x10
11gc/ml 
or 1x10
12gc/ml or vehicle were carried out and eGFP expression was analysed at 
1 week, 3 weeks and 8 weeks post-surgery to confirm a) how many viral particles 
(titre)  were  required  to  cause  eGFP  expression,  b)  what  length  of  time  was 
required for eGFP  expression and c)  how much spread of eGFP positive cells 
were observed at these time points.   Injections of vehicle at all time points 
resulted in a visible needle tract with very little tissue damage (as indicated by 
yellow  auto-fluorescing  cells  localised  to  the  needle  tract)  and  no  eGFP 
expression (Figure 4.7A).  At one week post-surgery injection of both titres of 
eGFP.rAAV produced localised eGFP expression in cells close to the needle tract, 
this level of eGFP expression was comparable to that observed at 8 weeks post-
surgery.  Peak expression of eGFP was observed at 3 weeks post-surgery with 
injection of 1x10
11gc/ml eGFP.rAAV resulting in slightly more eGFP positive cells 
than seen with the higher titre at 1 week post-surgery.  1x10
12gc/ml eGFP.rAAV 
injection  produced  a  spread  of  eGFP  positive  cells  of  approximately  0.65mm 
from the needle tract both in the medial-lateral plane (Figure 4.7B). At this time 
point eGFP positive cells were routinely observed over a series of 25-30 20m 
coronal sections indicating an approximate rostro-caudal spread of 0.6mm. 123 
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Figure 4.6  Validation of prL injection site in the rat brain.  Representative 
brain section cut at the level of the PrL showing the effects of 2l injection of cresyl 
violet dye into the left hemisphere compared to insertion of a Hamilton syringe 
without injection into the right hemisphere (A).  The co-ordinates to the site of 
injection as indicated by the red line at a 20° angle into the mPFC 3.2mm anterior 
to bregma (B) (Image taken from Paxinos & Watson, 2007). 
 
 
 
 
 124 
A                                                            B 
      
Figure  4.7  In  vivo  expression  of  eGFP  following  eGFP.rAAV  injection.  
Representative 20m coronal brain sections showing eGFP expression 5 weeks 
post-injection of 2l vehicle (A) or 2l 1x10
12gc/ml eGFP.rAAV (B) into the mPFC.  
Immunofluorescent staining was carried out to detect eGFP expression (section 
2.15.2). The cortical edge of the brain sections are bordered by a dashed white 
line.  Scale bar represents 200m. 
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4.3.3 Identification of cell types transduced by rAAV particles in 
vivo 
To  identify  which  cell  types  were  transduced,  sections  from  hemispheres 
injected with 1x10
12gc/ml eGFP.rAAV 3 weeks post-surgery were  analysed with 
antibodies for eGFP, Gfap (glial fibrillary acidic protein), N200 (Neurofilament 
200) and Pvalb (parvalbumin) (section 2.15.2).  eGFP positive cells were again 
prominent at this time point with this titre of virus (Figures 4.8, 4.9 and 4.10 top 
left  panels).  Glial  cells  were  identified  by  immunoreactivity  with  the  Gfap 
antibody and a proportion of the eGFP expressing cells were also reactive for 
Gfap (Figure 4.8, right panel).  Pyramidal cells were identified using the N200 
antibody and a fraction of the eGFP expressing cells were also reactive for N200 
(Figure  4.9,  right  panel).    Finally  eGFP  expressing  cells  were  also  seen  in  a 
subgroup of Pvalb containing interneurons (Figure 4.10, right panel). 
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Figure 4.8  Co-localisation of eGFP and Gfap in eGFP.rAAV transduced cells.  
Immunohistological staining of brain sections cut at the level of the mPFC 3 weeks 
post-injection of 2l 1x10
12gc/ml eGFP.rAAV.  Immunofluorescence shows cortical 
cells  positive  for  either  eGFP  (green,  top  left  panel)  or  Gfap  (red,  bottom  left 
panel),  merging  of  the  two  images  shows  co-localisation  of  eGFP  and Gfap  in 
some cortical glial cells (yellow, right panel).  Arrows indicate eGFP+Gfap positive 
cells.  Scale bar represents 20m. 
 
 
Figure 4.9 Co-localisation of eGFP and N200 in eGFP.rAAV transduced cells. 
Immunohistological staining of brain sections cut at the level of the mPFC 3 weeks 
post-injection of 2l 1x10
12gc/ml eGFP.rAAV.  Immunofluorescence shows cortical 
dendritic  processes  of  pyramidal  cells  positive  for  either  eGFP  (green,  top  left 
panel)  or N200  (red, bottom  left panel), merging  of  the two  images  shows  co-
localisation of eGFP and N200 in some dendritic processes (yellow, right panel).  
Arrows indicate eGFP+N200 positive processes.  Scale bar represents 20m. 127 
 
Figure  4.10  Co-localisation  of  eGFP  and  Pvalb  in  eGFP.rAAV  transduced 
cells.  Immunohistological staining of brain sections cut at the level of the mPFC 3 
weeks post-injection of 2l 1x10
12gc/ml eGFP.rAAV.  Immunofluorescence shows 
cortical cells positive for either eGFP (green, top left panel) or Pvalb (red, bottom 
left panel), merging of the two images shows co-localisation of eGFP and Pvalb in 
some  cortical  cells  (yellow,  right  panel).    Arrows  indicate  eGFP+Pvalb  positive 
cells.  Scale bar represents 20m. 
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4.3.4 Quantification of mRNA expression following rAAV injection 
in the mPFC 
To ensure that any changes in mRNA expression following viral injection were 
not  due  to  degradation  of  RNA,  RNA  quality  was  assessed  using  the  Agilent 
Bioanalyser 2100 (section 2.8.3).  Analysis of total RNA isolated from one PFC 
hemisphere of each rat 5 weeks post-stereotaxic surgery (vehicle, scr.RAAV and 
shErbb4.rAAV)  showed  that  the  RNA  quality  did  not  differ  between  surgical 
groups and therefore any subsequent changes in mRNA expression were unlikely 
to be due to RNA degradation.  The average RIN values of vehicle, scr.RAAV and 
shErbb4.rAAV  treated  rats  were  8.65  ±  0.59,  8.4  ±  0.46  and  8.78  ±  0.29, 
respectively.   
At  5  weeks  post-injection  of  2l  of  1x10
12  gc/ml  shErbb4.rAAV  there  was  no 
significant effect on Erbb4 mRNA expression in the PFC compared to the other 
surgical groups, with no effect of surgical group (F (2,22)=0.38 p>0.05) (Figure 
4.11A), although there appeared to be a trend towards decreased Erbb4 mRNA 
levels after shErbb4.rAAV injection.  In concordance with this result there was 
also no effect of surgical group on Nrg1 mRNA expression in these samples at this 
time point (F (2, 22) =0.72 p>0.05) (Figure 4.11B).  However, when the ratio of 
ligand mRNA to receptor mRNA was quantified there was a significant effect of 
surgical group (F (2, 22) =11.13 p<0.001) with post hoc comparisons revealing 
rats treated with shErbb4.rAAV had significantly higher Nrg1/Erbb4 mRNA ratio 
than scr.rAAV treated rats (p<0.01) and vehicle treated rats (p<0.001) (Figure 
4.12). 129 
 
Figure 4.11 Effect of in vivo viral-mediated targeting of Erbb4 on Erbb4 and 
Nrg1 mRNA expression.  % Erbb4 (A) and Nrg1 (B) mRNA expression remaining 
in one hemisphere of the mPFC dissected from rats 5 weeks post 2l injection of 
vehicle  =  veh  (n=7),  1x10
12gc/ml  scr.rAAV  =  scr  (n=8)  or  1x10
12gc/ml 
shErbb4.rAAV = shErbb4 (n=8) quantified by qRT-PCR using the 
2-CT method.  
Data represent mean ± S.E. relative to vehicle treated samples.  
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Figure 4.12 Effect of in vivo viral-mediated targeting of Erbb4 on the ratio of 
Nrg1/Erbb4  mRNA  expression.    The  ratio  of  Nrg1  mRNA  to  Erbb4  mRNA 
expression in one hemisphere of the mPFC dissected from rats 5 weeks post 2l 
injection of vehicle = veh (n=7), 1x10
12gc/ml scr.rAAV = scr (n=8) or 1x10
12gc/ml 
shErbb4.rAAV = shErbb4 (n=8) quantified by qRT-PCR using the 
2-CT method.  
Data represent mean ± S.E. relative to vehicle treated samples.  ** p<0.01, *** 
p<0.001 analysed using one-way ANOVA followed by Tukey’s post hoc test for 
multiple comparisons. 
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4.3.5 Quantification  of  protein  expression  following  rAAV 
injection in the mPFC 
Erbb4 protein quantification using an ELISA (section 2.14) showed that surgical 
group  had  a  significant  effect  on  Erbb4  protein  levels  (F(2,22)=11.2  p<0.001) 
with  rats  injected  with  2l  of  1x10
12  gc/ml  shErbb4.rAAV  having  significantly 
reduced Erbb4 protein expression in the PFC compared to vehicle (p<0.001) and 
scr.rAAV  injected  rats  (p<0.01)  (Figure  4.13A).    However,  the  expression  of 
phosphorylated  Erbb4  was  not  significantly  affected  by  surgical  group  (F  (2, 
2)0.98 p>0.05) (Figure 4.13B), although there was a non-significant decrease in 
pErbb4  levels  in  shErbb4.rAAV  treated  samples.    Furthermore  the  ratio  of 
phosphorylated  Erbb4  to  total  Erbb4  was  also  not  significantly  affected  by 
surgical group (F (2, 22) =0.01 p>0.05) (Figure 4.13C).   
To assess if injection of viral particles caused glial infiltration within the PFC, 
levels of Gfap were quantified by western blotting in each sample at 5 weeks 
post-surgery (section 2.13).  There was no significant effect of surgical group on 
Gfap expression (F (2, 21) =0.55 p>0.05).  Although both viral groups did appear 
to  have  slightly  heightened  Gfap expression,  this  was  not  significantly  higher 
than  vehicle  treated  rats  and  most  importantly  not  different  between  viral 
groups (Figure 4.14).  To ensure there was eGFP expression in all protein lysates 
isolated from viral treated PFC tissue 5 weeks post-surgery (as this was not a 
time point assessed in the previous validation study (section 4.3.2), eGFP protein 
levels were assessed by western blot analysis (section 2.13).  All scr.rAAV and 
shErbb4.rAAV  treated  samples  showed  eGFP  expression,  although  levels  were 
somewhat variable.  Importantly no eGFP was visible in vehicle treated samples 
(Figure 4.15).   
The  weight  of  the  rats  post-stereotaxic  surgery  was  monitored  to  assess  for 
adverse  effects  of  surgery  or  viral  infection.  There  was  no  difference  in  the 
weight of rats in different surgical groups (F (2, 68) = 2.80 p>0.05) (Figure 4.16A) 
or 5-CSRTT (F (2, 98) = 2.5 p>0.05) (Figure 4.16B)).  
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Figure 4.13 Effect of in vivo viral-mediated targeting of Erbb4 on Erbb4 and 
pErbb4 protein expression.  % Erbb4 (A), phosphorylated Erbb4 (pErbb4) (B) 
and the ratio of pErbb4 to total Erbb4 (C) protein expression remaining in one 
hemisphere of the mPFC dissected from rats 5 weeks post 2l injection of vehicle 
= veh (n=7), 1x10
12gc/ml scr.rAAV = scr (n=8) or 1x10
12gc/ml shErbb4.rAAV = 
shErbb4 (n=8) quantified by Erbb4 or phosphoErbb4 ELISA.  Data represent mean 
± S.E. relative to vehicle treated samples. ** p<0.01, *** p<0.001 analysed using 
one-way ANOVA followed by Tukey’s post hoc test for multiple comparisons. 133 
 
Figure  4.14  Effect  of  in  vivo  viral-mediated  targeting  of  Erbb4  on  Gfap 
protein expression. Representative immunoblots of Gfap (top panel) and Actin 
(lower panel) in lysates prepared from one hemisphere of the mPFC dissected 
from rats 5 weeks post-2l injection of vehicle = veh, 1x10
12gc/ml scr.rAAV = scr 
or  1x10
12gc/ml  shErbb4.rAAV  =  shErbb4  (A).    Quantification  of  Gfap  protein 
expression in lysates prepared from one hemisphere of the mPFC dissected from 
rats 5 weeks post-2l injection of vehicle = veh (n=7), 1x10
12gc/ml scr.rAAV = scr 
(n=8) or 1x10
12gc/ml shErbb4.rAAV = shErbb4 (n=8) normalised to the expression 
of Actin (B).  Data represent mean ± S.E. relative to vehicle treated samples.  
 
 
Figure  4.15  in  vivo  eGFP  protein  expression  5  weeks  post-stereotaxic 
surgery.  Representative  immunoblots  of  eGFP  in  lysates  prepared  from  one 
hemisphere  of  the  mPFC  dissected  from  rats  5  weeks  post-2l  injection  of 
vehicle=  veh,  1x10
12gc/ml  scr.rAAV  =  scr  or  1x10
12gc/ml  shErbb4.rAAV  = 
shErbb4. 
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Figure 4.16  Effect of stereotaxic surgery on weight.  Weight gain as measured 
by % of pre-surgery  weight of rats in prepulse inhibition and locomotor activity 
study (A) or 5-CSRTT study (B) at 1, 3 and 5 weeks post-injection of 2l injection 
of  vehicle  =  veh  (n=7-11),  1x10
12gc/ml  scr.rAAV    =  scrambled  (n=8-12)  or 
1x10
12gc/ml shErbb4.rAAV = shErbb4 (n=8-11). 
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4.3.6 Effects of rAAV injection in the mPFC on protein levels of 
the Nrg1-Erbb4 signalling pathway 
As there were significant reductions in Erbb4 protein levels 5 weeks post-surgery 
in the PFC of rats treated with shErbb4.rAAV particles, activity levels of the two 
downstream signalling pathways of Erbb4 were assessed.  The activity of the Erk 
signalling pathway as measured by the ratio of pErk expression to total Erk (tErk) 
expression was not significantly affected by surgical group (F(2,21)=0.39 p>0.05) 
(Figure  4.17).    In  comparison,  the  activity  of  the  Akt  signalling  pathway  as 
measured  by  the  ratio  of  pAkt  expression  to  total  Akt  (tAkt)  expression  was 
significantly  affected  by  surgical  group  (F(2,20)=3.82  p<0.05).    Post  hoc 
comparisons revealed shErbb4.rAAV treated rats had significantly less pAkt/tAkt 
than  vehicle  treated  rats  (p<0.05)  and  to  some  extent  scr.rAAV  treated  rats 
(although not to a significant level) (Figure 4.18). 
In agreement with mRNA results in vitro and to a certain degree in vivo, surgical 
group had a significant effect on Nrg1 protein expression (F (2,22)=8.82 p<0.01) 
with  shErbb4.rAAV  treatment  resulting  in  approximately  a  70%  increase  full 
length Nrg1 (100 kDa) expression compared to the scr.rAAV  group (p<0.05) and 
vehicle group (p<0.01) (Figure 4.19).  There were no effects on the expression of 
Nrg1  cleavage  products  (data  not  shown).    Pearson’s  correlation  analysis 
revealed  a  significant  negative  correlation  between  Erbb4  and  Nrg1  protein 
levels remaining 5 weeks after surgery (p<0.05) (Figure 4.20). 
 136 
 
              
Figure  4.17  Effect  of  in  vivo  viral-mediated  targeting  of  Erbb4  on  Erk 
signalling.    Representative  immunoblots  of  tErk2  (top  panel),  pErk2  (middle 
panel) and Actin (lower panel) in lysates prepared from one hemisphere of the 
mPFC dissected from rats 5 weeks post-2l injection of vehicle = veh, 1x10
12gc/ml 
scr.rAAV = scr or 1x10
12gc/ml shErbb4.rAAV = shErbb4 (A).  Quantification of the 
ratio of pErk2 to tErk2 protein expression in lysates prepared from one hemisphere 
of the mPFC dissected from rats 5 weeks post-2l injection of vehicle = veh (n=7), 
1x10
12gc/ml scr.rAAV = scr (n=8) or 1x10
12gc/ml shErbb4.rAAV = shErbb4 (n=8) 
normalised to the expression of Actin (B).  Data represent mean ± S.E. relative to 
vehicle treated samples. 
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Figure  4.18  Effect  of  in  vivo  viral-mediated  targeting  of  Erbb4  on  Akt 
signalling.  Representative immunoblots of tAkt (top panel), pAkt (middle panel) 
and Actin (lower panel) in lysates prepared from one hemisphere of the mPFC 
dissected  from  rats  5  weeks  post-2l  injection  of  vehicle  =  veh,  1x10
12gc/ml 
scr.rAAV = scr or 1x10
12gc/ml shErbb4.rAAV = shErbb4 (A).  Quantification of the 
ratio of pAkt to tAkt protein expression in lysates prepared from one hemisphere of 
the mPFC dissected from rats 5 weeks post-2l injection of vehicle = veh (n=7), 
1x10
12gc/ml scr.rAAV = scr (n=8) or 1x10
12gc/ml shErbb4.rAAV = shErbb4 (n=8) 
normalised to the expression of Actin (B).  Data represent mean ± S.E. relative to 
vehicle treated samples. * p<0.05 analysed using one-way ANOVA followed by 
Tukey’s post hoc test for multiple comparisons.  
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Figure  4.19  Effect  of  in  vivo  viral-mediated  targeting  of  Erbb4  on  Nrg1 
protein expression. Representative immunoblots of Nrg1 (top panel) and Actin 
(lower panel) in lysates prepared from one hemisphere of the mPFC dissected 
from rats 5 weeks post-2l injection of vehicle = veh, 1x10
12gc/ml scr.rAAV = scr 
or  1x10
12gc/ml  shErbb4.rAAV  =  shErbb4  (A).    Quantification  of  Nrg1  protein 
expression in lysates prepared from one hemisphere of the mPFC dissected from 
rats 5 weeks post-2l injection of vehicle = veh (n=7), 1x10
12gc/ml scr.rAAV = scr 
(n=8) or 1x10
12gc/ml shErbb4.rAAV = shErbb4 (n=8) normalised to the expression 
of Actin (B).  Data represent mean ± S.E. relative to vehicle treated samples. * 
p<0.05, ** p<0.01 analysed using one-way ANOVA followed by Tukey’s post hoc 
test for multiple comparisons. 
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Figure  4.20  Correlation  analysis  of  Erbb4  and  Nrg1  protein  levels.  
Correlation  between  Erbb4  protein  expression  and  full  length  Nrg1  (100  kDa) 
protein expression in PFC lysates prepared from one hemisphere of the mPFC 
dissected from rats 5 weeks post-2l injection of vehicle = veh, 1x10
12gc/ml (n=7), 
scr.rAAV = scr (n=8) or 1x10
12gc/ml shErbb4.rAAV = shErbb4 (n=7).  Solid line 
represents the equation of best fit.  Pearson’s correlation co-efficient (R) and p 
value  indicate  significant  negative  correlation  between  Erbb4  and  Nrg1  protein 
expression. 
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4.4 Discussion 
4.4.1 Validation of rAAV functionality in vitro 
Validation of the functionality of the rAAV particles was essential in this study as 
the particles themselves were a gift from an outside source, and evidence of 
their functionality in vitro or in vivo was not readily available.  The aim of this 
in  vitro  validation  study  was  not  to  calculate  a  titre  for  in  vivo  work.  This 
preliminary  analysis  however,  demonstrated  that  the  viral  particles  were 
capable  of  transducing  neuronal-like  (NG108-15)  and  neuronal  cells  (primary 
cortical cultures) and that they drove the expression of eGFP, indicative of likely 
co-expression of the short-hairpin sequences in the other viral particles used in 
this  study  (scr.rAAV  and  shErbb4.rAAV).    Additionally  the  in  vitro  validation 
study  was  successful  in  confirming  that  the  hairpin  sequence  of  the 
shErbb4.rAAV  particles  could  elicit  the  knockdown  of  Erbb4  expression  in 
primary  cortical  cultures,  to  a  significant  level  compared  to  treatment  with 
scr.rAAV particles.  This effect seems to be specific to the hairpin sequence as 
importantly  even  at  the  highest  titre  of  viral  particles  used,  there  was  no 
significant  difference  in  Erbb4  expression  between  vehicle  treatment  and 
scr.rAAV  treatment,  suggesting  that  the  viral  particles  themselves  were  not 
overtly  toxic.    This  validation  study  established  the  confidence  required  to 
progress to utilising these viral particles in vivo. 
4.4.2 Validation of rAAV particles in vivo 
The eGFP.rAAV viral particles were validated in vivo using 2 different titres and 
at 3 time points to assess viral tropism and expression of the eGFP transgene.  
The titres of viral particles used in this in vivo validation study were in line with 
multiple in vivo studies using rAAV particles within the CNS of rodents (Xia et 
al., 2004; Babcock et al., 2005; Ulusoy et al., 2009) and importantly were below 
the  threshold  of  those  shown  to  be  too  toxic  within  the  CNS  (Ulusoy  et  al., 
2009).  As  expected  the  higher  number  of  viral  particles  resulted  in  the 
transduction  of  more  cells  in  the  area  surrounding  the  needle  tract.    The 
presence of eGFP expressing cells at 1 week following surgery is in accordance 
with  a  study  which  showed  eGFP  expression  within  the  brain  from  4  days 141 
onwards  following  rAAV  treatment  (Reimsnider  et  al.,  2007).    In  the  present 
study peak eGFP expression was observed at 3 weeks post-surgery.  Akin to this a 
study  by  Reimsnider  et  al.,  (2007)  confirmed  that  peak  eGFP  expression 
following  rAAV  injection  into  the  striatum  was  by  4  weeks.    As  eGFP 
immunofluorescence analysis was not performed at 4 or 5 weeks post-surgery, it 
is  unclear  whether  eGFP  expression  increased  from  week  3  to  week  5.  
Interestingly, behavioural phenotypes emerged at 5 weeks post-surgery which 
may suggest that peak eGFP expression and thus hairpin expression will have 
already occurred by 5 weeks post-surgery.  Although in the present study eGFP 
expression appeared to have diminished by 8 weeks post-surgery many studies 
have shown strong eGFP  expression under the control of the same or similar 
promoters as this study at time points beyond 8 weeks (Kaplitt et al., 1994; Xu 
et al., 2001; Xue et al., 2010).  This may reflect region specific differences in 
factors  which  limit  the  expression  of  rAAV  transgenes  such  as  impaired 
intracellular trafficking (Ding et al., 2005), uncoating of the viral capsid (Hauck 
et al., 2004) or second strand DNA synthesis as single stranded rAAV genomes are 
only very transiently expressed in target cells before degradation (Hauck et al., 
2004).  Since at 8 weeks post-surgery eGFP levels had returned to a similar level 
of that of 1 week post surgery, this would suggest that target cells surrounding 
the needle tract were transduced by multiple rAAV particles resulting in longer 
term  eGFP  expression  than  cells  further  from  the  needle  tract  that  were 
presumably  transduced  by  fewer  rAAV  particles  owing  to  the  more  transient 
eGFP expression in cells out with the needle tract.   
Peak  spread  of  eGFP  expression  at  3  weeks  post-surgery  was  approximately 
0.65mm
2.  This level of transduction is very similar to that of previous studies 
(Hommel et al., 2003; Reimsnider et al., 2007; Burnet et al., 2011) and although 
this  level  of  transduction  has  been  sufficient  in  this  study  to  produce  both 
downstream behavioural and molecular alterations, it is of interest that previous 
studies  have  successfully  reported  behavioural  and  biochemical  changes 
following  injections  of  viral  particles  at  multiple  brain  sites  simultaneously 
(Winstanley et al., 2009).  Moreover, it has been shown that co-administration of 
viral particles along with agents that aid vasodilation such as mannitol increase 
spread of AAV transduction (Mastakov et al., 2001). 142 
Co-localisation of eGFP expression with multiple cell type markers revealed that 
within the mPFC rAAV serotype 9 is capable of transducing neurons and glia.  
Systemic injection of rAAV 9 has previously been reported to result in neuronal 
(Inagaki et al., 2006) and neuronal and glial transduction (Foust et al., 2009).  
However,  intra-striatal  injection  of  rAAV  9  was  only  efficient  in  transducing 
neurons but not glia (Xue et al., 2010).  This is in keeping with multiple reports 
of  rAAVs  having  preference  over  neuronal  than  glial  transduction  (Cearly  & 
Wolfe, 2006; Lawlor et al., 2009).  Although quantification was not carried out 
in  the present  study  it  was  evident that  the  ratio  of co-localised  eGFP/Gfap 
expressing cells to un-colocalised Gfap expressing cells was very low.  However, 
the  presence  of  glial  transduction  within  the  mPFC  in  the  present  study 
compared to the lack of this observation in previous studies could be due to the 
suggestion  that  the  tropism  of  rAAVs  may  vary  dramatically  between  brain 
regions due to the expression of the specific serotypes and cell surface receptors 
or co-receptors with the distinct brain region, and also regional differences in 
the  regulation  of  Gfap  expression  (Xu  et  al.,  2001).    eGFP  co-localisation  in 
selected  parvalbumin-expressing  cells  suggests  the  rAAVs  were  capable  of 
transducing parvalbumin-positive GABAergic interneurons; this is in agreement 
with a previous study which found AAV 1/2 were capable of transducing both 
cortical inhibitory and excitatory interneurons (Nathanson et al., 2009).   
It is not surprising that the rAAVs used in this study transduced multiple cell 
types since the laminin receptor (thought to be the cell surface receptor for 
rAAV 9) is widely expressed throughout the CNS and is expressed in glial cells 
and neuronal cells including parvalbumin-containing interneurons (Baloui et al., 
2004).  The wide tropism of eGFP expression observed in this study is indicative 
that the shRNA sequence of scr.rAAV  and shErbb4.rAAV particles will also be 
expressed in these multiple cells types, and although it would be interesting to 
investigate the effects of knockdown of Erbb4 in specific cell types it is unlikely 
that  the  pathophysiology  of  schizophrenia  is  due  to  gene  changes  in  gene 
expression in one individual cell type.  In addition, in the rodent brain Erbb4 is 
expressed in glial cells (Gereck et al., 2001), parvalbumin-containing intereurons 
(Yau et al., 2003; Vullhorst et al., 2009; Neddens & Buonanno, 2010) and also 
pyramidal cells (Gereck et al., 2001; Mechawar et al., 2007).  However, this has 
recently been under debate (Vullhorst et al., 2009; Neddens & Buonanno, 2010).  143 
One  very  recent  study  has  successfully  utilised  viral  mediated  technology  to 
selectively target cortical inhibitory interneurons expressing Erbb4 in the mouse 
brain,  but  no  functional  measurements  of  behaviour  or  signalling  were 
performed (Choi et al., 2010). 
4.4.3 Erbb4 mRNA and protein knockdown in vivo 
Knockdown of Erbb4 mRNA after injection of shErbb4.rAAV was not observed in 
the PFC at 5 weeks post-surgery, despite there being a significant decrease in 
the expression of Erbb4 protein. There are a number of reasons for why this is 
likely  including  that  that  the  mRNA  levels  of  Erbb4  within  shErbb4.rAAV 
transduced cells were successfully knocked down at 5 weeks post-surgery but 
this effect was diluted out by the large amount of tissue not transduced in the 
dissected PFC tissue analysed.  MRNA and protein knockdown via viral mediated 
shRNA expression have been previously shown to occur at different time points 
post-viral  injection  (Burnet  et  al.,  2011).    In  the  present  study  protein 
knockdown of Erbb4 within the PFC was on average 18%, suggesting that the 
transduced cells within the transduced region of the mPFC had a very low level 
of  Erbb4  expression  remaining.    Although  significant,  the  overall  level  of 
knockdown was subtle, suggesting that non-transduced cells within the dissected 
PFC tissue may have diluted out the Erbb4 knockdown levels.  Some studies have 
shown  greater  knockdown  levels  using  similar  titres  as  in  the  present  study 
however,  it  should  be  noted  that  many  studies  use  techniques  that  quantify 
more defined areas than a gross tissue dissection, such as fluorescence-activated 
cell sorting (FACS) to analyse only GFP positive cells or laser capture dissection 
to dissect out only the precise area transduced by the virus (Hommel et al., 
2003; Mao et al., 2009; McKee et al., 2010). 
4.4.4 The effect of Erbb4 knockdown on Nrg1-Erbb4 signalling 
Erbb4 knockdown led to increased Nrg1 mRNA levels in vitro and protein levels 
in vivo suggesting that the increase in the ligand expression compensates for the 
reduction  in  receptor  number  following  shErbb4.rAAV  treatment.    This  may 
explain  why  even though  there  is a  significant  knockdown in total  Erbb4  the 
activity  of  the  receptor  as  assessed  by  the  ratio  of  pErbb4/tErbb4  is  not 144 
changed,  presumably  caused  by  the  remaining  Erbb4  receptors  being  over-
stimulated by the increased Nrg1.  Moreover, this is strengthened by Pearson’s 
correlation analysis revealing that the compensatory increase in Nrg1 is even 
more evident with the decreasing levels of Erbb4.  Interestingly, although there 
have been numerous transgenic mouse lines produced with mutations in Nrg1 or 
Erbb4, none of these studies have analysed whether there is a secondary effect 
on Erbb4 or Nrg1 levels, respectively.  Similarly, many studies have measured 
Erbb4 and Nrg1 levels in the brains of patients with schizophrenia.  However, 
these studies rarely measure both the ligand and receptor instead solely showing 
a change in levels of Nrg1 or Erbb4 (Hashimoto et al., 2004; Law et al., 2006; 
Law et al., 2007; Silberberg et al., 2007).  One study correlated the level of 
both proteins in the PFC of patients with schizophrenia and found that increased 
NRG1 was correlated with increased ERBB4 levels (Chong et al., 2008).  Although 
these results are in opposition with what is seen in the present study, it should 
be noted that Chong and colleagues found a positive correlation with a cleaved 
form of NRG1 whereas here full length Nrg1 is changed and there was no effect 
of Erbb4 knockdown on any Nrg1 cleavage products.  This suggests that Erbb4 
knockdown in the mPFC did not affect the enzymatic cleavage of Nrg1.  In a 
recent study, knock-out of the gene bace which transcribes an enzyme important 
in  the  cleavage  of  Nrg1  resulted  in  decreased  Nrg1  but  no  changes  in  the 
expression levels of Erbb4 (Savonenko et al., 2008). 
As there was no significant change in the activity of the Erbb4 receptor following 
Erbb4  knockdown  it  was  not  expected  that  there  would  be  changes  in  the 
activity of either of the signalling pathways initiated by Erbb4.  In line with this 
hypothesis there was no effect of Erbb4 knockdown on Erk signalling.  However, 
shErbb4.rAAV treatment appeared to reduce Akt signalling.  Fascinatingly, in the 
PFC of brains from patients with schizophrenia the decrease in Erbb4 expression 
is limited to the CYT1 isoform, which signals through the Akt pathway (Law et 
al., 2007).  Moreover, Nrg1 induced changes in Akt activity in schizophrenia have 
been replicated in several studies, where although Nrg1 consistently increases 
activity of Akt in schizophrenia this increase in activity is attenuated (Sei et al., 
2007; Keri et al., 2009) whereas Erk activity appears to be unaltered (Sei et al., 
2007).   Studies looking at basal activity of Akt are less consistent with both 145 
decreases (Emamian et al., 2004) and no changes (Ide et al., 2006; Sei et al., 
2010) in Akt activity being identified.   
Whether the change in Akt activity is a direct effect of Erbb4 knockdown or an 
effect  of  the  secondary  change  in  Nrg1  levels  is  unclear,  and  although  the 
changes in levels of Erbb4 activity and Akt activity are not significantly different 
between  the  scr.rAAV  and  shErbb4.rAAV  treatment  groups,  it  is  known  that 
subtle changes in activity as measured by phosphorylation are less robust than 
changes in total protein levels.  Phosphorylation states are rapid and reversible 
modifications  that  are  dependent  on  cell  type  (Emamian  et  al.,  2004).  
Reductions  in  Akt  activity  have  been  associated  with  dopamine  receptor  D2 
(Drd2) over-activity (Beaulieu et al., 2004; Beaulieu et al., 2007).  Akt activity 
has also been associated with GABAergic (Wang et al., 2003; Oishi et al., 2009) 
and glutamatergic neurotransmission (Chalecka-Franaszek & Chuang, 1999).  The 
finding that Akt activity is altered following Erbb4 knockdown is of great interest 
as it is consistent with the growing opinion that Akt is a key mediator of Nrg1-
Erbb4  signalling  within  the  prefrontal  cortex,  dysregulation  of  which  may 
potentially  lead  to  symptoms  that  appear  to  be  dependant  upon  regulated 
function of this brain region.   
4.4.5 Potential off target effects and toxicity of rAAV injection 
GFAP expression is an indicator of astrocytic activation (gliosis) prior to visible 
anatomical neural tissue damage (O’Callaghan, 1988). There was no significant 
increase  in  Gfap  levels  in  viral  treated  samples  (scr.rAAV  or  shErbb4.rAAV) 
indicating  that  the  virus  itself  had  no  overt  adverse  effects  on  the  tissue 
surrounding the injection site.  Moreover, since there is no difference in Gfap 
levels between the viral treatment groups the shErbb4 sequence and thus Erbb4 
knockdown did not cause gliosis.  These findings are in agreement with injection 
of similar titres of rAAV than that used in the present study did not increase 
levels of gliosis (Klein et al., 2007).  The weights of the rats in either of the 
studies did not change after injection of rAAV, indicating there were no gross 
effects on the rat’s post-operative health which would lead to reduced eating 
and loss of body weight.  Finally, there were several measures where there was 
no change between treatment groups on Erbb4 and Nrg1 mRNA levels, as well as 146 
the  levels  of  housekeeping  gene  r18s  and  Erk  protein  levels,  suggestive  that 
Erbb4  knockdown  and  the  rAVV  particles  themselves  did  not  have  broad  off-
target effects. This finding is in concordance with a study that found only rAAVs 
used at titres above 3.7 x 10
12gc/ml had some toxicity and off target effects 
(Ulusoy et al., 2009). 
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4.5 Conclusions 
The data in this chapter present a host of data validating the knockdown of 
schizophrenia candidate Erbb4.   
I have shown in this chapter that following in vitro validation of rAAV particles 
expressing a hairpin sequence to rat  Erbb4 in NG108-15 cells and dissociated 
cortical cultures, it was possible to achieve a quantifiable knockdown of Erbb4 
protein expression in the rat PFC at 5 weeks post-surgery.  This knockdown of 
Erbb4 could be in pyramidal neurons, parvalbumin neurons and glial cells of the 
prefrontal cortex, as all of these cells types were capable of transduction by the 
rAAV particles. 
There was no quantifiable Erbb4 mRNA knockdown within the PFC at the time 
point  assessed,  however  the  ratio  of  Nrg1  to  Erbb4  mRNA  was  significantly 
increased,  which  was  in  accordance  with  the  finding  that  Nrg1  protein 
expression increased in response to Erbb4 knockdown.  Furthermore, the activity 
of  the  Akt  signalling pathway  was  significantly  reduced  by  Erbb4  knockdown, 
whereas the Erk signalling pathway was unaffected. 
Overall  this  chapter  provides  supporting  evidence  that  viral-mediated 
knockdown in vivo is achievable, and validates the view that any behavioural 
changes  due  to  shErbb4.rAAV  injection  will  be  due  to  subtle  but  significant 
knockdown of Erbb4 within the PFC.   
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5  Viral-mediated  Erbb4  knockdown  produces 
differential  effects  on  schizophrenia-related 
behaviours 
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5.1 Introduction 
Schizophrenia is characterised by several behaviour phenotypes, many of which 
have been induced in rodent models of schizophrenia by pharmacological agents, 
environmental insults and also by genetic insults (section 1.7).  Rodent models 
with manipulations of the schizophrenia candidate genes Nrg1 and Erbb4 show a 
diverse range of schizophrenia-related behavioural phenotypes (section 1.9.4); 
however it is unclear if these phenotypes are due to the function of Nrg1-Erbb4 
signalling in distinct brain regions.  It is therefore of great interest to determine 
region  specific  functionality  of  these  molecules  in  mediating  schizophrenia-
related behaviours in order to potentially dissect the roles of these candidate 
genes in schizophrenia.   
5.1.1 Prepulse inhibition of the startle response 
Prepulse  inhibition  of  the  startle  response  is  a  cross-species  phenomenon 
whereby a non-startling  “prepulse”  stimulus  suppresses  the  magnitude  of the 
startle  reflex  to  a  startling  stimulus.    This  test  is  widely  used  to  measure 
sensorimotor  gating  and  deficits  in  the  performance  of  this  task  have  been 
observed in patients with schizophrenia and also their unaffected relatives (Braff 
et  al.,  2001).    Decreased  PPI  is  also  apparent  in  multiple  other  neurological 
disorders  such  as  Huntington’s  disease,  obsessive  compulsive  disorder  (OCD), 
Tourette Syndrome and some forms of Bipolar disorder (Swerdlow et al., 1995; 
Castellanos et al., 1996; Hoenig et al., 2005; Gogos et al., 2009). 
5.1.2 Modalities of cognition assessed by PPI 
PPI  deficits in  schizophrenia  representing sensorimotor  gating  dysfunction are 
thought  to  correspond  to  the  inability  of  patients  to  filter  out  unimportant 
external stimuli leading to loss of focus and disorganised behaviour.  Although 
the exact functional consequence of deficits in PPI in schizophrenia is unknown 
PPI  has  been  termed  as  a  promising  endophenotype  for  schizophrenia  by  the 
CNTRICS program as a measure of “gain control” (Green et al., 2009).  Whether 
PPI deficits in schizophrenia are related to cognitive dysfunction is debatable, 
with  some  studies  showing  a  positive  correlation  of  PPI  performance  with 150 
performance in the CANTAB battery in healthy controls (Bitsios et al., 2006) and 
Global  Assessment    of  Function  and  Independent  Living  Scales  in  patients 
(Swerdlow et al., 2006) .  However, there appears to be no association of poor 
PPI with poor performance in tasks such as WCST in schizophrenia (Swerdlow et 
al., 2006). Therefore PPI deficits may be important in being an early signal to 
consequential  deficits  in  cognition.    However,  there  is  much  more  research 
needed to identify how deficits in PPI in schizophrenia patients manifest into 
cognitive deficits, and indeed which modality of cognition PPI deficits represent. 
5.1.3 Neuronal circuitry and neurotransmitters involved in PPI 
Studies  in  rats  have  helped  elucidate  the  brain  circuitry  involved  in  the 
maintenance  of  PPI;  this  complex  circuitry  involves  connections  between  the 
limbic cortex, ventral striatum, ventral pallidum and the pontine tegmentum, 
termed the CSPP circuit (Swerdlow & Geyer, 1999).  Lesioning or direct infusion 
of multiple substances directly into regions of the limbic cortex, including the 
mPFC, hippocampus and amygdala result in PPI disruption (Swerdlow, 2001).   
Pharmacological studies have highlighted some of the neurotransmitter systems 
that  disrupt  PPI  which  in  turn  may  elucidate  the  aberrant  neurotransmission 
occurring in schizophrenia resulting in dysfunctional PPI performance in patients.  
PPI is thought to be heavily dependant upon regulated dopaminergic signalling, 
as  over-stimulation  of  the  dopamine  system  by  direct  or  indirect  dopamine 
agonists such as amphetamine disrupts PPI in rodents (Mansbach 1998, Larrauri 
et al., 2010).  Moreover rats with genetic disruption of the dopamine transporter 
gene show deficits in PPI, namely due to the constant hyperdopaminergic state 
in the synaptic cleft via lack of dopamine clearance (Ralph et al., 2001; Barr et 
al., 2004).   
Blockade  of  glutamatergic  neurotransmission  also  results  in  PPI  deficits  in 
rodents  with  previous  work  from  our  laboratory  showing  that  acute  and  sub-
chronic PCP administration result in robust PPI deficits (Egerton et al., 2008). In 
addition, mice with a reduction in the expression of the NMDA receptor subunit, 
NR1, show PPI deficits (Duncan et al., 2004).  Other neurotransmitter systems 
also appear to play an important role in regulating PPI, with nicotine injection in 
rats resulting in increased PPI (Levin et al., 2005; Curzon 1994).  It is therefore 151 
clear  that  PPI  is  a  behaviour  regulated  by  a  distinct  but  complex  circuitry 
involving multiple neurotransmitter systems. 
5.1.4 Locomotor activity in response to a novel environment 
Although  positive  symptoms  such  as  hallucinations  and  delusions  cannot  be 
readily  assessed  in  rodents  other  positive  symptoms  such  as  psychomotor 
agitation, which is apparent in patients with schizophrenia, can be characterised 
by increased locomotor activity in response to a novel environment (Arguello & 
Gogos, 2006).  The open field task is an ideal way to measure locomotor activity 
utilising the inbuilt characteristic of rodents to be naturally explorative but also 
cautious  to  a  novel  environment.  Locomotor  activity  is  widely  used  to  study 
behavioural  phenotypes  similar to  positive  symptoms  in  schizophrenia  as  it is 
relatively easy and inexpensive to perform. 
Locomotor  activity  is  a  dopamine  dependent  process  and  in  some  studies 
increased  locomotor  activity  to  a  novel  environment  can  be  reversed  or 
dampened by antipsychotic treatment (which generally have high affinity for D2 
receptors)(Stefansson  et  al.,  2002).    Moreover,  mice  that  lack  D2  receptors 
perform at approximately half the locomotor activity of control mice (Kelly et 
al., 2008). 
5.1.5 Sensitivity to amphetamine 
In addition to assessing locomotor activity to a novel environment, many studies 
have employed the additional challenge of the psychostimulant amphetamine on 
locomotor activity.  This has been employed as it is known that amphetamine 
has psychosis- like effects in non-schizophrenic individuals (Carlsson & Lindqvist, 
1963) and also exacerbates positive symptoms in patients with schizophrenia.  
Moreover,  amphetamine  challenge  in  patients  with  schizophrenia  results  in  a 
much greater amphetamine-induced dopamine release than that seen in healthy 
controls (Laruelle et al., 1996; Breier et al., 1997; Abi-Dargham et al., 1998; 
Laruelle  et al., 1999)  and  therefore, changes in response to amphetamine in 
rodents  may  indicate  a  schizophrenia-like  dopaminergic  imbalance  due  to 
pharmacological challenge or gene manipulation.  Amphetamine acts primarily 
by  increasing  dopamine  levels  at  the  synaptic  cleft  (Seiden  et  al.,  1993). 152 
However, amphetamine not only increases dopamine levels but also levels of 
monoamines such as noradrenaline and serotonin (Kuczenski & Segal, 1997).   
Amphetamine  challenge  in  rodents  has  also  been  commonly  used  to  test  the 
intactness of the cortico-striatal loop which is essential in mediating the effects 
of  amphetamine  (Burns  et  al.,  1993).  Therefore  a  heightened  response  to 
amphetamine in response to a pharmacological agent or genetic modification 
may  indicate  a  disturbance  in  dopaminergic  signalling  resulting  from  a 
dysfunction in the cortico-striatal loop circuitry.   
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5.2 Aims 
The  aims  of  this  study  were  to  test  the  hypothesis  that  viral  mediated 
knockdown  of  Erbb4  within  the  mPFC  in  rats  produces  schizophrenia-related 
behaviour  in  rats.    This  was  achieved  by  examining  Erbb4  knockdown  on 
sensorimotor gating (PPI) and hyperactivity to a novel environment (open field), 
thus  determining  if  Erbb4  within  this  specific  brain  region  was  important  in 
mediating  or  regulating  these  behaviours.    In  addition,  the  effect  of  an 
amphetamine challenge on locomotor activity was investigated with the aim to 
determine if altering Erbb4 expression within the mPFC affected dopaminergic 
transmission and the integrity of the cortico-striatal loop.   
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5.3 Results 
5.3.1 Effect  of  viral-mediated  gene  manipulation  on  pre-pulse 
inhibition 
To assess if Erbb4 within the prefrontal cortex of the adult brain is important in 
regulation of sensorimotor gating rats underwent stereotaxic surgery receiving 
bilateral  injections  of  either  vehicle  (veh)n=7,  rAAV  encoding  a  scrambled 
hairpin sequence (scr) n=8 or rAAV encoding a hairpin sequence complementarily  
to  rat  Erbb4  (shErbb4)  n=8  (section  2.4.2).  One,  three  and  five  weeks  post-
surgery sensorimotor gating was assessed via measuring prepulse inhibition of 
the startle response (section 2.6.3).   
Startle response to 120dB startle alone pulses (i.e. those not preceded by pre-
pulse stimuli) was not affected by surgical group (F (2, 68) =1.19 p>0.05) (Figure 
5.1).  Startle response levels did not significantly change over the three time 
points  assessed  post-surgery,  with  no  significant  effect  of  week  on  startle 
response  (F(2,68)=1.64  p>0.05)  and  moreover  there  were  no  significant 
differences in startle levels between surgical groups at individual time points 
(surgical group x week interaction F(4, 68)=1 p>0.05).   
Mean % PPI (mean % PPI of 4, 8 and 16dB prepulse amplitudes) was significantly 
affected  by  surgical  group  (F  (2,  68)  =9.10  p<0.001),  with  post  hoc  analysis 
revealing  that  scrambled  hairpin  virus  (scr.rAAV)  treated  rats  (p<0.01)  and 
shErbb4  virus  (shErbb4.rAAV)  treated  rats  (p<0.001)  had  a  significantly  lower 
mean %PPI than vehicle treated rats.  This effect was a general observation over 
all time points with no significant interaction between surgical group and week 
being found (F (4, 68) =1.1 p>0.05).  Interestingly, there was a significant effect 
of  week  on  mean  %  PPI  (F  (2,  68)  =11.46  p<0.001)  with  mean  %  PPI  being 
significantly higher at week 5 than at weeks 1 (p<0.001) and 3 (p<0.05) (Figure 
5.2).   
To  probe  the  results  observed  with  mean  %  PPI  further,  the  effects  of  viral 
manipulation on % PPI were analysed by individual prepulse amplitudes.  The 
most striking finding was that prepulse amplitude had a very significant effect 155 
on  %  PPI  (F  (2,206)  =213.05  p<0.001),  with  %  PPI  increasing  with  increasing 
prepulse  amplitude  level.    %  PPI  at  a  prepulse  amplitude  of  16dB  was 
significantly higher than at amplitudes of 8dB (p<0.001) and 4dB (p<0.001) and 
prepulse amplitude of 8dB resulting in higher % PPI than 4dB (p<0.001).   The 
analysis of % PPI by individual prepulse amplitude yielded very similar findings to 
those of mean % PPI.  Again surgical group had a significant effect on % PPI (F (2, 
206) =13.07 p<0.001) with both viral groups showing reduced %PPI than vehicle 
treated rats.  In agreement with mean % PPI, week also had a significant effect 
on % PPI (F (2,206)=15.61 p<0.001) with % PPI being higher at week 5 than at 
weeks 1 and 3, however this effect was observed over all prepulse amplitudes 
with  no  prepulse  amplitude  x  week  interaction  being  found  (F  (4,206)=0.41 
p>0.05). 
Unlike  the  findings  of  mean  %  PPI,  %  PPI  analysed  by  individual  prepulse 
amplitudes showed there was a significant interaction between surgical group 
and week (F (4, 206) =2.57 p<0.05) owing to shErbb4.rAAV treated rats having a 
significantly  lower  %  PPI  than  vehicle  treated  rats  at  1  week  post-surgery 
(p<0.05) and scr.rAAV treated rats having significantly lower % PPI than vehicle 
treated rats at 3 weeks post-surgery (p<0.001).  These observations were general 
findings  over  all  prepulse  amplitudes  as  there  was  no  significant  interaction 
between surgical group x prepulse amplitude x week (F (8, 206) =0.95 p>0.05) 
(Figure 5.3).   
 
 
 
 
 
 
 156 
 
Figure 5.1 Effect of viral mediated gene manipulation on startle response.  
The startle response to 120dB startle only trials at 1, 3 and 5 weeks following 
bilateral injections of vehicle (veh) (n=7), scr.rAAV (scr) (n=8) or shErbb4.rAAV 
(shErbb4) (n=8) into the mPFC.  There was no effect of surgical group on startle 
response.  Data represents mean startle response (measured in arbitrary units 
(a.u.)) ± SE. 
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Figure 5.2 Effect of viral mediated gene manipulation on mean % PPI.  % PPI  
(mean of %PPI at prepulse amplitudes of 4dB, 8dB and 16dB) was measured at 1, 
3 and 5 weeks following bilateral injections of vehicle (veh) (n=7), scr.rAAV (scr) 
(n=8) or shErbb4.rAAV (shErbb4) (n=8) into the mPFC. Data represents mean ± 
SE.  Data were analysed using two-way repeated measures ANOVA followed by 
Tukey’s test for multiple comparisons.  Mean %PPI was overall significantly lower 
in  scr.rAAV  (p<0.01)  and  shErbb4.rAAV  (p<0.001)  treated  rats  compared  to 
vehicle treated rats.     
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Figure 5.3 Effect of viral-mediated gene manipulation on % PPI at prepulse 
amplitudes of 4dB, 8dB or 16dB.  % PPI was assessed at prepulse amplitudes 
of 4, 8 and 16dB at 1, 3 and 5 weeks following bilateral injections of vehicle (veh) 
(n=7),  scr.rAAV  (scr)  (n=8)  or  shErbb4.rAAV  (shErbb4)  (n=8)  into  the  mPFC.   
Data  represents  mean  ±  SE.    Data  were  analysed  using  two-way  repeated 
measures ANOVA followed by Tukey’s test for multiple comparisons.  %PPI was 
overall  significantly  lower  in  scr.rAAV  (p<0.001)  and  shErbb4.rAAV  (p<0.001) 
treated rats compared to vehicle treated rats   
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5.3.2 Effect  of  viral  mediated  gene  manipulation  on  locomotor 
activity 
In  the  same  rats  that  were  being  assessed  for  sensorimotor  gating  deficits, 
locomotor activity in response to amphetamine was also measured to assess if 
Erbb4 within the prefrontal cortex of the adult brain is important in regulation 
of cortico-striatal dopamine regulation.  23 rats that had received intra-mPFC 
injections  of  vehicle  (veh)  n=7,  rAAV  encoding  a  scrambled  hairpin  sequence 
(scr)  n=8  or  rAAV  encoding  a  hairpin  sequence  directed  against  rat  Erbb4 
(shErbb4) n=8 (section 2.4.2) were assessed in the open field one, three and five 
weeks  post-surgery  (section  2.5).    In  the  open  field  assessments  rats  were 
monitored for a 30 minute habituation period (2.5.2), and injected with vehicle 
(0.9% w/v saline) or 1mg/ml amphetamine before being monitored for a test 
period of 60 minutes (section 2.6).    
Analysis  of  locomotor  activity  during  the  30  minute  habituation  phase  to  the 
open  field  showed  that  there  was  no  significant  difference  in  the  distance 
travelled during this habituation period on the first or second exposure to the 
open field apparatus at each week that the locomotor activity was assessed (F 
(1,  827)  =1.75  p>0.05).    Therefore  any  further  effects  seen  during  the 
habituation  period  are  not  due to differences  by day.   There was  an  overall 
significant effect of surgical group on distance travelled during the habituation 
phase (F (2, 827)=7.08 p=0.001) with post hoc analysis showing vehicle treated 
rats travelled less distance than scrambled hairpin virus treated rats (p<0.01) 
and shErbb4 virus treated rats (p<0.01).  However these significant differences 
between  surgical  groups  were  not  observed  at  any  individual  week  assessed 
(surgical group x week interaction F (4, 827) =1.13 p>0.05) 
The rats in general travelled a significantly longer distance at week 5 than at 
weeks  1  (p<0.01)  or  3  (p<0.001)  explaining  the  significant  effect  of  week  on 
distance travelled during the habituation phase (F (2,827) =7.08 p<0.001).  There 
was also a significant effect of time on distance travelled during the habituation 
phase (F (5, 827)=280.91 p<0.001) with distance travelled dropping over time.   
Each time bin was significantly different from the previous time bin until 20 
minutes  into  the  habituation  phase  where  final  three  time  bins  were  not 160 
statistically significant from each other.  This drop in distance travelled over 
time during the habituation phase was observed over all surgical groups at all 
weeks owing to no significant surgical group x week x time interaction (F (20, 
827)=0.38 p>0.05) (Figures 5.4A-C).   
5.3.3 Effect of viral mediated gene manipulation on sensitivity to 
amphetamine 
Concurrent with the results of the locomotor activity habituation phase, there 
was a significant effect of surgical group on distance travelled during the test 
phase (F (2, 1655) =6.02 p<0.01).  Again, this was due to scr.rAAV treated rats 
(p<0.05) and shErbb4.rAAV treated rats (p<0.01) travelling longer distances than 
vehicle treated rats.  Distance travelled was significantly affected by the drug 
administered (F (1, 1655)  =323.6 p<0.001) with 1mg/kg amphetamine causing 
hyperlocomotor activity in all surgical groups in all weeks assessed.  Importantly, 
distance travelled was not affected by the cross-over design implemented in the 
experiment as the day amphetamine was administered (day 1 or 2 at each week) 
did not have a significant effect on distance travelled in the test phase ((F (1, 
1655)=0.25 p>0.05). 
Importantly at 5 weeks post-surgery rats with Erbb4 knockdown within the mPFC 
travelled significantly longer distance under the influence of amphetamine than 
vehicle (p<0.05) or scr.rAAV treated rats (p<0.001).  This led to a significant 
group x week x drug interaction ((F (4, 1655)=5.3 p<0.001) on distance travelled 
in the test phase.  Post hoc comparisons revealed that although there was an 
effect at 5 weeks post-surgery, there was no significant difference in the effect 
of amphetamine challenge between surgical groups at weeks 1 or 3 post-surgery. 
 Some similarities between the results of the habituation phase and test phase 
were apparent with saline administered scr.rAAV treated rat travelling longer 
distances than saline administered vehicle treated rats at weeks 3 and 5 post-
surgery. 
Time had a significant effect on distance travelled in the test phase ((F (11, 
1655)=7.22  p<0.001)  where  it  was  observed  that  at  30  minutes  after  saline 
injection the rats in all  surgical groups were travelling only very short distances.  161 
Amphetamine treated rats’ peak distance travelled was observed at 15 minutes 
post-injection. 
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Figure  5.4  Effects  of  viral  mediated  gene  manipulation  on  amphetamine 
induced hyperlocomotor activity.  Locomotor activity was assessed 1 (A), 3(B) 
and 5(C) weeks post-bilateral injections of vehicle (veh) (n=7), scr.rAAV (scr) (n=8) 
or shErbb4.rAAV (shErbb4) (n=8) into the mPFC of rats. Activity was measured 
during a 30 minute habituation phase (habituation, left panel of graphs) and a 1 
hour testing phase (test) immediately following s.c. injection of 0.9% saline (saline, 
lower data sets on graph) or 1mg/kg amphetamine (amph, upper data sets on 
graphs).    Data  represents  distance  travelled  in  5  minute  time  bins  ±SE  mean 
analysed using three-way repeated measures ANOVA followed by Tukey’s test for 
multiple  comparisons.  ANOVA  analysis  showed  an  overall  significant  effect  of 
drug administration on locomotor activity with amphetamine significantly increasing 
distance travelled compared to saline (p<0.001).  Post hoc comparisons showed 
shErbb4.rAAV treated rats had a significantly heightened locomotor response to 
amphetamine  at  5  weeks  post-surgery  compared  to  vehicle  (p<0.05=@)  and 
scr.rAAV (p<0.001=***) treated rats.  Saline injected vehicle treated rats travelled 
significantly shorter distances than saline injected scr.rAAV treated rats at 3 weeks 
(##=p<0.01)  and  5  weeks  (#=p<0.05)  post-surgery  and  saline  injected 
shErbb4.rAAV treated rats 3 weeks post-surgery ($=p<0.05). 
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5.4 Discussion 
5.4.1 Erbb4 knockdown does not disrupt PPI 
The lack of changes in the amplitude of startle response between surgical groups 
may suggest that there is no difference in the levels of anxiety following viral 
injection or Erbb4 knockdown, as increases in the startle levels per se have been 
previously associated with increased anxiety (Deakin et al., 2009).  The finding 
that  there  is  no  difference  in  %  PPI  between  the  rAAV.scr  and  rAAV.shErbb4 
treatments groups suggests that decreasing Erbb4 specifically in the mPFC does 
not affect sensorimotor gating. This is in agreement with a previous study using 
heterozygous null  Erbb4 transgenic mice (Stefansson  et al., 2002).  However, 
several studies have also shown deficits in PPI following CNS specific knock-out 
of Erbb2/4 (Barros et al., 2009) or knock-out of Erbb4 in parvalbumin-positive 
interneurons  (Wen  et  al.,  2010).    Variation  in  the  PPI  results  obtained  from 
transgenic Erbb4 mice may reflect differences in which isoforms are affected by 
the gene manipulation and in addition which background strains of mice are used 
for backcrossing.   
This is highlighted when reviewing the literature of Nrg1 mutant mice and PPI 
performance.  The effect on PPI appears to be dependant upon which isoform of 
Nrg1 is mutated: deficits in PPI have been reported in transmembrane domain 
knock-out mice (Stefansson et al., 2002) and type III Nrg1 knock-out mice, but 
no changes in PPI in epidermal growth factor containing isoforms (Ehrlichman et 
al., 2009).    Moreover, Nrg1 type I over-expression also results in deficits in PPI 
(Deakin et al., 2009), conflicting with results of this study, as an increase of 
Nrg1 in the mPFC, secondary to Erbb4 knockdown results in no change in PPI.  As 
well as differences in which isoforms are being manipulated, these studies are 
manipulating the expression of Erbb4/Nrg1 signalling in multiple brain regions.  
Therefore,  it  is  plausible  that  manipulation  of  Nrg1-Erbb4  signalling 
simultaneously in multiple brain regions disrupts PPI, as PPI depends on cortical, 
limbic and striatal systems (Swerdlow et al., 2001).  
Additionally, it is also possible that the level of Erbb4 expression changes in this 
study were too subtle to cause a gross effect on PPI.  However, a recent study 165 
using antisense oligodeoxynucleotides to knockdown the expression of mortalin 
within  the  mPFC  showed  that  even  though  there  was  only  a  trend  towards 
knockdown of mortalin protein within the PFC there was still a significant deficit 
in PPI in mortalin knockdown rats (Gabriele et al., 2010).  Interestingly, recent 
studies utilising viral-mediated gene manipulation to knock down the expression 
of Disc1 in the prefrontal cortex of mice in utero led to PPI deficits at postnatal 
day 56 (Niwa et al., 2010) suggesting Disc1 expression in the PFC is essential for 
intact  sensorimotor  gating.    A  subsequent  study  has  showed  that  Disc1 
expression is regulated by Nrg-Erbb signalling but it is not dependent on Erbb4 or 
the Erbb4-specific ligand, Nrg3 (Seshadri et al., 2010), further emphasising that 
Erbb4 may not be important in sensorimotor gating.   
Another pertinent point is that all of the studies of the effect of Nrg1 and Erbb4 
on PPI have been carried out in mice, whereas this present study has utilised 
rats.   Although  the neuroanatomical systems that underpin PPI are similar in 
mice and rats, there is some evidence that PPI differs between rat and mice 
with 5-HT-1A agonists (Gogos et al., 2008) and D2 receptor agonists (Mohr et al., 
2007) having differing roles between the species.  In further support of the lack 
of effect on PPI  in the present study, a recent study reported that although 
polymorphisms  in  the  5HT2R  and  COMT  genes  elicited  changes  in  PPI 
performance, a polymorphism in NRG1 had no effect on PPI levels (Quednow et 
al., 2009).  However, another study did show an effect of NRG1 genotype on PPI 
performance (Hong et al., 2008), albeit this study was investigating a different 
SNP.    This  strengthens  the  idea  that  the  isoform  or  exon  targeted  for  gene 
manipulation may have a strong impact in the behavioural outcome. 
Although  there  was  no  difference  in  %PPI  between  both  the  viral  treatment 
groups, the viral groups did have overall a reduced %PPI compared to vehicle 
treated rats.  This suggests that the viral particles themselves had a slight effect 
on PPI, in keeping with the findings that rats treated with viral particles were 
different from vehicle treated rats in terms of locomotor activity (see sections 
5.3.2 and 5.3.3) and response speeds in the 5-CSRTT (section 6.3).  These “off-
target” effects of the viral particles themselves are difficult to explain as the 
majority of other studies using viral particles in conjunction with behavioural 
analysis  do  not  include  comparison  of  data  from  viral-manipulated  rats  with 
vehicle treated rats and so therefore these off target effects may actually be 166 
routinely occurring.  As the main focus of the present study was to investigate 
the role of Erbb4 on behaviour the effects between viral treatment groups (or 
lack of effect) is the key observation. 
As a final point it is also significant to highlight that the lack of effects seen in 
this study on PPI performance is unlikely due to experimental limitations as the 
values  obtained  were  very  similar  to  that  of  another  study  in  rats  in  our 
laboratory where %PPI was altered by a pharmacological challenge (Egerton et 
al., 2008).  Also in concordance with this study %PPI increases with repetition of 
the task, suggesting sensitisation/habituation of the rats to the anxiolytic nature 
of the task.  Moreover, the quality of the experimental set-up is confirmed by 
%PPI  values  increasing  with  the  increasing  amplitude  of  the  pre-pulse.  
Furthermore, this also validates that the hearing of the rats was not impaired by 
the atraumatic earbars that were in place during stereotaxic surgery.   
5.4.2 Erbb4  knockdown  has  no  effect  on  general  locomotor 
activity 
As with PPI, knockdown of Erbb4 specifically within the mPFC did not result in a 
change in response to a novel environment.  Thus there were no differences 
between  scrambled  hairpin  virus  treated  rats  and  rats  treated  with  shErbb4 
virus.  All groups of rats appeared to habituate to the novel environment of the 
open field apparatus and this appeared to take around 20 minutes.  The increase 
in distance travelled during the habituation period at week 5 compared to weeks 
1 and 3 may be due to the rats becoming desensitised to the novelty of the open 
field  arenas,  and  therefore  less  anxious  to  their  surrounding  environment, 
resulting in the rats moving more freely around the arena.   
The hypolocomotor state of the vehicle treated group of rats compared to the 
virus treated groups reflects the increase in response speeds observed in the 5-
CSRTT in the virus treated rats (section 6.3).  In general, tissue damage caused 
by injection of the virus would be hypothesised to cause a motor retardation 
rather  than  an  increase  in  motor  activity.    As  seen  in  the  PPI  task,  where 
differences were observed between vehicle and virus treated rats there may be 
some minor off-target effect of the rAAV in general.  Yet again, this may be a 167 
common  occurrence  not  revealed  in  previous  studies  utilising  rAAV  by  the 
exclusion of “non-virus” behavioural control group.  For example many studies 
have  used  viral-mediated  gene  manipulation  to  target  genes  involved  in 
Parkinson’s  disease,  with  gene  manipulation  causing  a  blatant  motor  deficit 
(measured by lever pressing or open field) however the effect of viral injection 
alone on these measures is not assessed (Hommel et al., 2003).  Moreover, this 
hyperlocomotor effect by viral injection in the present study is not significant at 
individual  time  points  and  so  is  clearly  not  a  gross  deficit  while  the  vehicle 
treated  rats  are  still  travelling  an  average  of  7.4  meters  in  the  30  minute 
habituation  phase.    Interestingly,  Xue  and  collegues  (2009)  found  an  altered 
response to amphetamine in mice injected with rAAV expressing GFP compared 
to  saline  treated  rats.    The  authors  suggest  this  was  an  effect  of  the  viral 
particles themselves, and propose that the GFP expressed from the rAAV may 
have built up within the transduced cells, and led to neurotoxicity (Xue et al., 
2009).   
As with PPI there have been many studies of basal locomotor activity in Erbb4 
and Nrg1 transgenic mouse lines, and akin to the PPI data many of the studies of 
locomotor activity in these mice are contradictory.  Studies of Erbb4 transgenic 
mice  have  showed  locomotor  phenotypes  of  hyperactivity  (Stefansson  et  al., 
2002; Wen et al., 2010), hypoactivity (Golub et al., 2004) and in concordance 
with the present study locomotor activity akin to wildtype controls (Barros et 
al., 2009).  Neuregulin knock-out mice also show a varied response to novelty 
induced locomotor activity with multiple studies showing a hyperactive response 
compared to wildtypes (Gerlai et al., 2000; Stefansson et al., 2002; Karl et al., 
2007; O’Tuathaigh et al., 2007).  However some studies have also shown a motor 
response in Nrg1 knockouts that is not different from wildtypes (Rimer et al., 
2005; Chen et al., 2008; Ehrlichman et al., 2009). Over expression of type I Nrg1 
appears to result in a slight hypolocomotor activity phenotype which is more 
evident in female transgenic mice (Deakin et al., 2009). 
Divergence of the results in this study compared to previous studies again may 
be due to the region specific focus of the manipulation of gene expression in this 
study compared to global gene manipulation, due to the isoforms or ratio of 
heterodimers affected by the gene manipulation. 168 
5.4.3 Erbb4 knockdown induces hypersensitivity to amphetamine 
Firstly, the hyperlocomotor behaviour observed in the viral treated rats during 
the habituation phase was carried through to the testing phase to some extent in 
saline injected rats.  This effect was apparent at multiple time points (unlike 
the response to amphetamine which was present only at 5 weeks post-surgery) 
suggesting that this motor effect was not due to gene manipulation.  Moreover 
this general virus vs. vehicle hyperactivity was not observed when the rats were 
injected  with  amphetamine,  this  may  highlight  again  that  the  potential  “off 
target” effect of rAAV injection on motor activity is not a gross motor effect as 
under  the  influence  of  amphetamine  the  rats’  motor  systems  are  greatly 
challenged and motor deficits should thus be more apparent under amphetamine 
challenge than with saline. 
The  effect  of  amphetamine  increasing  locomotor  activity  was  in  complete 
agreement with previous studies and pharmacological evidence of amphetamine 
increasing dopamine levels in the synaptic cleft highlighting the soundness of the 
experimental set-up and behavioural analysis.  There was a clear distinction in 
the locomotor response to amphetamine between the shErbb4.rAAV treated rats 
and vehicle and scr.rAAV treated rats at 5 weeks post-surgery, although there 
were no changes in the response to amphetamine between surgical groups at 1 
or  3  weeks  post-surgery.    Thus,  at  5  weeks  post-viral  injection  there  was 
confirmed Erbb4 knockdown and also effects on multiple sites of the Nrg1-Erbb4 
signalling pathway (section 4.3.5), as well as the manifestation of heightened 
locomotor  response  to  amphetamine.    The  behavioural  response  at  this  time 
point  also  correlates  with  the  eGFP  expression  analysis  where  peak  viral 
expression appeared to be somewhere between 3 and 8 weeks post-surgery.  It is 
unclear whether peak knockdown of Erbb4 was also at 5 weeks post-surgery as 
the expression profiling was only carried out at one time point.  However, it is 
also conceivable that the behavioural response occurred following peak Erbb4 
knockdown as it is likely behavioural changes are due to changes in multiple 
aspects  of  neuronal  circuitry  which,  in  all  probability,  would  not  be  an 
instantaneous occurrence.   169 
Hypersensitivity  to  amphetamine  solely  in  shErbb4.rAAV  treated  rats  suggests 
that  Nrg1-Erbb4  signalling  within  the  mPFC  is  important  in  regulating  the 
cortico-striatal  loop  functionality  and  modulating  dopaminergic 
neurotransmission.    To  my  knowledge  only  one  previous  study  has  utilised 
amphetamine  challenge  in  Erbb4  manipulated  animals  and  the  results  are 
strikingly  similar  to  the  present  study.    Roy  et  al.  (2007)  showed  that  mice 
expressing a dominant negative form of Erbb4 in oligodendrocytes to eliminate 
Erbb4  function  in  white  matter  had  a  potentiated  locomotor  response  to 
amphetamine.    Furthermore,  this  study  also  showed  that  these  mice  had 
increased D1-like receptor binding and dopamine transporter levels in multiple 
brain regions including the cortex and have increased evoked dopamine release 
(Roy et al., 2007).  Taking the results of this previous study into consideration 
may  suggest  that  knockdown  of  Erbb4  in  the  mPFC  may  result  in  similar 
dopaminergic changes.   
In  addition,  there  is  evidence  to  suggest  that  Nrg1  function  is  important  in 
dopamine regulation specifically in the mPFC, as Nrg1 administration directly 
into this brain region results in a dopaminergic overflow in the mPFC of mice 
(Kato et al., 2010).  Increased Nrg1 expression and decreased Erbb4 expression 
in  the  mPFC  of  the  rats  in  this  study  following  shErbb4.rAAV  injection  may 
therefore have an increased release of dopamine within their mPFC which would 
lead to an increased sensitivity to the locomotor effects of amphetamine, but 
this  increased  response  to  amphetamine  may  also  be  due  to  changes  in 
dopamine re-uptake, changes in dopamine receptor number, altered dopamine 
transporter function/expression or reduced metabolism of amphetamine itself. 
Although  the  main  region  thought  to  elicit  the  hyperdopaminergic  effect  of 
hypersensitivity to amphetamine challenge is the striatum, it has been noted 
that the hyperdopaminergic state of this brain region is most likely caused by 
over activation of glutamatergic tracts of the PFC and hippocampus connecting 
to  the  mesolimbic  pathway  (Grace,  1991).    It  is  therefore  plausible  that 
manipulation of neurotransmission specifically in the mPFC would be capable of 
affecting  the  cortico-striatal  circuitry  resulting  in  the  observed  behavioural 
changes. 170 
Interestingly, manipulation of genes related to Nrg1-Erbb4 signalling results in 
altered response to amphetamine.  For example, mice with knock-out of genes 
encoding enzymes known to cleave Nrg1 and/or Erbb4 (and therefore aid their 
signalling capabilities) show heightened response to amphetamine (Dejaegere et 
al.,  2008).    It  is  worthy  to  note,  that  manipulation  of  other  schizophrenia 
candidate genes results in altered response to amphetamine with viral mediated 
knockdown  of  Disc1  within  the  mPFC  resulting  in  hypersensitivity  to  the 
hyperlocomotor effects of amphetamine.  It has been shown that amphetamine 
challenge dephosphorylates Akt, via increased dopamine signalling through D2 
receptors,  enabling  Gsk3b  activity  which  is  in  part  responsible  for  the 
development of the hyperlomotor response (Beaulieu et al., 2004; Beaulieu et 
al., 2005).  Therefore, if as a result of Erbb4 knockdown Akt signalling in the 
mPFC is somewhat already reduced (section 4.3.5) a challenge of amphetamine 
would have an even greater effect on these rats due to further reduced Akt 
activity.    The  data  of  the  present  study  are  therefore  consistent  with  Erbb4 
knockdown potentiating the ability of amphetamine to reduce Akt signalling in 
the prefrontal cortex, and this resulting in hyperlocomotion. 
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5.5 Conclusions 
The data in this chapter present multiple interesting findings regarding the role 
Nrg1-Erbb4  signalling  in  schizophrenia-related  behaviours  including  PPI  and 
locomotor  activity  in  response  to  a  novel  environment  and  an  amphetamine 
challenge. 
Lack of response of the manipulation of Nrg1-Erbb4 signalling in the mPFC on PPI 
and  novelty-induced  hyperactivity  strengthens  the  hypothesis  that  Erbb4 
signalling in the specific brain region of the mPFC does not play a key role in 
these  rather  general behaviours  and instead  may be  important in  modulating 
more  cognitive  based  behaviours.    Although  multiple  previous  studies  have 
shown  effects  of  Nrg1-Erbb4  manipulations  on  PPI  and  novelty  induced 
hyperactivity, the results of this present study further emphasise the need to 
investigate gene functions in specific brain regions and the validity of using viral 
mediated gene manipulation to accomplish this.   
Overall, a key finding of this study was that Erbb4 knockdown specifically within 
the mPFC results in hypersensitivity to amphetamine.  This suggests that, Nrg1-
Erbb4 signalling is important in regulating dopaminergic neurotransmission in the 
cortico-striatal loop.   
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6.1 Introduction  
Deficits in prefrontal cortex function are thought to be highly contributory to the 
cognitive deficits of schizophrenia; however the physiological origins of these 
deficits are still unknown.  Initiatives to identify potential therapeutic targets of 
the poorly treated cognitive deficits in schizophrenia are ongoing.  To progress 
pre-clinical translational animal models of cognitive deficits of schizophrenia, 
the cognitive domains that encompass this symptom group have been identified 
and suitable rodent behavioural paradigms recommended (Young et al., 2009).  
Of these the 5-choice serial reaction time task (5-CSRTT) has high validity for 
assessing  cognitive  modalities  dependent  on  regulated  prefrontal  cortical 
function.  Other rodent behavioural tasks are known to measure PFC-dependent 
behaviour and have been previously used to assess the effect of mutations in 
schizophrenia  candidate  genes,  such  as  the  attentional  set-shifting  task  to 
measure COMT function (Tunbridge et al., 2004).  However, the 5-CSRTT was the 
most appropriate task to use in the present study due to the large number of 
animals used.  We therefore required a behavioural task that is high throughput 
and automated, such as the 5-CSRTT.  The attentional set-shifting task requires 
manual monitoring of the rats behaviour, resulting in a maximum of 4 rats being 
able to be tested per day. 
Several  potential  risk  genes  for  schizophrenia  have  been  identified,  with  the 
NRG1-ERBB4  genes  strong  candidates.    Their  location  within  the  prefrontal 
cortex  and  expression  in  neuronal  subtypes  that  regulate  neurotransmission 
within this brain region make them attractive molecules to study in terms of 
cognition (sections 1.1.2 and 1.1.4).  However previous animal models of these 
genes have failed to assess prefrontal cortex dependent cognitive behaviours. 
6.1.1 Aspects of cognition assessed by 5-CSRTT 
The  5-CSRTT  was  originally  developed  to  investigate  attentional  deficit 
hyperactivity disorder (ADHD) as an assessment of sustained attention in rodents 
(Carli  et  al.,  1983).    This  basic  form  of  the  5-CSRTT  parallels  that  of  the 
continuous performance task (CPT) which is routinely used in the clinic to assess 
attentional deficits in humans with ADHD or schizophrenia (Rosvold et al., 1956).  174 
Although  originally  developed  to  quantify  sustained  attention,  the  5-CSRTT 
simultaneously  assesses  multiple  attributes  of  cognition  including:  sustained, 
divided and selective attention, impulse control, cognitive flexibility, motivation 
and processing speed (Robbins et al., 2002).  It is well known that many of these 
aspects  of  cognition  measured  by  the  5-CSRTT  are  dysfunctional  in 
schizophrenia,  adding  to  the  validity  this  task  has  in  serving  as  a  good  pre-
clinical  assessment  of  schizophrenia-related  cognitions  following 
pharmacological, neural or genetic manipulations.  As with the CPT task, the 5-
CSRTT can be modified by altering inter-trial interval or stimulus duration to 
further challenge the sensory and attentional demand on the rodents.   
 
6.1.2 Neural systems involved in 5-CSRTT performance 
The neuroanatomical involvement of brain regions in 5-CSRTT performance has 
been thoroughly assessed (in rats) by lesion studies.  The frontal cortical systems 
are of critical importance to 5-CSRTT performance with excitotoxic lesions of 
the  mPFC  producing  significant  deficits  in  performance  of  the  task  including 
increases in perseverative responses and response latencies simultaneous with a 
reduction  in  accuracy  (Muir  et  al.,  1996).    In  addition,  studies  quantifying 
neuronal  activity  support  the  importance  of  cortical  areas  on  5-CSRTT 
performance,  with  increased  [
14C]deoxyglucose  uptake  correlating  with 
increased  accuracy  in  regions  of  the  forebrain  (Barbelivien  et  al.,  2001).  
Furthermore, discrete areas of the prefrontal cortex have been shown to have 
distinct roles in 5-CSRTT performance, with lesions of the dorsal mPFC producing 
decreases in accuracy (Passetti et al., 2002; Chudasama et al., 2003), whereas 
lesions  of  more  ventral  regions  of  the  mPFC,  such  as  the  prelimbic  and 
orbitofrontal regions, result in increased perseverative responses (Chudasama & 
Muir,  2001;  Passetti  et  al.,  2002).    Concurrent  with  findings  in  human  CPT 
performance (Cohen et al., 1998), the hippocampus does not appear to have a 
major  role  in  5-CSRTT  performance  as  bilateral  lesions  have  little  effect  on 
performance (Kirkby & Higgins, 1998).  The medial striatum however, is thought 
to play a very important role in 5-CSRTT performance with the same disruptions 
in performance observed in rats with bilateral lesions of either mPFC or striatum 
as in rats with a unilateral lesion of the mPFC in one hemisphere and a lesion of 
the medial striatum in the contra-lateral hemisphere (Christakou et al., 2001).  175 
Together these data suggest that an intact cortico-striatal system is necessary 
for task performance.   
 
6.1.3 Neurotransmitter systems involved in 5-CSRTT performance 
Pharmacological  studies  have  allowed  some  elucidation  of  which 
neurotransmitter  systems  are  involved  in  aspects  of  5-CSRTT  performance.  
Studies  using  the  5-CSRTT  have  shown  involvement  of  several  monoaminergic 
neurotransmitter systems.  The regulation of the dopaminergic system is of great 
importance to 5-CSRTT performance, as dopamine depletion by 6-OHDA lesions 
of  the  mPFC  result  in  decreased  accuracy  when  the  task  parameters  are 
manipulated to challenge the rats further (Robbins et al., 1998).  Moreover, D1 
receptor activation in the PFC of rats increased accuracy only in rats performing 
sub-optimally (Granon et al., 2000).  As well as the dopaminergic system, the 
noradrenergic system is also vital in 5-CSRTT performance: the noradrenaline re-
uptake inhibitor, atomoxetine, reduces premature responses in the 5-CSRTT in 
rats (Navarra et al., 2008; Robinson et al., 2008) paralleling the improvement in 
attention and impulsivity seen with noradrenaline re-uptake inhibitors in clinical 
studies  in  patients  with  ADHD  (Chamberlain  et  al.,  2007).    However  clinical 
studies  in  patients  with  schizophrenia  show  little  effect  of  atomoxetine  on 
cognition (Kelly et al., 2009) or add-on therapies with other noradrenaline re-
uptake inhibitors (Poyurovsky et al., 2010).  However, as atomoxetine stimulates 
the overflow of both dopamine and noradrenaline in PFC it is unclear whether 
the  procognitive  effects  are  due  to  increases  in  dopamine  or  noradrenaline 
(Bymaster et al., 2002). 
 
Other drugs which are non-selective for their monoaminergic site of action also 
have effects on 5-CSRTT performance.  For example methylphenidate is a non-
selective dopamine/noradrenaline re-uptake inhibitor which has been previously 
shown  to  increase  accuracy  in  the  5-CSRTT  along  with  increasing  premature 
responding (Paine et al., 2007). Conversely, d-amphetamine, although it induces 
release  of  monoamines,  has  an  inhibitory  effect  on  5-CSRTT  performance, 
increasing  premature  and  perseverative  responses  (Cole  &  Robbins,  1987; 
Paterson  et  al.,  2011).    The  multiple  action  site  of  this  drug  including, 
dopamine,  5-HT  and  noradrenaline  make  its  actions  hard  to  interpret.    The 176 
COMT  inhibitor  tolcapone,  which  has  previously  been  shown  to  enhance 
performance  in  set-shifting  thought  to  be  by  increased  PFC  dopamine  levels 
(Tunbridge et al., 2004) has no effect in 5-CSRTT performance (Paterson et al., 
2011).   
 
Serotonergic  systems  also  play  a  central  role  in  5-CSRTT  and  are  thought  to 
mediate key effects on premature responding (Robbins et al., 2002).  However, 
the importance of the PFC in mediating these effects is under enquiry as direct 
infusions of 5-HT receptor antagonists into the infra-limbic or pre-limbic cortex 
had no effect on impulsivity in 5-CSRTT, but infusion of a 5-HT2A antagonist into 
the nucleus accumbens reduced impulsivity (Robinson, et al., 2008).  This may 
explain  why  newer  atypical  antipsychotic  treatments,  which  generally  have 
affinity  for  5-HT  receptors  as  well  as  dopamine  receptors,  have  had 
disappointing results in alleviating cognitive deficits in schizophrenia.   
 
In  line  with  the  opinion  that  the  high  rate  of  smokers  among  schizophrenia 
patients is for self-medicating purposes, nicotine administration to rats has been 
shown to increase performance in the 5-CSRTT (Young et al., 2004; Pattij et al., 
2007; Semenova et al., 2007).  However, many of these studies have shown that 
the subtle effect of nicotine on accuracy is only detectable after chronic/sub-
chronic nicotine in sub-optimally performing rats or mice in 5-CSRTT paradigms 
where the task parameters were manipulated.  
 
It is important to take into consideration the gross amount of interplay between 
these neurotransmitter types and also interplay between the brain regions that 
appear to be affected by these pharmacological agents.  It is most likely that it 
is a strict control between the levels of all these neurotransmitters that lead to 
optimal performance in the 5-CSRTT.  
 
6.1.4 The  effects  of  genetic  manipulation  on  5-CSRTT 
performance 
The  majority  of  studies  utilising  the  5-CSRTT  have  been  to  characterise  the 
involvement  of  neuronal  networks  in  attentional  functions  or  to  serve  as  a 177 
translational  pre-clinical  test  for  drug  functions.    However,  there  have  been 
some studies utilising the task to measure cognitive effects of gene manipulation 
allowing further dissection of the function of the gene product.  For example 
homozygous knock-out of the serotonin transporter gene Sert in rats results in 
decreased premature responses (Homberg et al., 2007).  These findings support 
the findings of studies showing systemic application of 5-HT antagonists or 5-HT 
re-uptake inhibitors reduce premature responses (Robinson et al., 2008).   
 
To  date  there  have  been  very  limited  studies  employing  the  5-CSRTT  to 
investigate the roles of genes related to the cognitive deficits in schizophrenia.  
This is probably due to genetic manipulations being mainly carried out in mice, 
and although the 5-CSRTT is suitable for mice (albeit slightly modified from the 
rat version, Humby et al., 2005) the majority of groups routinely using 5-CSRTT 
assess  rats  only.    However,  with  the  recent  commercialisation  of  genetically 
modified  rats,  this  lack  of  studies  will  undoubtedly  change  within  the  near 
future.  Interestingly, with respect to schizophrenia, transgenic mice lacking the 
-7 nicotinic acetylcholine receptor show deficits in the 5-CSRTT task (Young et 
al., 2004; Hoyle et al., 2006; Young et al., 2007).  Furthermore, there has been 
a huge amount of interest in recent years in -7 nicotinic acetylcholine receptor 
agonists as cognitive enhancers.  For example, the drug DMXBA has shown some 
promising procognitive effects in the 5-CSRTT.  However, when the drug was 
taken forward to clinical trials there have been problems with side-effects and 
desensitisation (see review by Thomsen et al., 2010).    
 
To my knowledge there have been no studies of 5-CSRTT performance in mice 
with genetic modifications of the most popular schizophrenia candidate genes 
such as Disc1, Nrg1 and Comt.  This is most likely due to the necessity of specific 
equipment  to  perform  the  task  and  also  because  the  training  and  testing 
schedule is somewhat long compared to other behavioural tests. 
 
Given  the  localisation  of  Nrg1  and  Erbb4  in  the  prefrontal  cortex,  previous 
studies showing regulation of several neurotransmitter systems that are involved 
in  optimal  5-CSRTT  performance  and  evidence  from  schizophrenia  patients 
identifying  variants  in  these  genes  lead  to  impaired  cognitive  ability,  it  is 178 
reasonable to propose that knockdown of Erbb4 in the rat prefrontal cortex will 
elicit measurable changes in cognition as assessed by the 5-CSRTT.  
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6.2 Aims 
The  aim  of  this  study  was  to  test  the  hypothesis  that  viral  mediated  gene 
manipulation of Erbb4, specifically within the mPFC, would affect performance 
in the 5-CSRTT in adult rats, thereby determining if Erbb4 within this distinct 
brain  region is  important  in cognitive  functions  known  to  be  dysfunctional in 
schizophrenia.    In  addition,  the  effect  of  manipulating  test  parameters  was 
investigated  with  the  aim  to  explore  if  any  changes  in  5-CSRTT  performance 
following Erbb4 knockdown were present in conditions of increased inhibitory or 
cognitive load.   
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6.3 Results 
6.3.1 Baseline  performance  of  rats  in  three  variations  of  the  5-
Choice Serial Reaction Time Task   
Prior to surgery, the rats were habituated to the 5-CSRTT (section 2.7.2), then 
trained in the task under basic parameters until the rats perform at a criterion 
of at least 80% accuracy with less than 20% omissions at a stimulus duration and 
inter-trial interval of 0.6 seconds and 5 seconds, respectively  (section 2.7.3).  
The baseline performance of the rats in three variations of the 5-CSRTT was 
assessed (n=35; one rat failed to meet criteria above training level 9 and so was 
discarded from the study). The performance of the rats was investigated in the 
basic task, the vITI task and the vSD task where attentional load is increased 
(section 2.7.4).  Baseline performance in the 5-CSRTT was performed prior to 
surgery to ensure that when the rats were split into surgical groups, each group 
was performing to an equal level, therefore any post-surgical effects would be 
due  to  the  agent  injected  during  surgery.    In  addition,  baseline  testing  was 
performed  to  confirm  that  manipulating  the  task  parameters  of  the  5-CSRTT 
resulted in an alteration in the rats behaviour, reflective of the challenge in 
cognition. 
 
Percentage accuracy in the basic task remained at a stable level of performance 
from  the  previous  training  level  at  79.5%  ±3.6%.  As  predicted,  percentage 
accuracy was overall significantly affected by manipulating task parameters (F 
(2,104)  =20.33,  p<0.001).  Tukey’s  post  hoc  analysis  revealed that  percentage 
accuracy was significantly reduced in the vITI task (p<0.05) and the vSD task 
(p<0.001) compared to the basic task (Figure 6.1A).  Further analysis of these 
tasks showed that individual inter-trial interval duration was not responsible for 
the drop in percentage accuracy in the vITI task (F (3,139)=0.99, p>0.05, Figure 
6.1B)  Conversely, the duration of stimulus was very significantly associated with 
a decrease in percentage accuracy observed in the vSD task (F (3,139)=42.25, 
p<0.001),  with  post  hoc  analysis  showing  that  this  reduction  in  percentage 
accuracy was mainly attributable to stimulus durations of 0.1 and 0.2 seconds 
(Figure 6.1C). 
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In  addition to  percentage accuracy,  percentage  omissions  and the  number of 
premature  responses  were  significantly  affected  by  altering  task  type  ((F  (2, 
104) =25.22, p<0.001) and (F (2, 104) =391.44, p<0.001) respectively) (Figures 
6.2A and 6.3A).  Percentage omissions was essentially doubled in the vITI task 
compared  to  the  basic  task  and  vSD  task  types  (p<0.001)  where  the  level  of 
omissions was very low at around 7%. More in depth analysis by individual Mann-
Whitney  tests  of  each  ITI  of  the  vITI  manipulation  confirmed  this  significant 
increase in omissions was a result of increasing inter-trial interval to 10 seconds 
or  more  (Figure  6.2B).  The  number  of  premature  responses  was  also 
significantly increased with increasing inter-trial duration (Figure 6.3B). 
 
Despite task type initiating  predicted changes in other parameters measured in 
the 5-choice serial reaction time task, task type had no effect on latency to 
correct  response    (F  (2,104)=0.07,  p>0.05)  or  latency  to  collect  reward  (F 
(2,104)=2.65, p>0.05)  (Figures 6.4A and 6.4B).   
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Figure 6.1 Effects of manipulation of stimulus duration and inter-trial interval 
duration upon percentage accuracy in the 5-CSRTT.  Figure A illustrates the 
effects of task type on percentage accuracy in rats prior to surgery.  vITI and vSD 
data  represents  cumulative  percentage  accuracy  values  of  all  ITI  and  SD 
durations.    Varying  ITI  or  stimulus  duration  decreased  percentage  accuracy.   
Figure  B  illustrates  the  effect  of  increasing  inter-trial  interval  duration  from  5 
seconds to 7, 10 and 12 seconds on percentage accuracy.  Increasing ITI duration 
did not alter percentage accuracy.  Figure C illustrates the effect of decreasing 
stimulus duration from 0.5 seconds to 0.4, 0.2 and 0.1 seconds on  percentage 
accuracy.  As  predicted,  decreasing  stimulus  duration  below  0.4  seconds 
decreased  percentage  accuracy.  Data  represent  mean  ±  SE  (n=35)  analysed 
using one-way ANOVA followed by Tukey’s post hoc test for multiple comparisons.  
*p<0.05,  ***p<0.001  between  task  types  indicated.    #  p<0.001  vs.  0.1s  SD, 
@p<0.001 vs. 0.2s SD.  ITI= inter-trial interval, SD= stimulus duration 
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Figure 6.2 Effects of manipulation of stimulus duration and inter-trial interval 
duration upon percentage omissions in the 5-CSRTT.  Figure A illustrates the 
effects of task type on percentage omissions in rats prior to surgery, as predicted 
varying  ITI  duration  increased  percentage  omissions.    Figure  B  illustrates  the 
effect  of  increasing  inter-trial  interval duration from 5  seconds  to  7, 10 and  12 
seconds  on  percentage  omissions,  increasing  ITI  duration  above  7seconds 
increased percentage omissions.  Data represent mean ± SE (n=35).  *** p<0.001 
vs. Basic or vSD task types analysed using one-way ANOVA followed by Tukey’s 
post hoc test for multiple comparisons. * p<0.05 vs. 5s ITI **p<0.01 vs. 7s ITI 
analysed  using  Mann-Whitney  non-parametric  U  tests.    vITI=variable  inter-trial 
interval, vSD=variable stimulus duration. 185 
 
Figure 6.3 Effects of manipulation of stimulus duration and inter-trial interval 
duration upon the number of premature responses in the 5-CSRTT.  Figure A 
illustrates the effects of task type on premature responding in rats prior to surgery.  
As  predicted  varying  ITI  duration  increased  premature  responding.  Figure  B 
illustrates the effect of increasing inter-trial interval duration from 5 seconds to 7, 
10  and  12  seconds  on  the  number  of  premature  responses.  The  number  of 
premature responses increased with longer ITI durations.  Data represent mean ± 
SE  (n=35).    ***  p<0.001  vs.  Basic  or  vSD  task  types  analysed  using  one-way 
ANOVA followed by Tukey’s post hoc test for multiple comparisons.  $ p<0.001 vs. 
5s ITI, ^ p<0.001 vs. 7s ITI, # p<0.001 vs. 10s ITI, @ p<0.001 vs. 12s ITI using 
Mann-Whitney  non-parametric  U  tests.  vITI=variable  inter-trial  interval, 
vSD=variable stimulus duration 186 
 
Figure 6.4 Effects of manipulation of stimulus duration and inter-trial interval 
duration upon latencies in the 5-CSRTT.  Figure A illustrates the effects of task 
type on latency to correct response in rats prior to surgery.  Varying ITI or SD did 
not affect the latency to correct response.  Figure B illustrates the effects of task 
type on latency to collect reward following correct response in rats prior to surgery.  
Varying ITI or SD did not affect the latency to collect reward.  Data represent mean 
± SE (n=35). 187 
6.3.2 Post-surgical testing in the basic 5-CSRTT performance   
Based on baseline performance in the basic, vITI and vSD task the rats were split 
into three equally performing groups (section 2.7.4).  Stereotaxic surgery was 
then carried out on the rats, with bilateral injections of either  vehicle, rAAV 
encoding  a  scrambled  hairpin  sequence  (scr.rAAV)  or  rAAV  encoding  a  short 
hairpin sequence corresponding to rat Erbb4 into the rat mPFC (section2.4.2). 
One, three and five weeks post-surgery the rats’ performance in the basic 5-
CSRTT was assessed (section 2.7.5).  Five variables were analysed: percentage 
accuracy, percentage omissions, the number of premature responses, latency to 
collect reward and latency to make a correct response.  Two rats died during 
surgery reducing group sizes to vehicle n=10, scr.rAAV n=12, shErbb4.rAAV n=11.   
 
In the basic task the main effect of Erbb4 knockdown was apparent at 5 weeks 
post-surgery where rats with Erbb4 knockdown within the PFC performed at a 
higher  percentage  accuracy  that  scr.rAAV  treated  rats  (p<0.05)(Figure  6.5).  
Importantly, percentage accuracy was equal between surgical groups at baseline 
level  (pre-surgery)  (F  (2,  32)  =0.03,  p>0.05)  (Figure  6.5A)  permitting  the 
interpretation that any changes in this parameter after surgery were due to the 
type of agent injected.  Surgical group had a significant effect on percentage 
accuracy overall (F (2, 131) =4.26), p<0.05).  Following a two-way ANOVA the 
post hoc Tukey’s analysis indicated a significant difference in the performance 
of scr.rAAV treated rats and shErbb4.rAAV treated rats (p=0.01).   
 
There was also a significant effect of week on percentage accuracy (F (3,131) 
=3.21,  p<0.05)  with  percentage  accuracy  dropping  slightly  at  1  week  post-
surgery compared to the baseline performance (p=0.066) and being significantly 
higher at week 5 compared to week 1 (p<0.05).   
 
Subsequent  to  this  analysis  the  percentage  accuracy  relative  to  the  rats’ 
baseline  performance  was  carried  out  to  analyse  whether  the  change  in 
percentage  accuracy  post-surgery  was  significantly  different  between  surgical 
groups.  Similar to the previous analysis, surgical group had a significant effect 
on relative percentage accuracy (F (2, 98) =9.23), p<0.001) this time with the 
performance  of  rats  that  had  received  virus  expressing  shErbb4  being 
significantly different from scrambled hairpin virus treated rats (p<0.001) and 188 
also  vehicle  treated  rats  (p<0.01)    Furthermore,  post  hoc  comparisons 
strengthened the previous finding at 5 weeks post-surgery with rats with Erbb4 
knockdown within the PFC performing the basic task with higher accuracy than 
scrambled virus treated rats (p=0.0025) (Figure 6.6). 
 
As with percentage accuracy, in the basic task percentage omissions, number of 
premature responses, latency to reward and latency to correct response were 
also  equal  between  groups  at  baseline  (Figures  6.7A,  6.8A,  6.9A  and  6.10A).  
Compared to baseline, percentage omissions were significantly increased in all 
surgical  groups  at  one  week  post-surgery  (p<0.001).    This  level  of  omissions 
returned  back  to  baseline  level,  with  omissions  at  weeks  3  and  5  not  being 
significantly different from baseline but significantly lower than at week 1.  This 
pattern is reflected by a significant effect of week on percentage omissions (F 
(3, 131) =10.58, p<0.001).  In addition, surgical group had a significant effect on 
percentage omissions (F (2, 131) =8.96, p<0.001) with rats treated with scr.rAAV 
performing significantly more omissions over all weeks than vehicle treated rats 
(p<0.01) and rats with Erbb4 knockdown (p<0.001).  These significant differences 
between  surgical  groups  are  reflected  by  a  significant  interaction  between 
surgical  group  and  week  at  3  weeks  where  scr.rAAV  treated  rats  performed 
significantly more omissions that shErbb4.rAAV treated rats.  At 5 weeks this 
effect was no longer apparent but scr.rAAV treated rats performed significantly 
more omissions than vehicle treated rats at this time point.   
 
Akin to percentage omissions and percentage accuracy, surgical group did have a 
significant  effect  on  the  number  of  premature  responses  (F  (2,  131)  =3.52, 
p<0.05)  with  shErbb4  virus  treated  rats  performing  a  significantly  different 
amount  of  premature  responses  over  all  weeks  than  vehicle  treated  rats 
(p<0.05).  Again there was also a significant effect of week on this parameter (F 
(3, 131) =3.90, p=0.01) with week three approaching significance compared to 
week  one  (p=0.059).    This  effect  was  a  consequence  of  vehicle  treated  rats 
performing  significantly  fewer  premature  responses  than  scrambled  hairpin 
virus-treated rats at week 3 (p<0.05) (Figure 6.8).   
 
Latency to reward was significantly affected by surgical group (F (2, 131) =3.58, 
p<0.05), with rats with Erbb4 knockdown retrieving rewards faster than vehicle 189 
treated rats.  This effect was a general observation with no significant effect of 
week (F (3. 131) =2.27, p>0.05) or surgical group x week interactions (Figure 
6.9).  Analysis of latency to correct response showed some results paralleling 
these of latency to reward, with there being no significant effect of week (F (2, 
131) =1.18, p>0.05) or surgical group x week interactions.  There was however a 
significant effect of surgical group on this parameter ((F (2, 131) =7.81, p<0.001) 
with scr.rAAV treated rats being slower to make a correct response than the 
vehicle treated rats (p<0.001) (Figure 6.10). 
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Figure  6.5  Effect  of  viral  mediated  gene  manipulation  on  percentage 
accuracy in basic 5-CSRTT.  Rats were split into three surgical groups based on 
baseline percentage accuracy performance (A) then received bilateral injections of 
vehicle (veh) (n=10), scr.rAAV (scr) (n=12) or shErbb4.rAAV (shErbb4) (n=11) into 
the mPFC.  Percentage accuracy was assessed in these rats at 1, 3 and 5 weeks 
post-surgery (B-D).  Data represent mean ± SE (n=10-12).  * p<0.05 analysed 
using two-way repeated measures ANOVA followed by Tukey’s post hoc test for 
multiple comparisons.  Two-way ANOVA showed main effects of surgical group on 
percentage accuracy (p<0.05) with shErbb4.rAAV treated rats performing over all 
significantly higher percentage accuracy than scr.rAAV treated rats (p<0.01).  A 
main  effect  of  week  was  also  found  (p<0.05)  with  percentage  accuracy  being 
significantly  lower  at  1  week  post-surgery  than  5  weeks  post-surgery  (p<0.05).  
Post hoc analysis revealed that at 5 weeks post-surgery shErbb4.rAAV treated 
rats performed more accurately than scr.rAAV treated rats (p<0.05). 
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Figure  6.6  Effect  of  viral  mediated  gene  manipulation  on  percentage 
accuracy relative to performance at baseline in basic 5-CSRTT.  percentage 
accuracy was determined relative to baseline performance at 1, 3 and 5 weeks 
following  bilateral  injections  of  vehicle  (veh)  (n=10),  scr.rAAV  (scr)  (n=12)  or 
shErbb4.rAAV  (shErbb4)  (n=11)  into  the  mPFC.    **  p<0.01  between  surgical 
groups analysed using two-way repeated measures ANOVA followed by Tukey’s 
post  hoc  test  for  multiple  comparisons.  Two-way  repeated  measures  ANOVA 
found main effect  of surgical group on percentage accuracy with  shErbb4.rAAV 
treated  rats  performing  more  accurately  than  scr.rAAV  (p<0.001)  and  vehicle 
treated rats (p<0.01).  Post hoc comparisons revealed at 5 weeks post-surgery 
shErbb4.rAAV  treated  rats  performed  with  increased  percentage  accuracy  than 
scr.rAAV treated rats (p<0.01). 
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Figure  6.7  Effect  of  viral  mediated  gene  manipulation  on  percentage 
omissions in basic 5-CSRTT.  Rats were split into three surgical groups based 
on baseline percentage omissions (A) then received bilateral injections of vehicle 
(veh)  (n=10), scr.rAAV (scr)  (n=12) or shErbb4.rAAV (shErbb4) (n=11) into the 
mPFC.  Percentage omissions were assessed in these rats at 1, 3 and 5 weeks 
post-surgery (B-D).  Data represent mean ± SE (n=10-12).  * p<0.05, ***p<0.001 
analysed using two-way repeated measures ANOVA followed by Tukey’s post hoc 
test  for  multiple  comparisons.  Two-way  ANOVA  showed  an  over  all  effect  of 
surgical group on percentage omissions with rats treated with scr.rAAV performing 
significantly  more  omissions  than  vehicle  (p<0.01)  or  shErbb4.rAAV  (p<0.001) 
treated rats.  There was also an over all effect of week on percentage omissions 
with significantly higher omissions performed at 1 week post-surgery compared to 
all  other  time  points.    Post  hoc  comparisons  revealed  scr.rAAV  treated  rats 
performed significantly more omissions than shErbb4.rAAV treated rats at 3 weeks 
post-surgery (p<0.001), and vehicle treated rats at 5 weeks post-surgery (p<0.05). 
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Figure  6.8  Effect  of  viral-mediated  gene  manipulation  on  the  number  of 
premature responses in the basic 5-CSRTT.  Rats were split into three surgical 
groups  based  on  baseline  premature  responding  (A)  then  received  bilateral 
injections  of  vehicle  (veh)  (n=10),  scr.rAAV  (scr)  (n=12)  or  shErbb4.rAAV 
(shErbb4)  (n=11)  into  the  mPFC.    The  number  of  premature  responses  was 
assessed in these rats at 1, 3 and 5 weeks post-surgery (B-D).  Data represent 
mean  ±  SE  (n=10-12).    *  p<0.05,  analysed  using  two-way  repeated  measures 
ANOVA followed  by  Tukey’s  post  hoc  test  for multiple  comparisons.  Two-way 
ANOVA showed an over all effect of surgical group on premature responding with 
shErbb4.rAAV  treated  rats  performing  significantly  more  premature  responses 
than vehicle treated rats overall (p<0.05).  Post hoc comparisons revealed that 
scr.rAAV treated rats performed more premature responses than vehicle treated 
rats at 3 weeks post-surgery (p<0.05). 197 
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Figure 6.9 Effect of viral-mediated gene manipulation on latency to collect 
reward in the basic 5-CSRTT.  Rats were split into three surgical groups based 
on baseline reward latency (A) then received bilateral injections of vehicle (veh) 
(n=10), scr.rAAV (scr) (n=12) or shErbb4.rAAV (shErbb4) (n=11) into the mPFC.  
Latency to reward was assessed in these rats at 1, 3 and 5 weeks post-surgery 
(B-D).  Data represent mean ± SE (n=10-12).  Data were analysed using two-way 
repeated  measures  ANOVA  followed  by  Tukey’s  post  hoc  test  for  multiple 
comparisons.  Two-way ANOVA showed an over all effect of surgical group on 
reward latency with shErbb4.rAAV treated rats having significantly lower latencies 
to collect reward than vehicle treated rats (p<0.05). 199 
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Figure 6.10 Effect of viral-mediated gene manipulation on latency to correct 
response  in  the  basic  5-CSRTT.  Rats  were  split  into  three  surgical  groups 
based on baseline response latency (A) then received bilateral injections of vehicle 
(veh)  (n=10), scr.rAAV  (scr) (n=12) or shErbb4.rAAV  (shErbb4) (n=11) into the 
mPFC.  Latency to correct response was assessed in these rats at 1, 3 and 5 
weeks  post-surgery  (B-D).    Data  represent  mean  ±  SE  (n=10-12).    Data  were 
analysed using two-way repeated measures ANOVA followed by Tukey’s post hoc 
test  multiple  comparisons.  Two-way  ANOVA  showed  a  significant  effect  of 
surgical group on latency to response with scr.rAAV treated rats having an overall 
significantly higher latency to make a correct response than vehicle treated rats 
(p<0.001).   
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6.3.3  Effect of Erbb4 knockdown on performance in vITI task 
To assess if viral-mediated gene knockdown of Erbb4 within the mPFC affected 
the performance of rats in a manipulated form of the 5-CSRTT, where the inter-
trial interval is made variable, rats who had undergone stereotaxic injection of 
vehicle, scr.rAAV or shErbb4.rAAV (2.4.2) were tested in the vITI version of the 
5-CSRTT 1, 3 and 5 weeks post-surgery (2.7.5). 
 
Rats in all three surgical groups performed at equal percentage accuracy in the 
vITI task at baseline (F (2, 32) =0.05, p>0.05) (Figure 6.11A) and this level of 
accuracy did not change significantly between groups at any time point post-
surgery with no significant effect of surgical group (F (2, 131) =0.43, p>0.05) or 
week  (F  (3,131)  =0.51,  p>0.05)  on  percentage  accuracy  (Figure  6.11  B-D).  
Similarly, there was no effect of surgical group (F (3, 131) =2.66, p>0.05) or 
week (F (3, 131) =0.16, p>0.05) on percentage omissions in the vITI task (Figure 
6.12).    Number  of  premature  responses  in  the  vITI  task  was  not  affected  by 
surgical group (F (2, 131)=1.33, p>0.05), however, there was a highly significant 
effect of week on premature responding (F (3, 131)=5.39,p<0.01) with post hoc 
comparisons indicating this effect was a result of significantly less premature 
responses  being  performed  at  3  weeks  (p<0.01)  and  5  weeks  (p<0.01)  post-
surgery compared to the number of premature responses made prior to surgery 
(Figure 6.13).   
 
Comparable to the basic task, mean latency to reward was significantly affected 
by  surgical  group  in  the  vITI  task  (F  (2,131)  =14.63,  p<0.001)  again  with 
shErbb4.rAAV treated rats being overall significantly quicker to collect reward 
following a correct response than vehicle treated rats (p<0.001) (Figure 6.14).  
In addition, in the vITI task scr.rAAV treated rats also had a significantly lower 
mean latency to reward than vehicle treated rats (p<0.001).  These effects were 
a general observation with no significant interaction between surgical group and 
week being identified.  Furthermore, there was no significant effect of week on 
mean latency to reward (F (3, 131) =0.75,>0.05) (Figure 6.14).  Mean latency to 
correct  response  was  not  significantly  affected  by  surgical  group  (F  (2,131) 
=0.19, p>0.05) or week (F (3,131) =0.71, 0>0.05) in the vITI task (Figure 6.15).   
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Figure  6.11  Effect  of  viral-mediated  gene  manipulation  on  percentage 
accuracy in the vITI task.  Rats were split into three surgical groups based on 
baseline percentage accuracy (A) then received bilateral injections of vehicle (veh) 
(n=10), scr.rAAV (scr) (n=12) or shErbb4.rAAV (shErbb4) (n=11) into the mPFC.  
Percentage accuracy was assessed in these rats at 1, 3 and 5 weeks post-surgery 
(B-D).  Data represent mean ± SE of the total percentage accuracy from trials with 
inter-trial  intervals  of  5,  7,  10  and  12  seconds  (n=10-12).  Two-way  ANOVA 
showed there was no effect of surgical group or week on percentage accuracy. 203 
 
Figure  6.12  Effect  of  viral-mediated  gene  manipulation  on  percentage 
omissions in the vITI task.  Rats were split into three surgical groups based on 
baseline  percentage  omissions  (A)  then  received  bilateral  injections  of  vehicle 
(veh)  (n=10), scr.rAAV  (scr) (n=12) or shErbb4.rAAV (shErbb4) (n=11) into the 
mPFC.  Percentage omissions were assessed in these rats at 1, 3 and 5 weeks 
post-surgery (B-D).  Data represent mean ± SE of the total percentage omissions 
from trials with inter-trial intervals of 5, 7, 10 and 12 seconds (n=10-12).  Two-way 
ANOVA  showed  there  was  no  significant  effect  of  surgical  type  or  week  on 
percentage omissions. 204 
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Figure  6.13  Effect  of  viral-mediated  gene  manipulation  on  the  number  of 
premature responses in the vITI task.  Rats were split into three surgical groups 
based on baseline premature responding (A) then received bilateral injections of 
vehicle (veh) (n=10), scr.rAAV (scr) (n=12) or shErbb4.rAAV (shErbb4) (n=11) into 
the mPFC. The number of premature responses were assessed in these rats at 1, 
3 and 5 weeks post-surgery (B-D).  Data represent mean ± SE of the total number 
of  premature  responses  from  trials  with  inter-trial  intervals  of  5,  7,  10  and  12 
seconds  (n=10-12).  Two-way  ANOVA  showed  the  number  of  premature 
responses  was  not  affected  by  surgical  group,  however,  there  was  an  overall 
effect of week on this parameter with more premature responses being made over 
all surgical groups at baseline compared to 3 (p<0.01) and 5 (p<0.01) weeks post-
surgery 206 
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Figure 6.14 Effect of viral-mediated gene manipulation on latency to reward 
in the vITI task.  Rats were split into three surgical groups based on baseline 
latency  to  reward  (A)  then  received  bilateral  injections  of  vehicle  (veh)  (n=10), 
scr.rAAV (scr) (n=12) or shErbb4.rAAV (shErbb4) (n=11) into the mPFC. Mean 
reward latency was assessed in these rats at 1, 3 and 5 weeks post-surgery (B-D).  
Data represent mean ± SE of the total mean reward latency from trials with inter-
trial intervals of 5, 7, 10 and 12 seconds (n=10-12).  Data were analysed using 
two-way repeated measures ANOVA followed by Tukey’s post hoc test for multiple 
comparisons.  Two-way  ANOVA  showed  an  overall  effect  of  surgical  group  on 
latency to reward with vehicle treated rats having an overall significantly higher 
latency to collect reward than scr.rAAV (p<0.001) and shErbb4.rAAV treated rats 
(p<0.001). 208 
 
Figure 6.15 Effect of viral-mediated gene manipulation on latency to correct 
response in the vITI task.  Rats were split into three surgical groups based on 
baseline response latency (A) then received bilateral injections of vehicle  (veh) 
(n=10), scr.rAAV (scr) (n=12) or shErbb4.rAAV (shErbb4) (n=11) into the mPFC.  
Mean latency to correct response was assessed in these rats at 1, 3 and 5 weeks 
post-surgery (B-D).  Data represent mean ± SE of the total mean response latency 
from trials with inter-trial intervals of 5, 7, 10 and 12 seconds (n=10-12).  Two-way 
ANOVA  showed  there  was  no  effect  of  surgical  group  or  week  on  latency  to 
correct response. 209 
6.3.4 Effect of Erbb4 knockdown on performance in the vSD task 
To assess if viral-mediated gene knockdown of Erbb4 within the mPFC affected 
the  performance  of  rats  in  a  manipulated  form  of  the  5-CSRTT,  where  the 
stimulus duration is made variable, rats who had undergone stereotaxic injection 
of vehicle, scr.rAAV or shErbb4.rAAV (2.4.2) were tested in the vSD version of 
the 5-CSRTT 1, 3 and 5 weeks post-surgery (2.7.5). 
 
At baseline each group of rats were performing at an approximately equal level 
of 67% accuracy in the vSD task (Figure 6.16A).  Two-way repeated measures 
ANOVA revealed there was no significant effect of surgical group (F (2, 131) = 
0.71, p>0.05) or week (F (3, 131) = 1.95, p>0.05) on percentage accuracy in the 
vSD  task.    Convergent  with  baseline  data,  this  level  of  percentage  accuracy 
achieved  in  the  vSD  task  was  mainly  due  to  poor  performance  at  stimulus 
durations of 0.1 and 0.2 seconds at all time points where three way repeated 
measures  ANOVA  showed  that  although  there  was  no  significant  effect  of 
treatment  or  week  on  percentage  accuracy,  stimulus  duration  was  highly 
significant (F (3,527) = 200.89, p<0.001).  
 
There was an overall significant effect of surgical group on percentage omissions 
(F (2,131) = 5.63, p<0.01) in the vSD task with vehicle treated rats performing 
significantly  differently  from  scrambled  hairpin  virus  treated  rats  (p<0.01).  
There were no significant week by surgical group interaction however, there was 
a significant effect of week on percentage omissions (F (3, 131) = 5.19, p<0.01).  
Post  hoc  comparisons  revealed  this  was  due  to  more  percentage  omissions 
occurring in week three than at baseline (p<0.001) (Figure 6.17).    
 
Similar  to  premature  responding  in  the  vITI  task,  the  number  of  premature 
responses  was  significantly  lower  at  week  3  (p<0.01)  and  week  5  (p<0.01) 
compared to baseline levels in the vSD task.  This contributed to “week” having 
a statistically significant effect on the number of premature responses (F (3,131) 
=5.99,  p<0.001).    Surgical  group  had  no  effect  on  the  number  of  premature 
responses performed (Figure 6.18) in the vSD task.  Surgical group did however 
have an effect on mean latency to reward (F (2,131)=5.86, p<0.01) with post hoc 
analysis  identifying  that,  identically  to  the  results  of  the  vITI  task,  vehicle 210 
treated rats were significantly slower to collect rewards after making a correct 
response compared to scr.rAAV (p<0.05) and shErbb4.rAAV (p<0.01) treated rats.  
There were no significant surgical group by week interactions and week itself did 
not  have  a  significant  effect  on  mean  latency  to  reward  in  the  vSD  task  (F 
(3,131) =1.09, p>0.05) (Figure 6.19).   
 
Unfortunately,  despite  best  efforts  of  equally  splitting  the  rats  into  three 
groups, at baseline mean latency to correct response was not equal between 
surgical  groups  prior  to  surgery  (F  (2,  32)  =  4.60,  p<0.05)  (Figure  6.20).  
Therefore,  further  analysis  of  this  data  was  performed  as  mean  latency  to 
reward  expressed  as  relative  to  baseline  performance.    Interestingly,  very 
similar  results  to  latency  to  reward  were  found  with  a  significant  effect  of 
surgical  group  (F  (2,  98)  =  6.92,  p<0.01).    Subsequent  post  hoc  comparisons 
showed that, as with reward latency, vehicle treated rats correctly responded at 
a significantly slower speed than rats that received scrambled virus (p<0.01) and 
rats that received virus expressing shErbb4 (p<0.01).  In addition no effect of 
week on this parameter was found (F (2, 98) =0.02, p>0.05) (Figure 6.21). 
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Figure  6.16  Effect  of  viral-mediated  gene  manipulation  on  percentage 
accuracy in the vSD task.  Rats were split into three surgical groups based on 
baseline percentage accuracy (A) then received bilateral injections of vehicle (veh) 
(n=10), scr.rAAV (scr) (n=12) or shErbb4.rAAV (shErbb4) (n=11) into the mPFC.  
Percentage accuracy was assessed in these rats at 1, 3 and 5 weeks post-surgery 
(B-D).  Data represent mean ± SE of the total percentage accuracy from trials with 
stimulus durations of 0.1, 0.2, 0.4 and 0.5 seconds (n=10-12).  Two-way ANOVA 
showed percentage accuracy was not affected by surgical group or week in the 
vSD task. 213 
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Figure  6.17  Effect  of  viral-mediated  gene  manipulation  on  percentage 
omissions in the vSD task.  Rats were split into three surgical groups based on 
baseline  percentage  omissions  (A)  then  received  bilateral  injections  of  vehicle 
(veh)  (n=10), scr.rAAV (scr)  (n=12) or shErbb4.rAAV  (shErbb4) (n=11) into the 
mPFC.  Percentage omissions were assessed in these rats at 1, 3 and 5 weeks 
post-surgery (B-D).  Data represent mean ± SE of the total percentage omissions 
from trials with stimulus durations of 0.1, 0.2, 0.4 and 0.5 seconds.  Data were 
analysed using two-way repeated measures ANOVA followed by Tukey’s post hoc 
test for multiple comparisons.  Two-way ANOVA showed a significant overall effect 
of surgical group on percentage omissions in the vSD task with scr.rAAV treated 
rats performing more omissions than vehicle treated rats (p<0.01).  There was also 
an  over  all  effect  of  week  on  percentage  omissions  with  significantly  more 
omissions being made over all surgical groups at 3 weeks post-surgery compared 
to baseline (p<0.001). 215 
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Figure  6.18  Effect  of  viral-mediated  gene  manipulation  on  the  number  of 
premature response in the vSD task.  Rats were split into three surgical groups 
based on baseline premature responding (A) then received bilateral injections of 
vehicle (veh) (n=10), scr.rAAV (scr) (n=12) or shErbb4.rAAV (shErbb4) (n=11) into 
the mPFC.  The number of premature responses were assessed in these rats at 1, 
3 and 5 weeks post-surgery (B-D).  Data represent mean ± SE of the total number 
of premature responses from trials with stimulus durations of 0.1, 0.2, 0.4 and 0.5 
seconds.  Two-way ANOVA showed premature responding was not affected by 
surgical  group,  however  there  was  a  significant  effect  of  week  on  premature 
responses  with  less  premature  responses  being  made  at  3  (p<0.01)  and  5 
(p<0.01) weeks post-surgery compared to baseline. 217 
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Figure 6.19 Effect of viral-mediated gene manipulation on mean latency to 
reward in the vSD task.  Rats were split into three surgical groups based on 
baseline  reward  latency  (A)  then  received  bilateral  injections  of  vehicle  (veh) 
(n=10), scr.rAAV (scr) (n=12) or shErbb4.rAAV (shErbb4) (n=11) into the mPFC.  
Mean reward latency was assessed in these rats at 1, 3 and 5 weeks post-surgery 
(B-D).  Data represent mean ± SE of the total mean latency to response from trials 
with stimulus durations of 0.1, 0.2,  0.4 and 0.5 seconds.  Data were analysed 
using two-way repeated measures ANOVA followed by Tukey’s post hoc test for 
multiple comparisons.  Two-way ANOVA showd an overall effect of surgical group 
on reward latency in the vSD task with vehicle treated rats  having significantly 
higher  latencies  to  collect  reward  than  scr.rAAV  (p<0.05)  and  shErbb4.rAAV 
(p<0.01) treated rats. 
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Figure  6.20  Baseline  mean  latency  to  correct  response  in  the  vITI  task.  
Baseline mean latency to correct response in rats prior to surgical procedure of 
bilateral injections of vehicle (veh) (n=10), scr.rAAV (scr) (n=12) or shErbb4.rAAV 
(shErbb4)  (n=11).    Data  represent  mean  ±  SE  of  the  total  mean  latency  to 
response  from  trials  with  stimulus  durations  of  0.1,  0.2,  0.4  and  0.5  seconds.  
Scr.rAAV  and  shErbb4  treated  rats  had  significantly  higher  latency  to  correct 
response than vehicle treated rats at baseline.  * p<0.05, analysed using one-way 
ANOVA followed by Tukey’s post hoc test for multiple comparisons. 
 
 
 
 
 220 
 
Figure 6.21 Effect of viral-mediated gene manipulation on mean latency to 
correct response in the vSD task relative to baseline mean latency to reward 
performance.  Rats were split into three surgical groups then received bilateral 
injections  of  vehicle  (veh)  (n=10),  scr.rAAV  (scr)  (n=12)  or  shErbb4.rAAV 
(shErbb4) (n=11) into the mPFC.  Mean response latency was assessed in these 
rats at 1, 3 and 5 weeks post-surgery.  Data represent mean ± SE of the total 
mean latency to response relative to baseline from trials with stimulus durations of 
0.1,  0.2,  0.4  and  0.5  seconds,  analysed  using  two-way  repeated  measures 
ANOVA followed  by  Tukey’s  post  hoc  test  for multiple  comparisons.  Two-way 
ANOVA  showed  a  significant  effect  of  surgical  group  on  respinse  latency  with 
scr.rAAV  (p<0.01)  and  shErbb4.rAAV  (p<0.01)  treated  rats  having  significantly 
lower latencies to correct response compared to vehicle treated rats. 
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6.4 Discussion 
6.4.1 Manipulation of 5-CSRTT parameters alters behaviour 
The present results show that altering the parameters of stimulus duration and 
inter-trial  interval  duration  had  the  profound  predicted  effects  on  many 
measurements of the 5-CSRTT.  This further highlights the validity of the task in 
a pre-clinical model of cognition as it known that when parameters of the CPT in 
humans  are  altered  the  performance  is  significantly  affected (Elvevåg  et al., 
2000). 
 
Manipulation of stimulus duration 
Percentage  accuracy  was  decreased  by  an  average  of  12%  in  the  vSD  task 
compared to the basic task, and this was undoubtedly due to changes in the 
stimulus duration; this is in agreement with Bari  et al., (2008). Moreover the 
trend seen for decreasing percentage accuracy with stimulus duration has been 
previously reported (Hille et al., 2008) and supports the notion that reducing the 
stimulus duration further challenges the rats’ cognitive ability by increasing the 
need for sustained attention.  As this change in percentage accuracy was the 
only change in the rats’ behaviour following reduction of the stimulus duration, 
the vSD task appears to be a good model system for assessing the specific effect 
of genetic manipulations/pharmacological agents on percentage accuracy. 
 
Manipulation of inter –trial interval 
The  number  of  premature  responses  were  hugely  affected  by  increasing  ITI 
duration, in agreement with Bari  et al.,  (2008), and this increase was highly 
correlated  with  increased  ITI  duration.    This  has  been  previously  reported 
(Navarra  et  al.,  2008;  Paterson  et  al.,  2011)  and  is  a  clear  indication  of 
increased impulsivity.  Percentage accuracy was also significantly reduced when 
the inter-trial interval was made variable.  However, this decrease in accuracy 
was a relatively small decrease with an average of 4.6% decrease, in comparison 
to the change in accuracy observed in the vSD task.  Furthermore, the fact that 
percentage accuracy was not significantly associated with increased ITI duration 
suggests that the drop in percentage accuracy was not due to the rats having to 
wait longer between trials, but more than likely was due to the novelty of the 222 
task,  as  this  was  the  first  time the rats were  exposed  to  the  vITI  paradigm.  
Moreover, it is important to note that in the vITI task the amount of “time outs” 
being given to the rats is  significantly increased due to increased number of 
premature responses and omissions being performed, and therefore the amount 
of  time  remaining  in  the  30  minute  task  time  is  decreased.    Therefore  it  is 
possible that the drop in percentage accuracy observed in the vITI task may be 
an overrepresentation, as fewer corrects and incorrects may be performed and 
thus small changes in percentage accuracy may be calculated as bigger changes 
than if 90 corrects and incorrects were performed as in the basic task.   
 
In  comparison  to  the  vSD  task,  the  vITI  task  appeared  to  give  a  more  broad 
manipulation to the rats’ behaviours.  As increasing ITI duration also increased 
percentage omissions, especially at ITIs of 10 seconds or more, indicating that in 
all probability the rats, when waiting this extended amount of time for the light 
to appear, had resorted to nose poking in the food magazine to initiate another 
trial, and missed the stimulus when it did appear   
 
Again, the results seen when ITI or SD is manipulated are in agreement with the 
results stated by Bari et al., (2008) in that neither response latency or reward 
latency were affected. 
 
Overall,  these  results  suggest  that  the  5-CSRTT  is  flexible,  and  can  be 
manipulated to tease apart specific modalities of cognition and will thus allow 
easier identification of agents which affect specific parameters of the task i.e. 
to  test  a  drug  that  reduces  impulsivity  in  the  vITI  task  where  premature 
responses is the main parameter being controlled.  Moreover, the changes in 
behaviour of the rats in the vSD and vITI task in comparison to the basic task 
imply that in the basic task the rats may have learned to rely on automatic 
processes  whereas  in  the  variable  tasks  the  rats  have  continually  to  sustain 
attention and adapt their responses.   
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6.4.2 Effects of Erbb4 knockdown on 5-CSRTT performance 
Surgery/training-related deficits 
The general finding that several of the parameters of the 5-CSRTT changed over 
the  testing  period  was  not  unexpected.    One  week  following  surgery  it  was 
observed that in the basic task  percentage accuracy dropped and  percentage 
omissions  increased  suggesting  that  there  was  an  overall  deficit  in  task 
performance  at  this  time  point.    This  deficit  was  observed  over  all  surgical 
groups and thus was not an effect of the agent injected per se but was most 
likely a general effect of stereotaxic surgery in combination with the fact that 
the  rats  had  not  received  training  for  one  week.    Moreover  the  deficits  in 
percentage  accuracy  and  percentage  omissions  were  short  lived  and 
performance  returned  to  at  least  baseline  levels  by  week  3,  supporting  the 
previous findings that there was very little tissue damage at the site of injection 
(section 4.3.2) and in addition that viral injection did not have an undesired 
global  effect  (supported  by  the  findings  that  body  weight  and  levels  of  glial 
infiltration did not alter following viral injections) (sections 4.3.5). 
 
The other trend of week having an effect on 5-CSRTT performance was evident 
in the vITI and vSD tasks where the number of premature responses was lower at 
weeks 3 and 5 compared to baseline performance.  This finding is in concordance 
with  previous  literature  suggesting  that  rats  become  quickly  adapted  to 
manipulated  forms  of  the  5-CSRTT  (Bari  et  al.,  2008).    Although  percentage 
accuracy appeared to be the most affected parameter by altering the stimulus 
duration, there was no evidence that the rats adapted to this parameter in the 
same  way  as  they  did  with  premature  responding.    This  may  suggest  that 
impulsivity is a more adaptable process than that of sustained attention. 
 
Specific effects of Erbb4 gene manipulation on task performance 
The increase in percentage accuracy in the basic task detected at 5 weeks post-
surgery in rats that received shErbb4.rAAV is a very interesting result, as this 
corresponds to the previous finding that Erbb4 protein levels were confirmed to 
be decreased in the PFC at this specific time point (section 4.3.5).  In addition, 
the  time  point  post-surgery  at  which  this  increase  in  percentage  accuracy 224 
became evident in shErbb4.rAAV treated rats (5 weeks) was the same time point 
post-surgery that the change in locomotor response to amphetamine manifested 
in  shErbb4.rAAV  treated  rats  in  the  locomotor  activity  task  (section  5.3.3).  
Again this emphasises the suggestion that whatever effects Erbb4 knockdown is 
having  on  behaviour,  it  is  taking  5  weeks  to  become  apparent;  this  may  be 
because this is when the optimal amount of hairpin is being expressed and thus 
when maximal gene knockdown is occurring, or it may be due to it taking 5 
weeks for Erbb4 knockdown to affect the prefrontal circuitry and manifest as 
behaviour changes.  
 
The  finding  of  an  increase  in  cognitive  ability  following  Erbb4  knockdown, 
although  subtle,  is  in  accordance  with  previous  literature  in  schizophrenia 
patients where the levels of ERBB4 within the dorsolateral prefrontal cortex are 
significantly increased, and expression is directly associated with a haplotype 
consisting of three intronic SNPs in linkage disequilibrium near exon 3 (Silberberg 
et al., 2006; Law et al., 2007; Chong et al., 2008).  It is therefore feasible to 
consider  that  decreasing  Erbb4  expression  within  the  PFC  (thought  to  be  a 
homolog of some aspects of the human DLPFC (Uylings et al., 2003; Seamans et 
al., 2008) would result in increased cognitive ability.  Interestingly one of the 
SNP’s from the risk haplotype, rs839523, has also been associated with poorer 
performance in the oddball task (in terms of reaction time) in healthy individuals 
homozygous for the risk allele (Konrad et al., 2009).  In addition a very recent 
study showed an epistatic interaction of SNPs in NRG1, ERBB4 and AKT1 resulting 
in reduced pre-frontal cortical engagement during the n-back task (Nicodemus et 
al., 2010).   
 
At 5 weeks post-surgery the protein expression of Nrg1 is also altered.  However, 
this is in the opposite direction to Erbb4, with increased expression being found 
(chapter 5).  These behavioural effects on percentage accuracy could therefore 
also be due to a change in the expression of Nrg1.  However, the studies showing 
differential expression of NRG1 in schizophrenia are somewhat unclear with type 
I NRG1 shown to be increased in DLPFC of patients (Hashimoto et al., 2004; Law 
et al., 2006; Chong et al., 2008).  However, studies have also shown decreased 
NRG1 expression at mRNA level (Barakat et al., 2010) and protein level in the 
prefrontal cortex in schizophrenia (Bertram et al., 2007).  Furthermore, studies 225 
have also showed no change in NRG1 expression (Boer et al., 2009).  Despite this 
ambiguity in expression studies, NRG1 appears to be important in cognition.  A 
variant in the  NRG1 gene which has shown association with increased risk to 
schizophrenia also shows association with decreased activity of the mPFC, and 
decreased premorbid IQ as assessed by the national adult reading test (Hall et 
al., 2006). 
 
Although there is no evidence of this cognitive enhancement effect of PFC Erbb4 
knockdown at 5 weeks post-surgery in the vSD task, this may be due to a “ceiling 
effect” in that the rats cannot perform at a higher level of percentage accuracy 
in the vSD task than they achieved pre-surgery and thus no pro-cognitive effect 
could emerge.  What is more, the cognitive enhancing effects seen by Erbb4 
knockdown  on  percentage  accuracy,  although  subtle,  are  similar  to  levels  of 
cognitive enhancement previously shown in the 5-CSRTT by nicotine (Hahn et 
al.,  2002;  Semenova  et  al.,  2007).    Another  explanation  for  not  detecting 
changes in the vSD task is that the rats were not performing at a high enough 
level  in  the  basic  task  before  the  task  was  manipulated  as  suggested  by 
Semenova and colleagues.   They state that for Sprague-Dawley rats performing 
at a baseline accuracy in the basic 5-CSRTT of 79.79±1.74% “there was concern 
that in the modified task, SD rats’ low baseline performance would preclude 
meaningful evaluation of the effects of manipulations”.  Wistar rats performing 
at a baseline level of 87% accuracy in the basic task were, however, thought to 
be  suitable  for  evaluation  in  the  vSD  task,  where  an  effect  of  nicotine  on 
accuracy was observed.   
 
Nrg1/Erbb4 signalling affects multiple neurotransmitter systems that are known 
to play an important role in the performance of the 5-CSRTT and in cognition in 
general.    For  example  Nrg1-Erbb4  signalling  is  important  in  maintaining 
glutamatergic neurotransmission, with Nrg1 mutant mice showing reduced NMDA 
receptor phosphorylation (Bjarnadottir et al., 2007) and fewer functional NMDA 
receptors in the forebrain (Stefansson et al., 2002). In addition, in a study by 
Hahn and colleagues in 2006, it was found that in brain tissue from patients that 
had schizophrenia the level of activity of Nrg1-Erbb4 signalling was enhanced 
and that this enhancement led to NMDA receptor hypofunction.  Moreover, Nrg1 
and  Erbb4  mutants  appear  to  have  some  behavioural  similarities  to  NMDA 226 
receptor  hypomorphs  (Mohn  et  al.,  1999).    This  evidence  is  suggestive  that 
disruption  of  Nrg1-Erbb4  signalling  affects  NMDA  receptor  functionality, 
interestingly;  the  NMDA  antagonist  phencyclidine  has  a  marked  effect  in 
disrupting 5-CSRTT performance (Amitai et al., 2008; Thomson et al., 2010) with 
acute NMDA blockade leading to deficits in premature responding and accuracy, 
and repeated treatment affecting speed of processing.   
 
Nrg1-Erbb4  signalling  is  also  important  in  regulating  dopaminergic 
neurotransmission, with a mouse line expressing  a dominant negative form of 
Erbb4 in oligodendrocytes having significantly more dopamine transporter and 
D1-like receptor binding in the cortex, striatum and nucleus accumbens (Roy et 
al., 2007).  More recently a study showing peripheral Nrg1 injections in mice 
results in Erbb4 receptor activation and elevated dopamine levels (Kato et al., 
2010).   Furthermore injection of Nrg1 into the dorsal substantia nigra stimulates 
striatal dopamine overflow (Yurek et al., 2004).  Therefore, in the current study 
it  is  possible  that  the  knockdown  of  Erbb4  in  the  mPFC  affected  prefrontal 
dopamine  levels  and  as  a  result  increased  percentage  accuracy  as  seen  with 
dopaminergic compounds (6.1.3).    
 
Type I Nrg1 (initially termed ARIA: acetylcholine receptor inducing activity) was 
initially identified as a factor which was capable of accumulating AChRs at the 
neuromuscular  junction  (Usdin  &  Fischbach,  1986)  and  later  in  hippocampal 
interneurons  (Liu  et  al.,  2001).  Several  recent  studies  have  implicated  Nrg1 
signalling  in  7-nicotinic  acetylcholine  receptor  (-7nAChR)  transmission  with 
Nrg1 affecting -7nAChR surface expression (Chang & Fischbach, 2006; Hancock 
et al., 2008) and fast inward currents (Chang & Fischbach, 2006).  Additionally, 
cultures from Nrg1 type III heterozygous knock-out mice revealed these mice 
have reduced functional -7nAChR expression (Zhong et al., 2008).  As described 
in  section  6.1.4,  -7nAChR  knock-out  mice  have  reduced  accuracy  in  the  5-
CSRTT whereas  -7nAChR agonists have shown some promise as pro-cognitive 
agents in the 5-CSRTT.  The manipulation of the Nrg1-Erbb4 signalling pathway 
leading to pro-cognitive effects, as seen in this study, could consequently be a 
result of elevated -7nAChR expression or activity.   
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It is difficult to compare the results of this behavioural task with those studies 
previously carried out in transgenic  Erbb4 and Nrg1 mice for several reasons.  
The primary comparative concern is that none of the previous studies have used 
5-CSRTT to assess the effect of mutations in Erbb4 or Nrg1 on behaviour; instead 
many of the cognitive assessments in these previous studies have relied heavily 
on  tests  that  are  hippocampus  based.    Previous  studies  have  shown  that 
performance in spatial and reference working memory tasks (such as the radial 
arm maze and the Morris water maze) is impaired by knock-out of Erbb4 in the 
CNS (Golub et al., 2004; Wen et al., 2010).  Transgenic Nrg1 mice also show 
deficits in tasks such as fear conditioning, novel object recognition, continuous 
T-maze alternation task and latent inhibition (Rimer et al., 2005; Chen et al., 
2008; Ehrlichman et al., 2009; Duffy et al., 2010).  However, some studies also 
show  no  effect  of  Nrg1  manipulation  on  spatial  learning  and  memory  tasks 
(Gerlai et al., 2000; O’Tuathaigh et al., 2007; Duffy et al., 2010).  Care must be 
taken to interpret the wealth of studies utilising transgenic Nrg1 mice as they 
vary in which isoform of Nrg1 is being manipulated.   
 
Interestingly,  Nrg1  type  I  over-expression  results  in  some  of  the  same 
behavioural observations from Nrg1 knock-out mice (Deakin et al., 2009).  This 
finding highlights the inverted U shaped hypothesis whereby either increased or 
decreased  levels  of  Nrg1-Erbb4  signalling  from  the  optimal  levels  result  in 
deficits in synaptic plasticity (Role & Talmage, 2007).  This may also hold true 
for behavioural dysfunction where in schizophrenia the directionality of change 
in expression of Nrg1/Erbb4 is not key for pathophysiology: what is important is 
that the signalling has shifted from the “norm”.   
 
Secondly, it is essential to take into account that the manipulation of Erbb4 in 
this study is region specific whereas previous in vivo studies of Erbb4 have opted 
for a more global depletion of the gene.  One limitation to analysing results (in 
particular  behavioural  phenotypes)  from  transgenic  mice  is  that  the  effects 
observed  may  be  complicated  by  the  interaction  between  abnormalities  in 
multiple  brain  regions  (Chen  et  al.,  1998).      Furthermore,  the  evidence  for 
altered Erbb4 expression in schizophrenia appears to be limited to the prefrontal 
cortex,  as  no  change  was  quantified  in  the  hippocampus  (Law  et  al.,  2006).  228 
Therefore, behavioural changes following Erbb4 manipulation specifically in the 
mPFC may be more representative of schizophrenia.   
 
Small  but  significant  changes  in  omissions  and  premature  responses  were 
observed in the present study; however many changes that were observed were 
not  stable  over  time.  The  amount  of  premature  responses  and  omissions 
performed in the 30 minute task period is very low, with on average in the basic 
task only 10 omissions and 12 premature responses being performed in the test 
period.  Therefore, a change between surgical groups in  premature responses 
and omissions is more likely to produce significant results as a few additional 
premature  responses  or  omissions  will  result  in  a  big  difference.    Moreover, 
there  was  no  significant  effect  of  surgical  group  on  premature  responses  or 
omissions  in  the  vITI  task,  despite  these  parameters  being  highlighted  by 
extending the inter-trial interval.  This task has been widely used to measure 
subtle  changes  in  impulsivity  and  visuo-spatial  attention,  and  has  been 
successful in identifying changes in these parameters not clearly evident in the 
basic task (Paterson et al., 2011). 
 
Changes in latencies suggest that the vehicle treated rats were slower to collect 
rewards than rats with Erbb4 knockdown in all three task types and also slower 
than scr.rAAV treated rats in both the vITI and vSD tasks.  Changes in latency to 
reward are generally thought to reflect changes in motivation (Robbins et al., 
2002).  However, as both viral-treated groups were quicker to collect rewards 
following  correct  response  this  would  suggest  the  viral  particles  themselves 
other  than  the  gene  manipulation  were  affecting  motivation.    There  also 
appeared to be a slight effect of viral treatment on latency to make a correct 
response with viral treated rats responding quicker than the vehicle treated rats 
in the vSD task.  This may suggest there was a slight effect on the motor system 
of vehicle treated rats.  These changes in response times in viral-treated rats 
compared  to  vehicle treated  rats  are  similar  to  the  observations  seen  in  the 
open field task where the vehicle treated rats travelled the least distance under 
vehicle treatment compared to the viral treatment groups (see chapter 5). 
However, the results with latency to response were less consistent than those of 
the latency to reward as there was no effect of viral treatment on latency to 229 
response in the vITI task and in the basic task the scrambled hairpin treated rats 
were slower than those that received vehicle.  It is important to note that the 
speed that  these highly  trained rats are performing at is  very  fast,  with  the 
speed of the vehicle treated rats in the basic task of 569ms ±16ms, vITI task of 
613ms±34ms and vSD task of 605ms±46ms.  These latencies are very similar to 
that of Bari et al., (2008) who suggest male Hooded Lister rats should perform at 
a  response  latency  of  571ms±41ms,  554ms±31ms,  598ms±41ms  in  the 
aforementioned tasks, respectively.  Furthermore, it should be noted that the 
differences between the latencies performed by the surgical groups (either to 
reward or correct response) are very small with the biggest difference between 
groups  being  for  reward  latency  a  100ms  difference  on  average  between 
shErbb4.rAAV treated rats and veh treated rats in the vSD task, and for latency 
to response a 97 ms difference on average between scr.rAAV treated rats and 
veh treated rats in the vSD task. 
6.5 Conclusions 
The data in this chapter present some interesting findings with respect to a) the 
utilisation  of  the  5-CSRTT  in  measuring  cognitive  changes  following  gene 
manipulation, b) the role of Erbb4 in the mPFC in terms of cognition. 
The findings of the change in rats’ performance in the 5-CSRTT when stimulus 
duration  is  shortened  or  inter-trial  interval  is  extended  are  in  complete 
agreement with the expected results previously reported (Bari et al., 2008) with 
percentage accuracy decreasing in the vSD task and the number of premature 
responses increasing and slight effects on percentage accuracy and percentage 
omissions in the vITI task compared to that of the basic task set-up.   These 
findings not only support that set-up in habituation, training and testing of the 
5-CSRTT  in  our  laboratory  are  accurate,  but  also  support  that  the  task  is 
versatile and can be manipulated to suit the experimental requirements.   
With respect to viral mediated gene manipulation, this study emphasises that 
this  technique  is  viable  in  investigating  schizophrenia  genes  and  will  allow 
further knowledge of what part these genes, which are generally very poorly 230 
understood  in  terms  of  their  potential  pathophysiological  roles,  may  play  in 
cognition in specific brain regions at specific stages of life.    
The main finding of this chapter was that viral-mediated Erbb4 knockdown in the 
mPFC resulted in an increase in percentage accuracy at 5 weeks post-surgery 
without having a great impact on any of the other parameters assessed in the 
task.  This would suggest that Erbb4 knockdown or Nrg1 over-expression within 
the mPFC is pro-cognitive and that the pre-frontal dependant cognitive deficits 
observed in schizophrenia may be partly due to an imbalance in this signalling 
pathway in this brain region.  Although no specific neurotransmitter system was 
analysed in depth following Erbb4 knockdown,  it is most likely that this pro-
cognitive  effect  is  a  result  of  changes  in  glutamatergic,  cholinergic  and 
dopaminergic  neurotransmission  as  Nrg1-Erbb4  are  known  to  have  important 
roles in all these systems (and most likely others too).  As the effect is subtle, 
and  is  not  emphasised  by  decreasing  SD,  these  data  support  the  general 
consensus that schizophrenia is not a single gene or network disorder but one 
that  is  a  result  of  insults  in  multiple  genes  which  can  impact  upon  multiple 
networks.   
The results of this study emphasise that further research should be invested in 
investigating the Nrg1-Erbb4 signalling pathway specifically in the mPFC in terms 
of cognition in order potentially to identify possible therapeutic drug targets to 
treat the cognitive deficits in schizophrenia or other disorders where Nrg1-Erbb4 
signalling may be dysfunctional.     
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The overall aims of this PhD study were to identify the roles of the schizophrenia 
candidate  gene  Erbb4  in  neuregulin  signal  pathway  transduction,  and 
schizophrenia-related behaviours dependent on prefrontal cortex functioning.  I 
demonstrated that adeno-associated viral mediated knockdown of Erbb4 within 
the prefrontal cortex of rats resulted in changes in selected behaviours including 
measures  of  cognition,  along  with  alterations  in  expression  and  activity  of 
several components of the Nrg1-Erbb4 signalling cascade.  These data allow a 
greater knowledge of how dysfunctional NRG1-ERBB4 signalling in schizophrenia 
may be potentially linked to the cognitive deficits observed in the disorder, and 
may prospectively lead to therapeutic targets for the treatments of these poorly 
managed symptoms.   
7.1 Nrg1-Erbb4 signalling in NG108-15 cells 
In initial experiments the expression and activity of endogenous Erbb4 in the 
neuronal cell line NG108-15 were studied, with the aim of potentially identifying 
a neuronal cell line that could be utilised to investigate Nrg1-Erbb4 signalling 
(chapter 3).  Western blotting and RT-PCR techniques were used to show that 
NG108-15  cells  express  murine  Erbb4  mRNA  and  protein,  and  moreover 
selectively express the JMa/CYT1 and JMa/CYT2 isoforms of Erbb4.  Although 
the levels of Erbb4 endogenous expression appeared to be low in NG108-15 cells, 
optimised siRNA-mediated knockdown of Erbb4 without overt off-target effects 
was achieved at the mRNA level.  Moreover, there was subtle but significant 
activation of Erbb4 and GSK3 following the application of NRG1 to the cells, 
indicative that Erbb4 receptors in NG108-15 cells are functional.  It has been 
previously  reported  that  NG108-15  cells  expressed  Nrg1  (Pun  et  al.,  2007); 
however, this is, to my knowledge, the first study specifically investigating the 
expression  of  Erbb4  in  this  cell  line.    As  Erbb4  is  expressed  endogenously  in 
NG108-15  cells  they  offer  a  superior  model  for  investigating  Nrg1-Erbb4 
signalling as compared to cells manipulated to  express these genes. Moreover 
since NG108-15 are a neuronal cell line, it is likely that the roles that these 
genes play in this cell line will be more representative of the brain than non-
neuronal cell lines such as HEK-293 cells.   Identifying cell lines, and specifically 
neuronal  cell  lines,  that  express  schizophrenia  candidate  genes  allowed 233 
preliminary investigations of the functions of these genes to be carried out prior 
to in vivo studies. 
7.2 Erbb4  knockdown  on  schizophrenia-related 
signalling pathways and behaviours 
The pinnacle finding of this PhD study was that knockdown of Erbb4 expression 
exclusively  in  the  mPFC  was  sufficient  for  producing  selective  behavioural 
phenotypes that relate to schizophrenia, such as increasing accuracy in the 5-
CSRTT which translates to increased sustained attention (chapter 6). 
This study utilised the innovative technique of viral-mediated gene manipulation 
which  to  date  has  only  been  used  by  a  small  number  of  groups  to  study 
schizophrenia-related genes (Mao et al., 2009; Burnet et al., 2011).  Although 
one very recent study has published viral-mediated targeting of Erbb4 (Choi et 
al.,  2010),  this  current  project  is  the  first  demonstration  of  the  functional 
effects  of  viral  –mediated  Erbb4  manipulation  in  vivo.    Moreover,  although 
several  studies  have elegantly  shown  behavioural  and  biochemical  changes in 
genetically  manipulated  rodents  that  express  altered  levels  of  Erbb4,  this 
present  study  is  the  first  to  identify  the  effects  of  altered  Erbb4  expression 
within a distinct brain region. 
By targeting a distinct brain region such as the mPFC, which has been highly 
implicated  in  the  cognitive  deficits  of  schizophrenia,  we  can  identify  the 
potential  role  Erbb4  may  have  distinctively  within  this  brain  region.    These 
findings  can  then  reflect  how,  if  the  function  of  this  gene  if  perturbed  in 
schizophrenia,  can  ultimately  lead  to  these  poorly  treated  symptoms.  
Remarkably  Erbb4  knockdown  within  the  mPFC  led  to  an  improvement  in 
performance of the 5-CSRTT, a measure of attentional processes and processing 
speed (Young et al., 2009). 
These data are not only significant from a technical perspective but also from a 
biological  standpoint.    No  previous  animal  models  of  altered  Nrg1  or  Erbb4 
expression have utilised the 5-CSRTT or measures of attention and processing 
speed and therefore cannot be compared to the present study, however, the 234 
finding  of  increased  accuracy  following  Erbb4  knockdown  parallels  human 
studies.  In post-mortem dlPFC tissue from schizophrenia patients expression of 
ERBB4 has repeatedly been found to be increased (Silberberg et al., 2006; Law 
et al., 2007; Chong et al., 2008), and that this increase is selective for this brain 
region (Law  et al.,  2007).   Moreover, patients with variations in ERBB4 have 
dysfunctional activity in this brain region (Nicodemus et al., 2010).  In rodents 
performance  accuracy  in  the  5-CSRTT  has  been  positively  correlated  with 
activity of the mPFC (Barbelivien et al., 2001) and lesions of this region result in 
reduced accuracy (Muir et al., 1996).  It can therefore be interpreted that tight 
regulation  of  ERBB4  within  the  dlPFC  is  essential  for  optimal  cognitive 
performance.   
In addition, the reliability of the 5-CSRTT finding is emphasised by the parallel 
finding  that  Erbb4  knockdown  within  the  mPFC  heightens  the  sensitivity  to 
locomotor response to amphetamine at exactly the same time point post-viral 
manipulation  –  5  weeks.    Not  only  does  this  finding  illustrate  that  the 
behavioural responses occurred at the same time, but also that it is likely that 
they  are  both  a  result  of  altered  dopamine  transmission.    The  locomotor 
response to amphetamine is due to increased dopamine availability (Seiden et 
al.,  1993)  and  dopamine  levels  in  the  frontal  cortex  have  been  positively 
correlated with choice accuracy in the 5-CSRTT (Puumala & Sirvio, 1998).  These 
findings are consistent with the hypothesis that reduced dopamine levels within 
the PFC of schizophrenia patients are responsible for cognitive deficits. 
Moreover this link between prefrontal Erbb4 expression and dopamine regulation 
was  highlighted  by  a  change  in  the  activity  of  Akt  signalling  within  the  PFC 
following Erbb4 knockdown.  Akt signalling has been repeatedly associated with 
dopamine regulation (Beaulieu et al., 2009), so this reduction in Akt signalling 
may  reflect  an  altered  dopaminergic  modulation  of  Akt  subsequent  to  Erbb4 
knockdown. The directional of the change in Akt activity in the PFC following 
Erbb4 knockdown is inconsistent with the results of Emamian et al., (2004) who 
reported  decreased  Akt  activity  in  the  PFC  of  patients  with  schizophrenia. 
However, the direction of the change is consistent with the data of Beaulieu et 
al. (2009), who reported that dopaminergic modulation of mouse behaviour, in 
behavioural  assays  such  as  locomotor  activity,  involves  a  suppression  of  Akt 
activity.      It  is  tempting  to  speculate  that  a  reduction  in  PFC  Erbb4  levels 235 
facilitates  dopaminergic  suppression  of  Akt  in  the  PFC,  and  thus  enhances 
performance in behavioural tasks involving the PFC.  Equally, it should be noted 
that  these  signalling  cascades  are  very  complex  and  have  multiple  inputs.  
Moreover,  since  dopamine  has  also  been  reported  to  stimulate  Akt,  the 
decreased  Akt  activity  may  reflect  a  compensatory  effect  to  reverse  the 
hyperdopaminergic  state  that  is  potentially  producing  the  behavioural 
phenotypes. 
This potential compensatory effect of decreased Akt activity is not unwarranted 
as we observed a compensatory increase in the expression of Nrg1 within the 
PFC  following  Erbb4  knockdown  that  led  to  a  significant  negative  correlation 
between Nrg1 and Erbb4 expression.  This finding leads to an interesting query 
that has not been addressed in previous animal models of altered Nrg1 and Erbb4 
expression,  of  whether  this  balance  of  Nrg1  and  Erbb4  expression  is  also 
affected.  Again, increasing the credibility of the findings in this present study to 
the observations of human studies, it has been repetitively found that there is 
an interaction between components of the NRG1-ERBB4-AKT1 signalling cascade 
(Benzel et al., 2007; Nicodemus et al., 2010; Sei et al., 2010).  The findings 
from  these  previous  studies  along  with  those  reported  in  the  current  study 
emphasise  that  with  the  complexity  of  schizophrenia,  it  is  unlikely  that 
expression changes in one gene or protein are solely pathogenic, but instead it is 
a combination of changes in multiple related genes.   Indeed, NRG1 and ERBB4 
have  also  been  associated  with  other  genes  including  COMT,  ESR1  (estrogen 
receptor 1) and DISC1 (Wong & Weickert, 2009; Sei et al., 2010; Seshadri et 
al., 2010). 
As expected Erbb4 knockdown did not lead to widespread behavioural deficits. 
Thus it appears that Erbb4 within the prefrontal cortex does not impact upon 
sensorimotor gating, as there was no effect of Erbb4 knockdown on prepulse 
inhibition performance.  This may reflect the more distributed neuronal network 
thought to be involved in PPI responses.  In addition, the lack of effect of Erbb4 
knockdown within the mPFC on PPI performance may also be due to the small 
area of mPFC transduced by the rAAV particles, or that the amount of Erbb4 
knockdown achieved by the rAAVs was insufficient to cause an effect on PPI.   236 
7.3 Further work 
The data generated from this study are very thought-provoking, and if more time 
and funding were available several interesting follow-up studies could be carried 
out.  Although the behavioural changes following Erbb4 knockdown within the 
mPFC provide promising insight into Erbb4 regulating cognitive behaviour which 
points towards altered dopaminergic transmission, it is uncertain as to which 
neurotransmitter  systems  are  altered,  as  neurotransmitter  levels  were  not 
measured in this study.  It would therefore be of great interest to measure the 
levels  of  neurotransmitters  related  to  Erbb4  function  such  as  dopamine, 
glutamate, serotonin and GABA within the mPFC following Erbb4 knockdown by a 
technique such as in vivo microdialysis. 
Due to time constraints, one limiting factor of the current study is that gene and 
protein expression were only quantified at one time point post-viral injection.  
Although  we successfully identified significant knockdown in Erbb4 expression 
and alterations in the levels of expression several related proteins, it would be 
of great interest to determine when the peak level of knockdown or secondary 
effects occurred by performing a time-line experiment.  However, to carry this 
out and to have a large enough sample size per time point, would require a 
substantial number of animals.  Consequently, it would also be worthwhile to 
assess the behaviours measured in this study at time points beyond 5 weeks post-
viral injection, to determine how long lasting these phenotypes were present 
and if they became more evident over time.   
Since it has been shown that specifically within the PFC it is distinct isoforms of 
ERBB4 that are over-expressed  (Silberberg  et al.,  2006;  Law  et al.,  2007),  it 
would be fascinating to use the techniques mastered in this present study to 
knockdown  specific  isoforms  of  Erbb4  within  the  mPFC.    It  would  be 
hypothesised that knockdown of JMa/CYT1 isoforms alone would produce a more 
distinct behavioural effect that knockdown of JMb/CYT2 isoforms.  Also, as it is 
unlikely that the complex range of symptoms which define schizophrenia result 
from dysfunction in one brain region alone, further studies akin to the present 
study  where  Erbb4  expression  is  manipulated  in  multiple  brain  regions 237 
simultaneously  would  identify  behavioural  and  biochemical  consequences  of 
dysfunctional Erbb4 signalling within a complete circuit.   
Finally, it would be appealing to repeat the current studies performed in NG108-
15  cells  in  cells  that  had  been  differentiated,  to  determine  whether  the 
expression  and  activity  of  Erbb4  in  this  cell  line  increases  in  response  to 
differentiation.    This  might  further  validate  this  cell  line  as  a  good  in  vitro 
model to study Nrg1-Erbb4 signalling. 
7.4 Conclusions 
This thesis presents a number of novel findings that impact on the understanding 
of  Erbb4  function  within  the  prefrontal  cortex.    The  innovative  technique  of 
using  adeno-associated  viral-mediated  manipulation  of  Erbb4  with  functional 
behavioural and biochemical analyses has been reported here for the first time.  
Following  primary  in  vitro  and  in  vivo  validation,  viral-mediated  Erbb4 
knockdown  was  achieved  within  the  PFC,  which  led  to  increased  accuracy 
performance in the 5-CSRTT and heightened sensitivity to the locomotor effects 
of amphetamine, without affecting sensorimotor gating function. 
As well as impacting on behavioural phenotypes, Erbb4 knockdown within the rat 
PFC  altered  biochemical  signalling,  with  an  increase  in  Nrg1  expression  and 
decreased Akt activity observed.  These behavioural and biochemical findings 
point  to  a  tentative  link  between  prefrontal  Erbb4  levels  and  dopamine 
regulation; however, it is likely that numerous other neurotransmitters may also 
be affected.   
Importantly, the data in this study highlight the validity of viral-mediated gene 
manipulation to investigate schizophrenia candidate genes, with the advantage 
of having control over spatial and temporal gene manipulation.  This innovative 
technique  has  enabled  the  investigation  of  the  function  of  Erbb4  specifically 
within  the  prefrontal  cortex  in  the  adult  rodent  brain,  and  has  led  to  the 
findings  that  1)  Erbb4  expression  within  the  PFC  is  important  in  cognitive 
function 2) prefrontal Erbb4 is not essential in regulating sensorimotor gating 
and 3) alterations in Erbb4 expression affect multiple components of the Nrg1-
Erbb4 signalling cascade. 238 
These  findings  are  a  vital  stepping  stone  to  a  greater  understanding  of  how 
ERBB4 may be potentially pathophysiological in schizophrenia, and with follow 
up studies can prospectively lead to new therapeutic targets for the treatment 
of the cognitive deficits of schizophrenia.   
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